US20230364248A1 - Mic-1 compounds and uses thereof - Google Patents

Mic-1 compounds and uses thereof Download PDF

Info

Publication number
US20230364248A1
US20230364248A1 US18/083,729 US202218083729A US2023364248A1 US 20230364248 A1 US20230364248 A1 US 20230364248A1 US 202218083729 A US202218083729 A US 202218083729A US 2023364248 A1 US2023364248 A1 US 2023364248A1
Authority
US
United States
Prior art keywords
seq
mic
chem
amino acid
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/083,729
Inventor
Xiang Gao
Xujia Zhang
Hongtao Guan
Henning Thoegersen
Kristian Sass-Oerum
Lars Fogh Iversen
Per Noergaard
Sebastian Beck Joergensen
Kristian Tage Hansen
Yi Wang
Kilian Waldemar Conde Frieboes
Birgit Wieczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US18/083,729 priority Critical patent/US20230364248A1/en
Publication of US20230364248A1 publication Critical patent/US20230364248A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to MIC-1 compounds and their pharmaceutical use.
  • MIC-1 Macrophage Inhibitory Cytokine-1
  • PTGF- ⁇ placental transforming growth factor beta
  • GDF15 growth differentiation factor-15
  • PDF prostate derived factor
  • NAG-1 non-steroidal anti-inflammatory drug-activated gene
  • PL74 PL74
  • MIC-1 circulates as a cysteine-rich homodimer with a molecular mass of 24.5 kDa.
  • Human wild-type MIC-1 has a short half-life, meaning that treatment with wt-MIC-1 requires daily administration to maintain efficacy.
  • WO 2005099746 concerns a method of modulating appetite and/or body weight by administering a MIC-1 modulating agent.
  • the present invention relates to MIC-1 compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension.
  • the MIC-1 compounds of the invention comprise a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension, wherein the amino acid extension comprises 3 to 200 amino acid residues, and the MIC-1 polypeptide with the amino acid extension has a calculated pI lower than 6.5.
  • the MIC-1 compounds of the invention have an N-terminal amino acid extension with one Cysteine residue, wherein the protractor is attached to the Cysteine residue.
  • the protractor comprises, or consists of at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
  • the MIC-1 compounds of the invention comprise an N-terminal extension that has surplus of acidic amino acid residues (Aspartic acid and/or Glutamic acid) of at least 3, 4, 5 or 6 compared to the number of basic amino acid residues (Lysine, Arginine and/or Histidine).
  • the MIC-1 compounds comprise N-terminal extensions composed of amino acid residues selected among the group consisting of A, C, E, G, P, S, T, Q, N and D, wherein the amino acid extension comprises at least three E and/or D amino acid residues.
  • the MIC-1 compounds of the invention comprise an MIC-1 polypeptide that display at least 85%, 90%, 95% or 98% sequence identity to MIC-1 of SEQ ID NO:1.
  • the MIC-1 compounds of the invention comprise an MIC-1 polypeptide that comprises a deletion of the first three residues (MIC-1-A1-3) or a deletion of Asparagine 3 (des-N3) compared to MIC-1 of SEQ ID NO: 1.
  • the MIC-1 compound comprises a MIC-1 polypeptide and an N-terminal amino acid extension with an amino acid sequence according to SEQ ID NO: 87, 90, 92, 93, 94, 97, 98, 99, 100, 101, 102, 108, 109, 111, 112, 113, 114, 115, 116, 117, 164, 288, 289, 290, 291 or 292.
  • the MIC-1 compounds of the invention have retained MIC-1 receptor potency and in vivo efficacy on lowering food intake and body weight. These MIC-1 compounds can therefore be used for treatment of metabolic disorders such as obesity, diabetes, cardiovascular diseases like dyslipidaemia and arteriosclerosis and other disorders such as steatohepatitis and diabetic nephropathy.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the MIC-1 compound of the invention or a pharmaceutically acceptable salt, amide or ester thereof, and one or more pharmaceutically acceptable excipients.
  • the invention provides a MIC-1 compound for use in the prevention and/or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, type 2 diabetes, dyslipidemia, or diabetic nephropathy.
  • the invention provides a MIC-1 compound for use in the prevention and/or treatment of dyslipidaemia, arteriosclerosis, non-alcoholic steatohepatitis, or diabetic nephropathy.
  • the MIC-1 compounds of the invention have a protracted plasma exposure, i.e. a prolonged half-life compared to human wild type MIC-1.
  • the MIC-1 compounds of the invention have improved solubility. In one aspect, the MIC-1 compounds of the invention have improved chemical stability.
  • FIG. 1 The expression of MIC-1 polypeptides with N-extensions with single 12-mer building blocks. All cells were grown in TB at 37° C. and proteins were induced to express by adding 0.5 mM IPTG after OD600 reached 1.0. Cells were harvested after overnight and the expression level was checked by loading the total lysate on SDS-PAGE. Wild type human MIC-1 (MIC-1) was loaded as the positive control.
  • FIG. 2 The expression of MIC-1 polypeptides with N-extensions with double 12-mer building blocks. All cells were grown in TB at 37° C. and proteins were induced to express by adding 0.5 mM IPTG after OD600 reached 1.0. Cells were harvested after overnight and the expression level was checked by loading the total lysate on SDS-PAGE. MIC-1 was loaded as the positive control.
  • FIG. 3 a) Comparison of expression levels among MIC-1 polypeptides with N-extensions initiating with 12 mer-(4+2+_), -(4+4+_) and -(4+3+_). It should be noticed that the group bearing 12 mer-(4+3_) and the construct indicated by the dot contain M57L in the MIC-1 polypeptide sequence. b) the effects of the extended 12 mers on the expression level. In addition, the lowest data point in the group of 3.6 is the MIC-1 polypeptide containing M57L. In this figure, “1.6 latter” represents TSTEEG, “2.6” represents TSESAT, “3.6” represents TSTEPS and “4.6” represents SEPATS.
  • FIG. 4 SDS-PAGE of representatives bearing 12 mer-(4+2+_), 12 mer-(4+3+_)+M57L, 12 mer-(three repeats) and 12 mer-(four repeats).
  • T total protein
  • S soluble fraction
  • P cell pellet (inclusion body).
  • FIG. 5 MIC-1 polypeptides with in-sequence mutations.
  • the MIC-1 polypeptide sequence is MIC-1 A1-3.
  • T total protein
  • S soluble fraction
  • P cell pellet (inclusion body).
  • FIG. 6 Body weight change over time during Pharmacodynamic (PD) study in pigs. 01: Compound 01; 05: Compound 05
  • the invention relates to MIC-1 compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension.
  • the MIC-1 compounds of the invention comprise a MIC-1 polypeptide an N-terminal amino acid extension and a protractor attached to the amino acid extension, wherein the amino acid extension comprises 3 to 200 amino acid residues, and the MIC-1 polypeptide and the amino acid extension together have a calculated pI lower than 6.5.
  • the MIC-1 compounds of the invention are biologically active. For example, they are potent, retain full efficacy compared to MIC-1 and also, they have a protracted plasma exposure profile, i.e. have a pronged half-life. The particular combination of potency and long half-life is desirable.
  • MIC-1 Macrophage Inhibitory Cytokine-1 (MIC-1), also known as Growth Differentiation Factor 15 (GDF-15), placental bone morphogenetic protein (PLAB) and nonsteroidal anti-inflammatory drug-activated gene (NAG-1).
  • GDF-15 Growth Differentiation Factor 15
  • PLAB placental bone morphogenetic protein
  • NAG-1 nonsteroidal anti-inflammatory drug-activated gene
  • MIC-1 is synthesized as a 62 kDa intracellular homodimer precursor protein which subsequently is cleaved by a furin-like protease into a 24.5 kDa homodimer.
  • the sequence of the full length wild type human MIC-1 is available from the UNIPROT database with accession no. Q99988.
  • the 308 amino acid precursor sequence includes a signal peptide (amino acids 1-29), a propeptide (amino acids 30-196) and a MIC-1 monomer sequence (amino acids 197-308).
  • the 112 amino acid MIC-1 monomer sequence is included herein as SEQ ID NO:1.
  • MIC-1 monomer contains nine cysteine residues which give rise to the formation of 4 intrachain disulphide bonds and one interchain disulphide bond to create a covalently linked 24.5 kDa homodimer.
  • a naturally occurring mutation corresponding to H6D in the MIC-1 monomer sequence (SEQ ID NO:1) has been described.
  • MIC-1 compound refers to a compound comprising a MIC-1 polypeptide, an N-terminal amino acid extension, and a protractor.
  • the MIC-1 compound is typically in the form of a homodimer.
  • MIC-1 polypeptide refers to the human MIC-1 monomer sequence of SEQ ID NO:1 or an analogue thereof. Numerical references to particular MIC-1 residues, if not stated otherwise, refer to the 112 amino acid monomer sequence (i.e., residue 1 is Alanine (Al), and residue 112 is Isoleucine (I112).
  • MIC-1 analogue refers to a MIC-1 polypeptide, which is an amino acid variant of the monomer MIC-1 sequence of SEQ ID NO: 1.
  • a MIC-1 analogue is a MIC-1 polypeptide in which a number of amino acid residues have been changed when compared to human MIC-1 (SEQ ID NO: 1). These changes may represent, independently, one or more amino acid substitutions, additions, and/or deletions.
  • MIC-1 analogues may be described by reference to the amino acid residue which is changed, the number of the amino acid residue (i.e. the corresponding position in the MIC-1 monomer sequence (SEQ ID NO:1)), and the change (e.g. the amino acid residue change to).
  • the MIC-1 analogue is a functional variant of the MIC-1 of SEQ ID NO:1.
  • the MIC-1 analogues display at least 85%, 90% or 95% sequence identity to MIC-1 of SEQ ID NO: 1.
  • sequence identity of the H6D MIC-1 analogue relative to MIC-1 of SEQ ID NO:1 is given by the number of aligned identical residues divided by the total number of aligned residues in MIC-1 of SEQ ID NO: 1.
  • sequence identity in percentage is (112-1)/112 ⁇ 100.
  • the N-terminal amino acid extension is not included.
  • a suitable alignment program can be tested with a suitable alignment program “needle”, which is a Needleman-Wunsch alignment. The algorithm for this alignment program is described in Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48: 443-453.
  • the MIC-1 analogues comprise less than 15, 10 or 5, amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to human MIC-1 of SEQ ID NO:1.
  • amino acid modification used throughout this application is used in the meaning of a modification to an amino acid as compared to monomer MIC-1 (SEQ ID NO:1). This modification can be the result of a deletion of an amino acid, addition of an amino acid, substitution of one amino acid with another or a substituent covalently attached to an amino acid of the peptide.
  • amino acids may be substituted by conservative substitution.
  • conservative substitution denotes that one or more amino acids are replaced by another, biologically similar residue. Examples include substitution of amino acid residues with similar characteristics, e.g. small amino acids, acidic amino acids, polar amino acids, basic amino acids, hydrophobic amino acids and aromatic amino acids.
  • amino acids may be substituted by non-conservative substitution.
  • non-conservative substitution denotes that one or more amino acids are replaced by another amino acid having different characteristics. Examples include substitution of a basic amino acid residue with an acidic amino acid residue, substitution of a polar amino acid residue with an aromatic amino acid residue, etc.
  • the non-conservative substitution is substitution of a coded amino acid to another coded amino acid having different characteristics.
  • the MIC-1 analogues may comprise substitutions of one or more unnatural and/or non-amino acids, e.g., amino acid mimetics, into the sequence of MIC-1.
  • the asparagine in the position corresponding to position 3 of monomer MIC-1 sequence is substituted to Serine (N3S), Glutamic acid (N3E), Alanine (N3A), or Glutamine (N3Q).
  • the asparagine in the position corresponding to position 3 of human MIC-1 monomer sequence is substituted to Glutamic acid (N3E).
  • the arginine in the position corresponding to position 2 of human MIC-1 monomer sequence (SEQ ID NO: 1) has been substituted to alanine (R2A), and the asparagine in the position corresponding to position 3 of human MIC-1 monomer sequence (SEQ ID NO:1) has been substituted to Glutamic acid (N3E).
  • the arginine in the position corresponding to position 2 of human MIC-1 monomer sequence (SEQ ID NO: 1) has been substituted to Glutamic acid (R2E), and the asparagine in the position corresponding to position 3 of human MIC-1 monomer sequence (SEQ ID NO: 1) has been substituted to Serine (N3S).
  • the MIC-1 analogues of the invention may have one or more amino acid residues deleted from the amino acid sequence of MIC-1 (SEQ ID NO:1), alone or in combination with one or more insertions or substitutions.
  • MIC-1 analogues with amino acid deletions may be described by “des”, reference to the amino acid residue which is deleted, and followed by the number of the deleted amino acid (i.e. the corresponding position in the monomer MIC-1 (SEQ ID NO:1)).
  • the asparagine in the position corresponding to position 3 of human monomer MIC-1 is deleted (MIC-1 des-N3, SEQ ID NO:2).
  • the alanine in the position corresponding to position 1 of human monomer MIC-1 is deleted (MIC-1, des-A1).
  • MIC-1 analogues with a truncation of one or more amino acid residues at the N or C terminal may be described by “MIC-1-A” and reference to the number(s) of the deleted amino acid residues (i.e. the corresponding position in the monomer MIC-1 (SEQ ID NO: 1)).
  • the first three residues (A1, R2, N3) at the N terminal are deleted (MIC-1-A1-3, SEQ ID NO:3).
  • the MIC-1 analogues of the invention have one or more amino acid residues inserted into the amino acid sequence of human MIC-1, alone or in combination with one or more deletions and/or substitutions.
  • the MIC-1 analogues of the invention include insertions of one or more unnatural amino acids and/or non-amino acids into the sequence of MIC-1.
  • protein or “polypeptide”, as e.g. used herein, refers to a compound which comprises a series of amino acids interconnected by amide (or peptide) bonds.
  • Amino acids are molecules containing an amine group and a carboxylic acid group, and, optionally, one or more additional groups, often referred to as a side chain.
  • amino acid includes coded (or proteinogenic or natural) amino acids (amongst those the 20 standard amino acids), as well as non-coded (or non-proteinogenic or non-natural) amino acids. Coded amino acids are those which are naturally incorporated into proteins. The standard amino acids are those encoded by the genetic code. Non-coded amino acids are either not found in proteins, or not produced by standard cellular machinery (e.g., they may have been subject to post-translational modification). In what follows, all amino acids of the MIC-1 proteins for which the optical isomer is not stated is to be understood to mean the L-isomer (unless otherwise specified).
  • amino acid residues may be identified by their full name, their one-letter code, and/or their three-letter code. These three ways are fully equivalent.
  • amino acid codes are provided below:
  • Glycine G and Gly; Proline: P and Pro; Alanine: A and Ala; Valine: V and Val; Leucine: L and Leu; Isoleucine: I and Ile; Methionine: M and Met; Cysteine: C and Cys; Phenylalanine: F and Phe; Tyrosine: Y and Tyr; Tryptophan: W and Trp; Histidine: H and His; Lysine: K and Lys; Arginine: R and Arg; Glutamine: Q and Gin; Asparagine: N and Asn; Glutamic Acid: E and Glu; Aspartic Acid: D and Asp; Serine: S and Ser; and Threonine: T and Thr.
  • the MIC-1 compounds of the invention comprise an N-terminal amino acid extension.
  • N-terminal amino acid extension means that the N-terminal of the MIC-1 polypeptide is attached to the C-terminal of the N-terminal amino acid extension via a peptide bond.
  • N-terminal amino acid extension means the same thing and are used interchangeably.
  • the compound of the invention comprises human MIC-1 monomer sequence (SEQ ID NO: 1) with an amino acid extension attached at the N-terminal, i.e. the Alanine at positon 1 (A1) via a peptide bond.
  • the N-terminal amino acid extension is up to 200 amino acid residues long. In a particular embodiment of the invention the N-terminal amino acid extension has from 3 to 36 amino acid residues.
  • the N-terminal amino acid extension has a surplus of acidic amino acid residues (Aspartic acid and/or Glutamic acid) of at least 3, 4, 5 or 6 compared to the number of basic amino acid residues (Lysine, Arginine and/or Histidine).
  • a “surplus” of acidic amino acid residues means that the number of acidic residues exceeds the number of basic residues.
  • a defined value of the surplus of acidic amino acid residues is calculated as the number of acidic residues minus the number of basic residues.
  • Methionine is the initial amino acid for protein expression in prokaryotic cells (e.g. bacteria, for instance, E. coli ).
  • the initial Methionine is removed from the protein during the protein expression. Therefore, the initial Methionine is not included in the sequence of the N-extension of MIC-1 compound.
  • the start codon, coding the initial Methionine is required for the protein translation initiation and should be incorporated right in front of the nucleotide sequence for protein expression without exception.
  • the MIC-1 compounds of the invention comprise a protractor.
  • the protractor is covalently attached to a specific amino acid residue of the MIC-1 polypeptide or N-terminal amino acid extension.
  • protractors relates to the properties of conveying extended plasma exposure (“half-life extending moiety”) and is herein understood to refer to a chemical group attached to an amino acid site chain functionalities such as —SH, —OH, —COOH, —CONH2, —NH2 that can increase in vivo circulatory half-life of MIC-1 when conjugated to the MIC-1.
  • protractors include but are not limited to: fatty acids and derivatives thereof, Hydroxy Alkyl Starch (HAS) e.g.
  • HES Hydroxy Ethyl Starch
  • PEG Poly Ethylen Glycol
  • HAP Poly (Glyx-Sery)n
  • HAP Hyaluronic acid
  • HEP Heparosan polymers
  • PC polymer Phosphorylcholine-based polymers
  • Fleximers Dextran
  • Poly-sialic acids PSA
  • Fc domain Transferrin
  • Albumin Elastin like peptides
  • unstructured and repeated amino sequences e.g. XTEN polymers
  • Albumin binding peptides e.g. XTEN polymers
  • the protractor is capable of forming non-covalent associations with albumin, thereby increasing the blood/plasma exposure time of the MIC-1 compound, and also having the effect of protracting the time of action of the MIC-1 compound, due to the fact that the association of the MIC-1 compound and albumin is only slowly disintegrated to release the active pharmaceutical ingredient.
  • the fatty acid comprising protractors of the invention are capable of forming non-covalent associations with albumin and thereby prolonging plasma half-life of the MIC-1 compound compared to human wide type MIC-1.
  • the protractor is covalently attached to a cysteine residue of the N-terminal amino acid extension of the MIC-1 polypeptide.
  • the protractor comprises a haloacetamide group, which reacts with the thiol group of a cysteine residue, under formation of a covalent sulfur-carbon bond (this process being referred to as Cys-alkylation) which is also referred to as a thio-ether bond.
  • the protractor comprises a maleimide group, which reacts with the thiol group of a cysteine residue, under formation of a covalent sulfur-carbon bond.
  • the protractor is covalently attached the N-terminal amino acid of the N-terminal amino acid extension.
  • the protractor comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3, and Chem. 4:
  • the protractor of the invention comprises one Chem. 1, one Chem. 4, and one or more of Chem. 2 and Chem. 3.
  • the protractor consists of one Chem. 1 element, two Chem. 2 elements, two Chem. 3 elements, and one Chem. 4 element.
  • Chem. 2 and Chem. 3 both hold a —NH— and CO— end allowing them to be linked by amide bonds to each other and to either —CO— or —NH— of Chem. 1 or Chem. 4.
  • Chem. 4 has a —NH— end (capable of forming an amide bond with Chem. 2 or Chem. 3).
  • a —NH—CO—CH 2 — end which in the unreacted form is a haloacetamide capable of reacting with the thiol group of a cysteine residue, or a (—N*—CO—CH 2 —CH**—CO)-end, the parenthesis representing a cyclic structure, which in the unreacted form is a maleimide capable of reacting with the thiol group of the cysteine; or an aldehyde capable of reacting with the N-terminal amino group in a reductive alkylation reaction.
  • the length of the carbon chain of Chem.1 defined by x or y may vary from 12-20 for x and 5-15 for y. Shorter or longer versions may be favoured for different types of protractors.
  • *—(CH 2 ) x * refers to straight alkylene in which x is an integer in the range of 12-20, such as 14-18 or such as 16.
  • This Chem. 1 may be briefly referred to as C18 diacid, i.e. a fatty di-carboxylic acid with 18 carbon atoms.
  • x 16 the structure of this linker element corresponds to Chem. 1a: HOOC—(CH 2 ) 16 —CO—*.
  • Chem. 1 is selected from the group consisting of:
  • Chem. 2 is selected from the group consisting of:
  • protractor is attached to a Cysteine residue; and the protractor comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
  • the protractor is attached to an N-terminal amino acid, and comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
  • x is an integer in the range of 12-20, wherein y is an integer in the range of 5-15;
  • the compounds/protractors of the invention may exist in different stereo-isomeric forms having the same molecular formula and sequence of bonded atoms, but differing only in the three-dimensional orientation of their atoms in space.
  • the stereoisomerism of the exemplified compounds/protractors of the invention is indicated in the experimental section, in the names as well as the structures, using standard nomenclature. Unless otherwise stated the invention relates to all stereoisomeric forms of the claimed compounds/protractors.
  • the calculated pI of the MIC-1 polypeptide with an N-terminal amino acid extension is defined as the pH at which the net calculated charge of the MIC-1 polypeptide with the N-extension is zero.
  • the calculated charge of the MIC-1 polypeptide with the N-extension as a function of pH is obtained using the pKa values of the amino acid residues described in Table 1 and the method described by B. Skoog and A. Wichman (Trends in Analytical Chemistry, 1986, vol. 5, pp. 82-83).
  • the side chain pKa of cysteine (Cys) is only included in the charge calculation for cysteines with a free sulfhydryl group.
  • the calculated pI value of human wild type MIC-1 as the homodimer is 8.8.
  • pKa of amino acid residues used for calculating pI are those described in “Correlation of Electrophoretic Mobilities from Capillary Electrophoresis with Physicochemical Properties of Proteins and Peptides by Rickard EC, Strohl MM, Nielsen RG. Analytical Biochemistry 1991, vol 197, pp 197-207”.
  • the MIC-1 compounds of the invention have good biophysical properties.
  • the MIC-1 compounds of the invention are biologically active. For example they are potent, binds to and activate the MIC-1 receptor complex. Also MIC-1 compounds exhibit protracted plasma exposure defined as longer half-life. For example MIC-1 compounds have a markedly longer plasma half-life when administered i.v. to rat and/or mini pigs compared to MIC-1 (SEQ ID 1). The particular combination of retained receptor potency and long plasma half-life may be highly desirable.
  • the compounds of the invention have retained MIC-1 receptor potency relative to human MIC-1 (SEQ ID NO:1).
  • Receptor potency and efficacy can be measured in mammalian cells transfected with human MIC-1 receptor (hGFRAL, GDNF family receptor alpha like) and its signalling co-receptor hRET (proto-oncogene tyrosine-protein kinase receptor Ret).
  • MIC-1 compounds activation of the receptor complex is measured by phosphorylation of extracellular signal-regulated kinases (ERKs) as described in Example 6.
  • receptor potency and efficacy is measured on MIC-1 compounds as homodimers.
  • the compounds of the invention are potent in vivo, which may be determined as is known in the art in any suitable animal model.
  • the non-obese Sprague Dawley rat is one example of a suitable animal model, and the changes in food intake may be determined in such rats in vivo, e.g. as described in Example 14.
  • the compounds of the invention inhibits in vivo food intake in non-obese Sprague Dawley rats.
  • the MIC-1 compounds of the invention are protracted and have an extended in vivo plasma half-life, which can be determined in a suitable pharmacokinetic in vivo study.
  • Extended plasma exposure may be determined as plasma half-life (T1 ⁇ 2) after i.v. administration to animals such as rats or mini pigs.
  • the MIC-1 compounds of the invention have a plasma half-life after i.v. administration to rat of at least 10 hour, more preferably between 25-50 hours, or most preferably at least 50 hours, determined as described in Example 16.
  • the MIC-1 compounds of the invention have a plasma half-life after i.v. administration to mini pigs of at least 50 hours, more preferably between 50-200 hours, even more preferably at least 200 hours or most preferably at least 300 hours, determined as described in Example 17.
  • the compounds of the invention are protracted and at the same time retain in vivo potency.
  • the particular combination of retained potency and long plasma half-life may be highly desirable.
  • the human wild type MIC-1 is a hydrophobic protein, with a calculated pI 8.8 based on the homodimer. Consequently, wild type MIC-1 can only be solubilized to around 0.5 mg/ml in neutral pH aqueous buffer systems.
  • the low solubility of MIC-1 significantly hampers its pharmaceutical formulation properties and therapeutic use, so developing a MIC-1 compound with improved solubility would greatly improve the therapeutic utility.
  • the MIC-1 polypeptides with an N-extension of the invention have improved solubility (i.e. are more soluble) relative to human MIC-1 of SEQ ID NO:1.
  • solubility is measured as described in Example 4.
  • the MIC-1 polypeptides with an N-extension of the invention have a solubility of at least 1 mg/ml in Tris buffer at pH 8.0. In other embodiments, the MIC-1 polypeptides with an N-extension of the invention have a solubility of at least 5 mg/ml, at least 10 mg/ml, at least 30 mg/ml, or at least 40 mg/ml in Tris buffer at pH 8.0.
  • solubility is measured on MIC-1 compounds and MIC-1 polypeptides with an N-extension as homodimers.
  • the human wild type MIC-1 sequence is chemically unstable and several residues of the amino acid sequence could be modified during storage, including deamidation on Asparagine at position 3 (N3) and oxidation of methionines M43, M57 and M86. Chemical instability of certain residues could impact pharmaceutical properties so developing chemical stable MIC-1 compounds would be another important part of making a MIC-1 therapeutic compound.
  • the compounds of the invention have improved chemical stability relative to human MIC-1 of SEQ ID NO:1.
  • chemical stability refers to chemical changes in the polypeptide structure leading to formation of chemical degradation products potentially having a reduced biological activity, decreased solubility, and/or increased immunogenic effect as compared to the intact polypeptide.
  • the chemical stability can be evaluated by measuring the amount of chemical degradation products at various time-points after exposure to different environmental conditions, e.g. by SEC-HPLC, and/or RP-HPLC.
  • certain residues of the MIC-1 monomer sequence (SEQ ID NO:1) is modified, e.g. by substitution to increase the chemical stability of the MIC-1 compounds.
  • N3 is deleted or substituted with other amino acids, e.g. E or Q.
  • Methionine is substituted with other amino acids, e.g. E or L.
  • the MIC-1 compounds of the invention have low immunogenicity risk.
  • MIC-1 polypeptides with an N-terminal amino acid extension of the present invention may be produced by means of recombinant protein technology known to persons skilled in the art.
  • nucleic acid sequences encoding the proteins of interest or functional variants thereof are modified to encode the desired MIC-1 polypeptide with an N-extension. This modified sequence is then inserted into an expression vector, which is in turn transformed or transfected into the expression host cells.
  • the nucleic acid construct encoding the MIC-1 polypeptide with an N-extension may suitably be of genomic, cDNA or synthetic origin. Amino acid sequence alterations are accomplished by modification of the genetic code by well-known techniques.
  • the DNA sequence encoding the MIC-1 polypeptide with an N-extension is usually inserted into a recombinant vector which may be any vector, which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector, which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the DNA sequence encoding the MIC-1 polypeptide with an N-extension is operably linked to additional segments required for transcription of the DNA.
  • operably linked indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence coding for the polypeptide until it terminates within a terminator.
  • expression vectors for use in expressing the MIC-1 polypeptide with an N-extension will comprise a promoter capable of initiating and directing the transcription of a cloned gene or cDNA.
  • the promoter may be any DNA sequence, which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • expression vectors for expression of the MIC-1 polypeptide with an N-extension will also comprise a terminator sequence, a sequence recognized by a host cell to terminate transcription.
  • the terminator sequence is operably linked to the 3′ terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
  • Expression of the MIC-1 polypeptide with an N-extension can be aimed for either intracellular expression in the cytosol of the host cell or be directed into the secretory pathway for extracellular expression into the growth medium.
  • Intracellular expression is the default pathway and requires an expression vector with a DNA sequence comprising a promoter followed by the DNA sequence encoding the MIC-1 polypeptide with an N-extension followed by a terminator.
  • a secretory signal sequence (also known as signal peptide or a pre sequence) is needed as an extension of the MIC-1 sequence.
  • a DNA sequence encoding the signal peptide is joined to the 5′ end of the DNA sequence encoding the MIC-1 polypeptide with an N-extension in the correct reading frame.
  • the signal peptide may be that normally associated with the protein or may be from a gene encoding another secreted protein.
  • the host cell into which the DNA sequence encoding the MIC-1 polypeptide with an N-extension is introduced may be any cell that is capable of expressing the MIC-1 polypeptide with an N-extension either intracellularly or extracellularly.
  • the MIC-1 polypeptide with an N-extension may be produced by culturing a host cell containing a DNA sequence encoding the MIC-1 polypeptide with an N-extension and capable of expressing the MIC-1 polypeptide with an N-extension in a suitable nutrient medium under conditions permitting the expression of the MIC-1 polypeptide with an N-extension.
  • Non-limiting examples of host cells suitable for expression of MIC-1 polypeptide with N-extension are: Escherichia coli, Saccharomyces cerevisiae , as well as human embryonic kidney (HEK), Baby Hamster Kidney (BHK) or Chinese hamster ovary (CHO) cell lines. If posttranslational modifications are needed, suitable host cells include yeast, fungi, insects and higher eukaryotic cells such as mammalian cells.
  • MIC-1 polypeptide with an N-extension may be recovered and purified to the required quality by conventional techniques.
  • Non-limiting examples of such conventional recovery and purification techniques are centrifugation, solubilization, filtration, precipitation, ion-exchange chromatography, immobilized metal affinity chromatography (IMAC), Reversed phase—High Performance Liquid Chromatography (RP-HPLC), gel-filtration and freeze drying.
  • MIC-1 proteins examples include Chich et al, Anal. Biochem, 1995, 224, pp 245-249 and Xin et al., Protein Expr. Purif. 2002, 24, pp 530-538.
  • MIC-1 polypeptides with an N-terminal amino acid extension can be expressed in bacteria such as E. coli .
  • large scale protein production of the MIC-1 polypeptides with an N-extension could take of using Inclusion Bodies (IB) as this represent an advantageous approach to controlling process recovery, protein purity, protease degradation and general protein stability. This becomes particular important for large scale protein production.
  • IB Inclusion Bodies
  • the balance of MIC-1 polypeptides with an N-extension solubility partly controlled by the calculated pI and IB formation.
  • the route of administration may be any route which effectively transports a compound of this invention to the desired or appropriate place in the body, such as parenterally, for example, subcutaneously, intramuscularly or intraveneously.
  • a compound of this invention can be administered orally, pulmonary, rectally, transdermally, buccally, sublingually, or nasally.
  • the amount of a compound of this invention to be administered is decided in consultation with a practitioner who is familiar with the treatment of obesity and related disorders.
  • compositions comprising a compound of the invention or a pharmaceutically acceptable salt, amide, or ester thereof, and a pharmaceutically acceptable excipient may be prepared as is known in the art.
  • excipient broadly refers to any component other than the active therapeutic ingredient(s).
  • the excipient may be an inert substance, an inactive substance, and/or a not medicinally active substance.
  • the excipient may serve various purposes, e.g. as a carrier, vehicle, diluent, tablet aid, and/or to improve administration, and/or absorption of the active substance.
  • the treatment with a compound according to the present invention may also be combined with one or more pharmacologically active substances, e.g., selected from antiobesity agents, appetite regulating agents, and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • one or more pharmacologically active substances e.g., selected from antiobesity agents, appetite regulating agents, and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • the present invention relates to a compound of the invention, for use as a medicament.
  • the compound of the invention may be used for the following medical treatments:
  • the invention relates to a method for weight management. In some embodiments the invention relates to a method for reduction of appetite. In some embodiments the invention relates to a method for reduction of food intake.
  • the invention relates to a method for treatment or prevention of obesity. In some embodiments the invention relates to use of the MIC-1 compounds of the invention for treatment or prevention of obesity.
  • the subject suffering from obesity is human, such as an adult human or a paediatric human (including infants, children, and adolescents).
  • a human subject suffering from obesity has a BMI of ⁇ 30; this subject may also be referred to as obese.
  • the human subject suffering from obesity has a BMI of ⁇ 35 or a BMI in the range of ⁇ 30 to ⁇ 40.
  • the obesity is severe obesity or morbid obesity, wherein the human subject has a BMI of ⁇ 40.
  • the invention relates to a method for treatment or prevention of overweight, optionally in the presence of at least one weight-related comorbidity. In some embodiments the invention relates to use of the MIC-1 compounds of the invention for treatment or prevention of overweight, optionally in the presence of at least one weight-related comorbidity.
  • the subject suffering from overweight is human, such as an adult human or a paediatric human (including infants, children, and adolescents).
  • a human subject suffering from overweight has a BMI of ⁇ 25, such as a BMI of ⁇ 27.
  • a human subject suffering from overweight has a BMI in the range of 25 to ⁇ 30 or in the range of 27 to ⁇ 30.
  • the weight-related comorbidity is selected from the group consisting of hypertension, diabetes (such as type 2 diabetes), dyslipidaemia, high cholesterol, and obstructive sleep apnoea.
  • the invention relates to a method for reduction of body weight. In some embodiments the invention relates to use of the MIC-1 compounds of the invention for reduction of body weight.
  • a human to be subjected to reduction of body weight according to the present invention has a BMI of ⁇ 25, such as a BMI of ⁇ 27 or a BMI of ⁇ 30. In some embodiments the human to be subjected to reduction of body weight according to the present invention has a BMI of ⁇ 35 or a BMI of ⁇ 40.
  • the invention relates to a method for treatment or prevention of cardiovascular diseases like arteriosclerosis and other disorders such as steatohepatitis, and diabetic nephropathy.
  • a MIC-1 polypeptide means one MIC-1 polypeptide or more than one MIC-1 polypeptide.
  • Main peak refers to the peak in a purification chromatogram which has the highest UV intensity in milliabsorbance units and which contains the fusion protein.
  • HPLC High performance liquid chromatography
  • SDS-PAGE is Sodium dodecyl sulfate Polyacrylamide gel electrophoresis.
  • IMAC is immobilized metal affinity chromatography.
  • SEC is size exclusion chromatography
  • MS is mass spectrometry.
  • MIC-1 polypeptides were designed to have increased solubility.
  • solubility was enhanced and stability was improved by modification of the amino acid sequence of the MIC-1 polypeptide.
  • modification was done within the amino acid sequence of the MIC-1 polypeptide (in-sequence mutation).
  • MIC-1 polypeptides with an N-terminal amino acid extension can be expressed in bacteria such as E. coli .
  • large scale protein production of the MIC-1 polypeptides with an N-extension could take of using Inclusion Bodies (IB) as this represent an advantageous approach to controlling process recovery, protein purity, protease degradation and general protein stability. This becomes particular important for large scale protein production.
  • IB Inclusion Bodies
  • F, I, L, M, V, W and Y were excluded, since they could contribute to protein aggregation.
  • H, K, and R were also excluded, since they could cause undesired binding on cell membrane.
  • A, C, E, G, P, S, T, D, N, and Q are preferred for the N-extension sequence.
  • E and D are particularly preferred since they increase the solubility by decreasing pI value of the compound.
  • C could provide a —SH group which can be used for protraction purpose, such as fatty acid conjugation and PEGylation.
  • one or two additional Alanine(s), Glycine(s) or Serine(s) were added at the very N-terminal to increase the initial Methionine removing efficiency when MIC-1 polypeptides with N-extension were expressed in E. coli.
  • N-extensions comprise sequences originating from human proteins (humanized sequences); some comprise artificially designed sequence(s) (e.g. GS, SG, AEE, AES, GEPQ (SEQ ID NO: 123), GEPS (SEQ ID NO:118)); some comprise several repeats of the humanized sequences or artificial sequences; some comprise a combination of the above.
  • Several 6-residue sequences (6-mers) were designed. N-extensions could comprise one or more of a 6-mers, part of a 6-mers (e.g., 1-5 residues of a 6-mers), or a combination of the above.
  • the amino acid residues of the artificial sequences (including 6-mers) and the humanized sequences could be arranged in any order.
  • 6-mer-1 SPAGSP (SEQ ID NO: 4)
  • 6-mer-2 TSESAT (SEQ ID NO: 5)
  • 6-mer-3 TSTEPE (SEQ ID NO: 6)
  • 6-mer-4 SEPATS (SEQ ID NO: 7)
  • 6-mer-5 TSTEEG (SEQ ID NO: 8)
  • 6-mer-6 PESGPG (SEQ ID NO: 9)
  • 6-mer-7 SGSAPG (SEQ ID NO: 10)
  • GSETPG SEQ ID NO: 11)
  • N-extensions Residue SEQ ID NO number Sequence of N-extension SEQ ID NO: 54 6 AEEAES SEQ ID NO: 55 3 AES SEQ ID NO: 56 9 (AEE) 2 AES SEQ ID NO: 57 20 (GEPS) 5 SEQ ID NO: 58 24 SPAGSPTSTEEGTSESATPESGPG SEQ ID NO: 59 21 (AEE) 6 AES SEQ ID NO: 60 18 (AEE) 5 AES SEQ ID NO: 61 12 (AEE) 3 AES SEQ ID NO: 62 26 AASPAGSPTSTEEGTSESATPESGPG SEQ ID NO: 63 24 TSESATPESGPGTSESATPESGPG SEQ ID NO: 64 26 AASPAGSPTSTEEGTSESATPESGPG SEQ ID NO: 65 22 AAPEDEETPEQEGSGSGSGSGSGS SEQ ID NO: 66 12 AAPEDEETPEQE SEQ ID NO: 67 22 AAPDEGTEEETEGSGSGSGSGSGS SEQ ID NO:
  • Certain internal residues of MIC-1 were modified, e.g. by substitution.
  • a hydrophobic residue of MIC-1 could be substituted with a hydrophilic residue, preferably by with an acidic residue; a positive charged residue could be substituted with an acidic residue, etc.
  • methionine could be substituted with other amino acids, e.g. E, F or L.
  • In-sequence mutations for increasing solubility include but are not limited to: P11E, H18E, R21E, ⁇ 30E, ⁇ 47E, R53E, ⁇ 54E, M57E, H66E, R67E, L68E, K69E, ⁇ 75E, ⁇ 81E, P85E, Q90E, T92E, L105E and K107E.
  • In-sequence mutations for decreasing oxidation include but are not limited to: M43L, M43E, M57E, M57L, M86F and M86L.
  • In-sequence mutations for increasing chemical stability include but are not limited to N3S, N3E, N3A, N3T, N3P, N3G, N3V, N3H, N3Y and N3Q.
  • In-sequence mutations for conjugation include but are not limited to K69R, K107R and K91R.
  • in-sequence mutations include but are not limited to a deletion of N3 (des-N3) and/or a deletion of the first 3 residues.
  • the calculated pI of a MIC-1 polypeptide with an N-terminal amino acid extension is defined as the pH at which the net calculated charge of the MIC-1 polypeptide with a N-terminal amino acid extension is zero.
  • the calculated charge of the MIC-1 polypeptide with the N-terminal amino acid extension as a function of pH is obtained using the pKa values of the amino acid residues described in Table 1 and the method described by B. Skoog and A. Wichman (Trends in Analytical Chemistry, 1986, vol. 5, pp. 82-83).
  • the side chain pKa of cysteine (Cys) is only included in the charge calculation for cysteines with a free sulfhydryl group.
  • the N-extension may contain one cysteine mutation.
  • the calculated pI value of human wild type MIC-1 is 8.8 as the homodimer.
  • the calculated pI values of MIC-1 polypeptide are shown in Table 4.
  • Example-1 Expression and Fermentation of the MIC-1 Polypeptide or the MIC-1 Polypeptide with an N-Terminal Extension
  • the cDNA of MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension was sub-cloned into a pET11b derived vector.
  • Overexpression of MIC-1f polypeptide or MIC-1 polypeptide with an N-terminal extension as inclusion bodies was induced in E. coli by 0.5 mM isopropyl ⁇ -d-thiogalactoside (IPTG) when the cell density reached an OD600 of 1.0.
  • IPTG isopropyl ⁇ -d-thiogalactoside
  • Fermentation was carried out on fed-batch process in chemical defined medium as supplement. Fermentation yield largely depended on different polypeptide, which varied from 1 g/L to 8 g/L from polypeptide to polypeptide.
  • the MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension were further purified as follows:
  • the MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension in the resulting supernatant was collected and diluted into the refolding buffer (50 mM Tris, pH 8.5 and 10% DMF or 10% DMSO) to the final concentration of 0.1 mg/ml.
  • the refolding process lasted for 48 hours in the cold room.
  • the resulting solution was filtered by 0.4 ⁇ m filter and loaded onto Hydrophobic Interaction column or anion exchange chromatography (50 mM Tris pH 8.0, 0-500 mM NaCl) using Q Sepharose Fast Flow resin (GE Healthcare), as generally described in Protein Purification. Principles and Practice Series: Springer Advanced Texts in Chemistry Scopes, Robert K.
  • SEQ ID NO: 82 MIC-1(R2A, N3E, M57E) 6.4 1.7 SEQ ID NO: 83 MIC-1(R2A, N3E, P85E) 6.4 N.D.
  • SEQ ID NO: 84 MIC-1(R2A, N3E, P11E) 6.4 1.6 SEQ ID NO: 85 MIC-1(R2A, N3E, R21E) 6.1 1.8
  • SEQ ID NO: 90 AES-MIC-1- ⁇ 1-3 6.8 0.9 SEQ ID NO: 91 (AEE) 2 AES-MIC-1- ⁇ 1-3 5.5 N.D.
  • SEQ ID NO: 92 GEPS 5 -MIC-1(SEQ ID NO: 1) 5.8 35.1
  • SEQ ID NO: 93 SPAGSPTSTEEGTSESATPESGPG- 6.1 44.5
  • MIC-1(SEQ ID NO: 1) SEQ ID NO: 94 (AEE) 6 AES-MIC-1(SEQ ID NO: 1) 4.5 39.0 SEQ ID NO: 95 (AEE) 5 AES-MIC-1- ⁇ 1-3 4.6 35.0 SEQ ID NO: 96 (AEE) 3 AES-MIC-1- ⁇ 1-3 5.0 36.0
  • PG-MIC-1(SEQ ID NO: 1) SEQ ID NO: 98 TSESATPESGPGTSESATPESGPG- 5.5 N.D.
  • MIC-1(R2A, N3E) SEQ ID NO: 99 AASPAGSPTSTEEGTSESATPESG 5.8 N.D.
  • PG-MIC-1- ⁇ 1-3 SEQ ID NO: 100 AAPEDEETPEQEGSGSGSGS- 5.2 35.7 MIC-1- ⁇ 1-3 SEQ ID NO: 101 AAPEDEETPEQE-MIC-1- ⁇ 1-3 5.2 N.D.
  • SEQ ID NO: 102 AAPDEGTEEETEGSGSGSGSGS- 5.2 N.D.
  • SEQ ID NO: 116 GEPS 6 -MIC-1- ⁇ 1-3 5.2 N.D.
  • SEQ ID NO: 117 SEPATSGSETPG 2 -MIC-1-des- 6.1 N.D. N3 *N.D.: Not determined
  • Example-3 pH-Dependent Solubility of MIC-1 Polypeptide with an N-Terminal Extension
  • the purpose of this experiment was to screen for a MIC-1 polypeptide with an N-extension with improved solubility, and determine the optimal pH window for formulation.
  • MIC-1 polypeptides with N-terminal extensions were dissolved in a mixture of water and ethanol (60% water and 40% ethanol) with a concentration range between 3 mg/ml to 10 mg/ml. The solvent was evaporated with SpeedVac (Concentrator Plus, Eppendorf) for 6 hours to obtain pellet of the MIC-1 polypeptide with N-terminal extension.
  • SpeedVac SpeedVac
  • Buffers were added into each well of the 96-well plate together with the MIC-1 polypeptides with N-terminal extensions.
  • the amount used may not be exactly the same but all targeting a theoretical concentration within 12-18 mg/ml.
  • the concentration of MIC-1 polypeptide with N-terminal extension in the supernatant was determined by UPLC (Table 6). Based on the results, solubility of the MIC-1 polypeptide with N-terminal extension of the invention was significantly improved between pH 6-9 compared with wtMIC-1.
  • the optimal pH window of the MIC-1 polypeptides with an N-extension falls into the pH range that is preferred for formulation, e.g. pH 6.5-8.5.
  • the MIC-1 polypeptides with an N-terminal extension were dissolved in a mixture of water and ethanol (60% water and 40% ethanol) with a concentration range between 3 mg/ml to 10 mg/ml. Then the solution (150 ⁇ L each well) was aliquot into a 96-well plate (Corning). The solvent was evaporated with SpeedVac (Concentrator Plus, Eppendorf) for 6 hours to obtain pellet of the MIC-1 polypeptide with an N-terminal extension. Tris buffer (pH 8.0, without excipients) was added into each well of the 96-well plate. The amount of buffer added to the well was less than the amount needed for solving the whole pellet in the well, so that maximal concentration was achieved.
  • the plate was shaken on a plate shaker at 800 rpm (MixMate, Eppendorf) for 2 hours. The pellet was spun down at 3600 g for 5 min. The supernatants were transferred to a 96-deep-well plate and diluted 20 times with 40% ethanol. Then all of the samples were subject to UPLC (Acquity, Waters), plate reader (Infinite M200 pro, Tecan) and UV spectrometer (NanoDrop 8000, Thermo Scientific) to determine the concentration (Table 7)
  • solubility of the MIC-1 polypeptides with an N-terminal extension of the invention was significantly improved at pH 8.0.
  • the MIC-1 polypeptides with an N-terminal extension achieved solubility of more than 30 mg/ml at pH 8.0.
  • the purpose of this example was to establish a cell based in vitro assay for testing MIC-1 activity.
  • Mammalian cells were transfected and stably expressed full length MIC-1 receptor (hGFRAL) and its full signaling co-receptor hRET51.
  • Plasmids expressing full length hGFRAL and full length hRET51 were constructed by inserting synthesized DNA nucleotides encoding full length hGFRAL and full length hRET51 into mammalian expression vector pEL.
  • IRES internal ribosome entry site
  • pEL vector backbone was provided by Taihegene CRO company.
  • BHK21 cells Two millions of BHK21 cells were seeded in a 10 cm petri dish and cultured for overnight in culture medium (DMEM+10% FBS+1% PS). Cells were transfected with pEL-hGFRAL-IRES-hRET plasmids. Transfected cells were split into new 10 cm dishes at different densities and grew in selection medium (DMEM+10%/FBS+1%/PS+1 mg/ml G418) for more than 2 weeks to get single clones. The single clones were transferred to 6 well plates and cultured to 1000/confluence. mRNA expression of hGFRAL and hRET was measured by qPCR. Successfully transfected clones were picked up and tested for MIC-1 binding.
  • Example 6 MIC-1 Cell-Based In Vitro Activity Assay
  • Results from screening MIC-1 polypeptides with an N-terminal extension using BHK21-hGFRAL-IRES-hRET is shown in Table 8.
  • Collected data are expressed as daily food intake (24 hour food intake) measured from the onset of each daily 12 hour dark phase to the next day dark phase.
  • Daily changes in food intake in response to administrated compound were calculated by subtracting the average daily food intake of the vehicle group from the average daily food intake of the treatment group. Changes were considered significant if p ⁇ 0.1 using a two-tailed student's t-test.
  • Results are expressed as the “maximum reduction” in food intake compared with vehicle (percentage) recorded during the study period.
  • Data are also expressed as the “accumulated reduction” in food intake which as the sum of significant (p ⁇ 0.1) daily reductions in food intake (percentage) during the study period.
  • MIC-1 polypeptides with an N-extension not only increased the solubility molecules but also resulted in efficacy equal to or even better than wtMIC-1 (Table 9).
  • compounds according to SEQ ID NO: 105 and SEQ ID NO:106 had a maximum and accumulated in vivo efficacy which was 40-50% greater than wtMIC-1 with subcutaneous dosing.
  • the increase in efficacy was furthermore associated with an increase in solubility as compounds according to SEQ ID NO:92, SEQ ID NO: 104, SEQ ID NO: 105 and SEQ ID NO:106 all had elevated solubility and a significant greater in vivo efficacy compared with wtMIC-1.
  • N-Formyl-Methionine is recognized by the immune system as foreign material, or as an alarm signal released by damaged cells, and stimulates the body to fight against potential infection (Pathologic Basis of Veterinary Disease5: Pathologic Basis of Veterinary Disease, By James F. Zachary, M. Donald McGavin).
  • Methionine is an instable residue that could be easily oxidized. Therefore, the N-Met cleavage efficiency is very important to MIC-1 expression.
  • the cDNA of MIC-1 polypeptide with N-terminal extension was sub-cloned into a pET11b derived vector.
  • Overexpression of MIC-1 polypeptides with an N-terminal extension as inclusion bodies or soluble protein was induced in E. coli by 0.5 mM isopropyl ⁇ -d-thiogalactoside (IPTG) when the cell density reached an OD600 of 1.0.
  • IPTG isopropyl ⁇ -d-thiogalactoside
  • Fermentation was carried out on fed-batch process in chemical defined medium as supplement. Fermentation yield largely depended on different compounds, which varied from 1 g/L to 8 g/L from compound to compound.
  • N-Met cleavage N- MIC-1 efficiency extension N-aa sequence polypeptide (%) 12mer-1 SPAGSPTSTEEG MIC-1 ⁇ 1-3 N/A (SEQ ID NO: 166) 12mer-2 TSESATPESGPG 0 (SEQ ID NO: 167) 12mer-3 TSTEPSEGSAPG 0 (SEQ ID NO: 168) 12mer-4 SEPATSGSETPG 100 (SEQ ID NO: 169) N/A: means MIC-1 with the N-terminal extension did not express in E. coli . Compounds bearing double 12 mers are listed in Table 11, and the results are shown as well (see Table 11 and FIG. 2 ).
  • N-extensions starting with the 2mer-1 block could not be expressed in E. coli .
  • protein expression was achieved but only 12 mer-4 as the initial sequence resulted in complete methionine cleavage.
  • the N-met cleavage efficiency of 12 mer-2 series is better than that of 12 mer-3 series.
  • Example 9 Expression Level and Inclusion Body Ratio of MIC-1 Polypeptide with 2* or 2.5*12 Mer N-Extension
  • Example 8 See Example 8 for protein production method. The results are shown in Table 12, FIG. 3 and FIG. 4 .
  • inclusion body is usually considered as a good choice mainly due to its better up-scaling properties, which mainly include: high expression level, simple recovery step and high purity, protease-resistant and good process stability.
  • MIC-1 polypeptides with an N-terminal extension could be expressed either inclusion body or soluble form, which is mainly dependent on compounds' pI and extension The results are shown in Table 13 and FIG. 4 .
  • MIC-1 polypeptides initiating with 12 mer-(4+2+_), -(4+4+_) and -(4+3+_) were investigated with their ability to express inclusion body. It was shown that the inclusion body ratio is >90 when pI>5.1.
  • MIC-1 polypeptides with in-sequence mutations M57E/H66E mainly expressed soluble fractions.
  • WtMIC-1 homo-dimer contains total of 9 pairs of disulphide bonds and in theory, introducing a new cysteine will disturb the original disulphide bond matching by disulphide bond scrambling, which could further decrease refolding yield. While in our experiments, it is surprising to find that these Cys mutants listed were tested in the same refolding buffer used for wtMIC-1 refolding and showed similar refolding yield ( ⁇ 50% to 60%) as wtMIC-1 or solubility-engineered MIC-1 polypeptide with an N-terminal extension described.
  • Example 10.1 Preparation of 17-[(S)-1-carboxy-3-(2- ⁇ 2-[(2- ⁇ 2-[(4-formylbenzylcarbamoyl)methoxy]ethoxy ⁇ ethylcarbamoyl)-methoxy]ethoxy ⁇ ethylcarbamoyl)propylcarbamoyl]heptadecanoic acid
  • t-Bu-N-(4-Formylbenzyl) carbamate 100 mg was treated with TFA/DCM (1:1) for 1 h. The mixture was concentrated in vacuo and co-concentrated with toluene (twice).
  • 2-Chlorotrityl resin 100-200 mesh 1.7 mmol/g (3, 40.1 g, 68.1 mmol) was left to swell in dry dichloromethane (250 mL) for 20 minutes.
  • a solution of ⁇ 2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy ⁇ -acetic acid (Fmoc-Ado-OH, 17.5 g, 45.4 mmol) and N,N-diisopropylethylamine (30.1 mL, 173 mmol) in dry dichloromethane (50 mL) was added to resin and the mixture was shaken for 5 hours.
  • Resin was filtered and treated with a solution of N,N-diisopropylethylamine (15.8 mL, 90.8 mmol) in methanol/dichloromethane mixture (4:1, 250 mL, 2 ⁇ 5 min). Then resin was washed with N,N-dimethylformamide (2 ⁇ 250 mL), dichloromethane (2 ⁇ 250 mL) and N,N-dimethylformamide (3 ⁇ 250 mL). Fmoc group was removed by treatment with 20% piperidine in dimethylformamide (1 ⁇ 5 min, 1 ⁇ 10 min, 1 ⁇ 30 min, 3 ⁇ 250 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (2 ⁇ 250 mL), dichloromethane (2 ⁇ 250 mL) and N,N-dimethylformamide (250 mL). Fmoc group was removed by treatment with 20% piperidine in dimethylformamide (1 ⁇ 5 min, 1 ⁇ 10 min, 1 ⁇ 30 min, 3 ⁇ 250 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 250 mL), 2-propanol (2 ⁇ 250 mL) and dichloromethane (300 mL, 2 ⁇ 250 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (2 ⁇ 250 mL), dichloromethane (2 ⁇ 250 mL) and N,N-dimethylformamide (250 mL). Fmoc group was removed by treatment with 20% piperidine in dimethylformamide (1 ⁇ 5 min, 1 ⁇ 10 min, 1 ⁇ 30 min, 3 ⁇ 250 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 250 mL), 2-propanol (2 ⁇ 250 mL) and dichloromethane (300 mL, 2 ⁇ 250 mL).
  • Resin was shaken for 1 hour, filtered and washed with N,N-dimethylformamide (3 ⁇ 250 mL), dichloromethane (2 ⁇ 250 mL), methanol (2 ⁇ 250 mL) and dichloromethane (350, 6 ⁇ 250 mL).
  • the product was cleaved from resin by treatment with 2,2,2-trifluoethanol (250 mL) for 18 hours.
  • Resin was filtered off and washed with dichloromethane (2 ⁇ 250 mL), 2-propanol/dichloromethane mixture (1:1, 2 ⁇ 250 mL), 2-propanol (250 mL) and dichloromethane (3 ⁇ 250 mL).
  • Triethylamine (5.72 mL, 41.0 mmol) was added to a suspension of (2-amino-ethyl)-carbamic acid benzyl ester hydrochloride (6.94 g, 30.1 mmol) in dry dichloromethane (165 mL) and the resulting mixture was added to the above solution. The mixture was stirred at room temperature overnight, and then it was evaporated to dryness.
  • N,N-Diisopropylethylamine (4.98 mL, 28.6 mmol) was added to a solution of the above amine (6, 20.5 g, 23.8 mmol) in dry dichloromethane (290 mL) at ⁇ 30° C. under argon.
  • Bromoacetyl bromide (2.48 mL, 28.6 mmol) was added dropwise and the resulting solution was stirred at ⁇ 30° C. for additional 3 hours. The cooling bath was removed, the mixture was stirred at room temperature for 1 hour, and then the solvent was removed in vacuo.
  • Step 1 benzyl 18-[[(1S)-4-[2-[2-[2-[2-[2-[2-[2-(2-aminoethylamino)-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-benzyloxycarbonyl-4-oxo-butyl]amino]-18-oxo-octadecanoate
  • Step 2 benzyl 18-[[(1S)-1-benzyloxycarbonyl-4-[2-[2-[2-[2-[2-[2-[(2-chloroacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoate
  • Step 3 18-[[(1S)-1-Carboxy-4-[2-[2-[2-[2-[2-[2-[(2-chloroacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoic acid
  • Step 4 8-[[(1S)-4-[2-[2-[2-[2-[2-[2-[(2-Bromoacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-carboxy-4-oxo-butyl]amino]-18-oxo-octadecanoic acid
  • the compound was prepared by the same method as described as for example 10.1.
  • Resin was filtered and treated with a solution of N,N-diisopropylethylamine (4.12 mL, 23.7 mmol) in methanol/dichloromethane mixture (4:1, 2 ⁇ 5 min, 2 ⁇ 100 mL). Then resin was washed with N,N-dimethylformamide (2 ⁇ 100 mL), dichloromethane (2 ⁇ 100 mL) and N,N-dimethylformamide (3 ⁇ 100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 5 min, 1 ⁇ 30 min, 2 ⁇ 100 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (2 ⁇ 100 mL), dichloromethane (2 ⁇ 100 mL) and N,N-dimethylformamide (3 ⁇ 100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 5 min, 1 ⁇ 30 min, 2 ⁇ 100 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 100 mL), 2-propanol (2 ⁇ 100 mL) and dichloromethane (3 ⁇ 100 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (2 ⁇ 100 mL), dichloromethane (2 ⁇ 100 mL) and N,N-dimethylformamide (2 ⁇ 100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 5 min, 1 ⁇ 30 min, 2 ⁇ 100 mL). Resin (2) was washed with N,N-dimethylformamide (3 ⁇ 100 mL), 2-propanol (2 ⁇ 100 mL) and dichloromethane (3 ⁇ 100 mL). Resin was divided into 4 equal parts and this synthesis was continued with one quarter of the original amount (4.50 mmol).
  • Resin was filtered and washed with N,N-dimethylformamide (2 ⁇ 100 mL), N,N-dimethylformamide/water (2:1, 2 ⁇ 100 mL), dimethylsulfoxide (2 ⁇ 100 mL), water (2 ⁇ 100 mL) and N,N-dimethylformamide (3 ⁇ 100 mL).
  • the product was cleaved from resin by treatment with 1,1,1,3,3,3-hexafluoro-2-propanol (80 mL) for 2 hours. Resin was filtered off and washed with dichloromethane (4 ⁇ 100 mL).
  • Triethylamine (1.82 mL, 13.1 mmol) was added to a suspension of (2-amino-ethyl)-carbamic acid benzyl ester hydrochloride (5, 1.93 g, 8.37 mmol) in dry dichloromethane (20 mL) and the resulting mixture was added to the above solution. The mixture was stirred overnight at room temperature.
  • 2,4,6-Collidine (1.60 mL, 12.0 mmol) was added to a solution of the above amine (7, 2.06 g, 2.11 mmol) in anhydrous N,N-dimethylformamide (20 mL) at 0° C. under argon.
  • 2-Bromoacetic anhydride (0.68 g, 2.61 mmol) was added and the resulting solution was stirred at 0° C. for 1 hour. Reaction mixture was then evaporated to dryness under reduced pressure and the residue was triturated with diethyl ether (2 ⁇ 10 mL).
  • Remaining compound (S)-1-bromo-28-(tert-butoxycarbonyl)-2,7,16,25,30-pentaoxo-9,12,18,21-tetraoxa-3,6,15,24,29-pentaazapentatetracontane-45-sulfonic acid (8) was used for the next step without further purification.
  • the resin was drained and washed with N,N-dimethylformamide (4 ⁇ 60 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (2 ⁇ 60 mL, 2 ⁇ 15 min). Resin was washed with N,N-dimethylformamide (6 ⁇ 60 mL) A solution of Fmoc-OEG-OH and Oxyma in DMF (53.2 mL, 0.3 M) was mixed with DIC (26.6 mL, 0.6M) in DMF. The AA was activated over 10 min then added to the resin and the mixture was shaken for 8 hours. The resin was drained and washed with N,N-dimethylformamide (4 ⁇ 60 mL) and then with acetonitrile (2 ⁇ 60 mL 2 ⁇ 8 h).
  • the Resin was drained and washed with N,N-dimethylformamide (2 ⁇ 15 mL), DCM (5 ⁇ 15 mL).
  • the MTT group was cleaved by 1,1,1,3,3,3-hexafluoro-2-propanol/DCM/Triisopropylsilane 80/18/2, 3 ⁇ 20 ml, (3 ⁇ 20 min with DCM wash between each treatment) and then washed with 4 ⁇ 20 mL DCM.
  • Bromoacetic acid (1.10 g, 7.92 mmol) and DIC (0.62 mL, 3.96 mmo) in 10 mL DMF were added to the resin and shaken for 1 h.
  • the resin was washed with N,N-dimethylformamide (3 ⁇ 20 mL) and dichloromethane (5 ⁇ 20 mL).
  • the product was cleaved from the resin with TFA (98%), water (2%), 20 mL for 1 h and 20 mL for 1 ⁇ 2h.
  • the resin was washed with 20 mL DCM.
  • the solvents were evaporated to give a yellow oil.
  • the oil was dissolved in EtOAc (50 mL) and washed with water 2 ⁇ 100 mL).
  • the amount of EtOAc was reduced in vacuum and filtered. The precipitate was washed with EtOAc and dried on the filter giving 270 mg of white solid.
  • Resin was filtered and treated with a solution of N,N-diisopropylethylamine (0.94 mL, 5.40 mmol) in methanol/dichloromethane mixture (4:1, 2 ⁇ 5 min, 2 ⁇ 40 mL). Then resin was washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL) and N,N-dimethylformamide (4 ⁇ 40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 40 mL).
  • Resin was washed with N,N-dimethylformamide (3 ⁇ 40 mL), 2-propanol (2 ⁇ 40 mL), dichloromethane (3 ⁇ 40 mL) and N,N-dimethylformamide (3 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL) and N,N-dimethylformamide (4 ⁇ 40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 40 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 40 mL), 2-propanol (2 ⁇ 40 mL), dichloromethane (3 ⁇ 40 mL) and N,N-dimethylformamide (3 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL) and N,N-dimethylformamide (4 ⁇ 40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 40 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 40 mL), 2-propanol (2 ⁇ 40 mL), dichloromethane (3 ⁇ 40 mL) and N,N-dimethylformamide (3 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL), N,N-dimethylformamide (4 ⁇ 40 mL) and dichloromethane (10 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 50 mL), dichloromethane (4 ⁇ 50 mL) and N,N-dimethylformamide (4 ⁇ 50 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 50 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 50 mL), 2-propanol (2 ⁇ 50 mL), dichloromethane (3 ⁇ 50 mL) and N,N-dimethylformamide (3 ⁇ 50 mL).
  • the product (4) was cleaved from the resin by the treatment with trifluoroacetic acid/dichloromethane mixture (2:1, 30 mL) for 3 hours. Resin was filtered off and washed with dichloromethane (4 ⁇ 40 mL). The solvent was evaporated to dryness to afford pure (2S,29S)-29-(2-bromoacetamido)-2-(10-(4-carboxyphenoxy)decanamido)-5,14,23-trioxo-9,12,18,21-tetraoxa-6,15,24-triazatriacontanedioic acid (4) as yellow oil.
  • 2-Chlorotrityl chloride resin 100-200 mesh 1.5 mmol/g (2.60 g, 3.90 mmol) was left to swell in dry dichloromethane (40 mL) for 30 minutes.
  • a solution of ⁇ 2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy ⁇ -acetic acid (Fmoc-OEG-OH, 1.02 g, 2.60 mmol) and N,N-diisopropylethylamine (1.75 mL, 10.0 mmol) in dry dichloromethane (40 mL) was added to resin and the mixture was shaken overnight.
  • Resin was filtered and treated with a solution of N,N-diisopropylethylamine (0.90 mL, 5.20 mmol) in methanol/dichloromethane mixture (4:1, 2 ⁇ 5 min, 2 ⁇ 40 mL). Then resin was washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL) and N,N-dimethylformamide (4 ⁇ 40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 40 mL).
  • Resin was washed with N,N-dimethylformamide (3 ⁇ 40 mL), 2-propanol (2 ⁇ 40 mL), dichloromethane (3 ⁇ 40 mL) and N,N-dimethylformamide (3 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL) and N,N-dimethylformamide (4 ⁇ 40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 40 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 40 mL), 2-propanol (2 ⁇ 40 mL), dichloromethane (3 ⁇ 40 mL) and N,N-dimethylformamide (3 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL) and N,N-dimethylformamide (4 ⁇ 40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 40 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 40 mL), 2-propanol (2 ⁇ 40 mL), dichloromethane (3 ⁇ 40 mL) and N,N-dimethylformamide (3 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 40 mL), dichloromethane (4 ⁇ 40 mL), N,N-dimethylformamide (4 ⁇ 40 mL) and dichloromethane (10 ⁇ 40 mL).
  • Resin was filtered and washed with N,N-dimethylformamide (4 ⁇ 50 mL), dichloromethane (4 ⁇ 50 mL) and N,N-dimethylformamide (4 ⁇ 50 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1 ⁇ 10 min, 1 ⁇ 30 min, 2 ⁇ 50 mL). Resin was washed with N,N-dimethylformamide (3 ⁇ 50 mL), 2-propanol (2 ⁇ 50 mL), dichloromethane (3 ⁇ 50 mL) and N,N-dimethylformamide (3 ⁇ 50 mL).
  • the product was cleaved from resin by treatment with 1,1,1,3,3,3-hexafluoro-2-propanol in dichloromethane (2:8, 80 mL) for 2 hours. Resin was filtered off and washed with dichloromethane (2 ⁇ 80 mL). Solutions were combined; solvents evaporated to obtain product (4) as brownish oil. The crude product contained 2 equivalents of 1,1,1,3,3,3-hexafluoro-2-propanol.
  • protractor (example 10.4, 8 equivalents) was dissolved in 1.5 mL of sat. NaHCO 3 and added to 108 mg MIC-1 polypeptide with N-extension (SEQ ID NO: 288) in PBS buffer, pH 7.4, 2.1 mg/mL. Added 19 mg bis(p-sulfonatophenyl)phenylphosphine, Kalium salt dihydrate, Sigma-Aldrich 698539 (8 equivalent). After 24 h standing at room temperature the protein was purified on a C4 reverse phase column using a 10-50% ethanol/phosphate buffer pH 3.0 gradient. Yield ⁇ 20% after purification.
  • Compound 02 was prepared using the procedure described in example 11.1 using MIC-1 polypeptide with N-extension (SEQ ID NO: 291).
  • Compound 03 was prepared using the procedure described in example 11.1 using the protractor described in example 10.2 and MIC-1 polypeptide with N-extension (SEQ ID NO: 291).
  • Compound 04 was prepared using the procedure described in example 11.1 using the protractor described in example 10.3 and MIC-1 polypeptide with N-extension (SEQ ID NO: 291).
  • Compound 05 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 289).
  • Compound 06 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 303).
  • Compound 07 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 292).
  • Compound 08 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 293).
  • protractor (example 10.1, 8 equivalents) dissolved in 2 mL 40% Hydroxypropyl-beta-cyclodextrin was added to 75 mg of MIC-1 polypeptide with N-extension (SEQ ID NO: 164) in 40 mL PBS buffer, pH 7.4. 100 ⁇ L of borane pyridine complex (8M) was added. After 24 h standing at room temperature 20 mg of the protractor and 100 ⁇ L of borane reagent were added again.
  • Compound 11 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 290).
  • Example 11.12 and Example 11.13 Compound 12 and Compound 13
  • Compound 14 was prepared using the procedure described in example 11.10 using the protractor described in example 10.5 and MIC-1 polypeptide with N-extension (SEQ ID NO: 311).
  • Example 11.15 and Example 11.16 Compound 15 and Compound 16
  • Compounds 20 was prepared using the procedure described in Example 11.17 using the protractor described in Example 10.9 and MIC-1 polypeptide with N-extension (SEQ ID NO: 288).
  • Compounds 21 was prepared using the procedure described in Example 11.17 using the protractor described in Example 10.10 and MIC-1 polypeptide with N-extension (SEQ ID NO: 288).
  • Compound 09, Compound 13 or Compound 15 as a dimer has only one protractor attached to one of its two N-terminal extensions.
  • one protractor is attached to each of the two N-terminal extensions of the dimer, i.e. two protractors per dimer Compound.
  • Samples of MIC-1 compounds was prepared in PBS buffer pH 7.4 followed by an up-concentrating the samples to above 35 mg/ml.
  • MIC-1 compound samples in PBS were concentrated on a Vivaspin 20 10 kDa MWCO (Sartorius) according to the description in the Vivaspin manual.
  • a Heraus Multifuge X3R centrifuge equipped with swinging-bucket rotor (Thermo Scientific) was used at 4000 rpm (3310 ⁇ g) to concentrate the MIC-1 compound samples.
  • the concentration was subsequently determined by measuring UV at 280 nm on a Nanodrop 2000 (Thermo Scientific). The measured concentrations are presented in Table 19.
  • the stable cell line BHK21-hGFRAL-IRES-hRET was generated at Novo Nordisk with the addition of a vector with the Serum Response Element (SRE) in front of the luciferase reporter (See Example 5). Sequence for human GFRAL and human RET was obtained at Uniprot: UniProtKB—Q6UXVO (GFRAL_HUMAN) and UniProtKB—P07949 (RET_HUMAN). This cell line was used for the functional luciferase assay as well as for membrane preparation for Scintillation proximity assay (SPA) binding.
  • SRE Serum Response Element
  • Luciferase assay BHK21 cells stably transfected with hGFRAL, hRET receptors and SRE-Luciferase reporter genes were treated by different concentrations of MIC-1 compounds. Activation of receptors was measured by quantification of luciferase activity and potencies of compounds were calculated by EC50.
  • SPA binding Cell membrane of BHK21-hGFRAL-IRES-hRET, SRE-Luciferase cells were isolated treated by 50 pM of 1125 labelled MIC-1 with different concentrations of MIC-1 compounds. Binding potencies of MIC-1 compounds were calculated by IC50 of displacement curves.
  • Vials with frozen cells were rapidly thawed and the cells moved to a 50 ml corning tube with 10 ml pre-warmed complete medium consisting of DMEM with high glucose and sodium pyrovate, heat inactivated 10% Fetal Bovine Serum, 1% Penicillin-Streptomycin, 1 mg/ml G418-Geneticin and 400 ⁇ g/ml Hygromycin. Cells were centrifuged at 1200 rpm and the supernatant was discarded. This washing procedure was repeated once resulting in 2 times washing of the cells. Cells were resuspended in complete media to a concentration of 1.2 ⁇ 10 6 cells per ml.
  • Cells were seeded 1.2 ⁇ 10 5 cells per well (100 ⁇ l/well) in 96 well Poly-D-Lysine coated assay palates. Cells were let to attach to the bottom surface of the wells for 4-6 hours at +34° C. followed by change of medium to 80 ⁇ l starvation medium consisting of RPMI medium with 15 mM HEPES. Cells were left to incubate over night at +34° C. in a humidified milieu with 5% C02. Test compounds were serial diluted in assay medium consisting of RPMI, 15 mM HEPES and 0.5% ovalbumin with or without 5% human serum albumin (HSA).
  • HSA human serum albumin
  • BHK21-hGFRAL-IRES-hRET cells were cultured at +37° C. in a humidified atmosphere with 5% CO 2 in complete medium consisting of DMEM with high glucose and sodium pyrovate, heat inactivated 10% Fetal Bovine Serum, 1% Penicillin-Streptomycin, 1 mg/ml G418-Geneticin and 400 ug/ml Hygromycin.
  • Cells were washed twice in ice cold Dulbecco's phosphate-buffered saline (DPBS) and detached mechanically by scraping, transferred in ice cold DPBS into conical centrifuge tubes and centrifuged for 5 min at 1500 rpm at +20° C.
  • DPBS Dulbecco's phosphate-buffered saline
  • Cell pellet was resuspended in a total amount of 10 ml ice cold homogenization buffer A (50 mM Tris, 2.5 mM EDTA, adjust pH7.4 with one EDTA-free protease inhibitor cocktail tablet/50 ml) and homogenized for 20 seconds. The homogenate was centrifuged at 16000 rpm in 20 minutes at +4° C.
  • homogenization buffer A 50 mM Tris, 2.5 mM EDTA, adjust pH7.4 with one EDTA-free protease inhibitor cocktail tablet/50 ml
  • the supernatant was discarded and the pellet was reconstituted in 10 ml homogenization buffer B (50 mM Tris, 320 mM Sucrose, adjust pH 7.4 with one EDTA-free protease inhibitor cocktail tablet/50 ml) and homogenized for 20 seconds and centrifuged at 16000 rpm in 20 minutes at +4° C. This procedure was repeated one more time.
  • the supernatant was discarded and the pellet was reconstituted in 3 ml homogenization buffer B and homogenized for 10 seconds at low speed. Protein concentration was determined by standard Bradford method and 1.5 mg protein/tube was aliquoted to cryotubes and stored at ⁇ 80° C.
  • Binding assays were performed in white 96-well plates in a total volume of 200 ⁇ l per well.
  • Wheat germ agglutinin SPA beads were reconstituted in assay buffer (50 mM Tris/HCl, 4.5 mM MgCl 2 , 0.020/Tween 20 and 0.250/Ovalbumin pH 7.4) and mixed with membrane preparation to give a final concentration of 0.5 mg SPA beads and 10 ⁇ g total protein per well.
  • Fifty thousand counts per minute per well of the radio ligand human [125I]-MIC-1 was added corresponding to a concentration of 50 pM.
  • MIC-1 compounds to be tested were serial diluted in assay buffer to give a final assay concentration ranging from 1 ⁇ M to 1 pM.
  • the plate was sealed and incubated at +22° C. for 2 hours in a plate shaker set at 350 rpm and thereafter centrifuged at 1500 rpm for 10 minutes prior to reading of SPA bead light emission. Displacement of radio ligand was measured as reduction of light emission from SPA beads and IC 50 values were calculated by nonlinear regression analysis of sigmoidal dose-response curves (Table 20).
  • MIC-1 compounds with fatty acids have similar in vitro potency compared to MIC-1 polypeptides without fatty acids. But in vitro potency would be lower if the Cys mutation is close to N-terminal of MIC-1 polypeptide, such as Cys mutation S( ⁇ 3)C.
  • the in vivo efficacy of MIC-1 compounds of the invention was measured in 9-11 weeks old lean male Sprague Dawley rats. Animals were injected daily with a dose of 8 nmol/kg body weight 1-2 hrs before the onset of the dark period. Compounds were administrated subcutaneously (1-4 ml/kg) in appropriate buffered solution. Changes in food intake were measured for 7 days using automatic food monitoring systems (BioDAQ system and HM2 system for rat). In the BioDAQ system animals were single housed; and in the HM2 system animals were in group housed with up to 3 animals per cage. On day 8, a tail blood sample was collected 2-3 hrs after administration of compound, and this sample was used for measuring plasma concentrations of administrated compounds.
  • Data are also expressed as the “accumulated reduction” in food intake which as the sum of significant (p ⁇ 0.1) daily reductions in food intake (percentage) during the study period.
  • the body weight of the animals was measured at the day of study termination using a calibrated scale.
  • the effect of treatment on the body weight was calculated as the percentage difference in body weight between compound treated animals compared with vehicle treated animals at study termination (Table 21).
  • the purpose of this experiment was to investigate the effect of the MIC-1 compounds on food intake and body weight in pigs. This was done in a pharmacodynamic (PD) study as described below, in which food intake was measured from 1 to 21 days after administration of a single dose of the MIC-1 compound, as compared to a vehicle-treated control group.
  • PD pharmacodynamic
  • the animals were fed ad libitum with pig fodder (Svinefoder Danish Top SI 611+3′, Danish Agro) at all times both during the acclimatisation and the experimental period. Food intake was monitored on line by logging the weight of fodder continuously using the HMview system (Ellegaard Systems, Faaborg, Denmark). Any notable spillage was collected and weighed, and the automatically measured food intake was corrected for this amount.
  • pig fodder Svinefoder Danish Top SI 611+3′, Danish Agro
  • Body weight was measured once or twice weekly during the study.
  • the MIC-1 compounds were dissolved in an appropriate buffer at concentrations of approximately 25 or 100 nmol/ml corresponding to doses of 1 or 9 nmol/kg.
  • the buffer solution also served as vehicle.
  • mice were dosed with a single subcutaneous dose of the MIC-1 compounds or vehicle on the morning of day 1, and food intake was measured for 21 days after dosing. At the end of the study the animals were euthanised with an i.v. overdose of Euthasol administered through the ear vein catheter.
  • Food intake was calculated in 24 h intervals (0-24 h, 24-48 h, 48-72 h, 72-96 h up to 20-21 days).
  • the resulting mean food intake is presented as percentage of the mean food intake of the vehicle group in the same time interval.
  • the data shows that a single s.c. injection of the tested compounds in pigs caused a reduced food intake for up to and even more than 21 days after the injection (for the 9 nmol/kg doses of Compound 01).
  • T/2 terminal half-life
  • MRT mean residence time
  • Tmax time for maximal plasma levels
  • F bioavailability time
  • T1 ⁇ 2 the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase with intravenous dosing
  • MRT is in general meant the average amount of time that the compound in question stays in the body.
  • Tmax is in general meant the point in time after subcutaneous administration of the compound in question when the compound in question reaches the highest concentration in the blood plasma during.
  • F is in general meant the fraction of subcutaneously administrated compound which appears in the blood plasma.
  • the aforementioned PK parameters were measured in 300 g-500 g lean SD rats by injecting the compound into either the tail vein or to the subcutis of the neck followed by collection of blood plasma samples at various time points for exposure analysis.
  • Compounds (4-5 nmol/kg body weight) were administered intravenously (1 ml/kg) in an appropriate buffer solution.
  • the group size of the intravenous group was typically 4 and the groups size of the subcutaneous group was typically 5.
  • the rats were awake during the whole experiment and have access to food and water.
  • blood samples were collected from the tongue typically at time 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 14 h, 22 h, 30 h, 48 h after dosing or at times 0 min, 15 min, 30 min, 60 min, 90 min, 2 h, 21 ⁇ 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 24 h, 30 h, 48 h after dosing.
  • blood samples were typically collected from the tongue at time 5 min, 15 min, 30 min, 60 min, 120 min, 360 min, 720 min, 24 h, 30 h, 48 h, 54 h, 72 h, 96 h, 168 h, 216 h, 264 h, 336 h after dosing, 200 ⁇ l of blood was collected into EDTA tubes and stored on ice for up to 20 minutes. Plasma samples were generated by centrifuging blood samples for 5 minutes at 10000 G at 4° C. The sample was subsequent pipetted into Micronic tubes on dry ice, and kept at ⁇ 20° C.
  • NA NA 02 Compound 4 nmol/kg IV 62.4 89.3 NA NA 03
  • Compound 4 nmol/kg IV 15.6 16.8 NA NA 04 Compound 4 nmol/kg IV 46.6 63.8 NA NA 06
  • Compound 4 nmol/kg IV 50 72 NA NA 11
  • Compound 4 nmol/kg SC 57 116 50 52 11 Compound 4 nmol/kg SC 55.8 57.2 55.5 42.3 17
  • MIC-1 compounds with protractors have much longer T1 ⁇ 2, MRT and Tmax compared to their non-protracted MIC-1 polypeptides with N-extensions.
  • Protraction of pharmaceutical biological compounds with comparable fatty acid protractors in general results in a terminal half-life rarely exceeding 12 hours in rat. The finding of terminal half-lives of more than 48 hours is unexpected and surprising.
  • the purpose of this study was to determine the protraction in vivo of the MIC-1 compound after i.v. administration to minipigs, i.e. the prolongation of their time in the body and thereby their time of action. This was done in pharmacokinetic (PK) studies, where the terminal half-life of the compound in question was determined.
  • terminal half-life is meant the time it takes to halve a certain plasma concentration in the terminal elimination phase.
  • mice Female Gottingen minipigs were obtained from Ellegaard Gottingen Minipigs (Dalmose, Denmark) approximately 8 months of age and weighing approximately 23-25 kg were used in the studies. The minipigs were housed individually (pigs with permanent catheters) in pens with straw as bedding and fed restrictedly once daily with Altromin 9030 minipig diet (Altromin Spezialfutter GmbH & Co. KG).
  • Intravenous injections (the volume corresponding to 0.17 ml/kg) of the compound was given through one catheter, and blood was sampled at predefined time points for up till 12 days post dosing (preferably from the other catheter).
  • Plasma was pipetted into Micronic tubes on dry ice, and kept at ⁇ 20° C. until analysed for plasma concentration of the MIC-1 compound using LOCI. Individual plasma concentration-time profiles were analysed by a non-compartmental pharmacokinetic method in Phoenix v. 6.4 (Pharsight Inc., Mountain View, CA, USA), and the resulting terminal half-lives (harmonic mean) determined.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of U.S. application Ser. No. 16/614,454, filed Nov. 18, 2019 which is a 35 U.S.C. § 371 National Stage application of International Application PCT/EP2018/063476 (published as WO 2018/215525), filed May 23, 2018, which claims priority to Chinese Patent Applications PCT/CN2017/113335, filed Nov. 28, 2017 and PCT/CN2017/085576, Filed May 23, 2017; the contents thereof which are incorporated by reference in their entirety.
    • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to MIC-1 compounds and their pharmaceutical use.
    • INCORPORATION-BY-REFERENCE OF THE SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted in XML format via the USPTO patent electronic filing system and is hereby incorporated by reference in its entirety. Said XML file, created on Dec. 14, 2022, is named 170039US03.xml and is 405 kilobytes in size.
    • BACKGROUND OF THE INVENTION
  • Macrophage Inhibitory Cytokine-1 (MIC-1) was first described in 1997 (Bootcov et al, Proc. Natl. Acad. Sci. October 1997) based on experiments showing increased expression in activated macrophages. MIC-1 has subsequently been identified by others and given several additional names such as placental transforming growth factor beta (PTGF-β), placental bone morphogenetic protein, growth differentiation factor-15 (GDF15), prostate derived factor (PDF), non-steroidal anti-inflammatory drug-activated gene (NAG-1) and PL74. MIC-1 is a distant member of the TGF-beta super family, a family of peptide hormones involved in cell growth and differentiation. MIC-1 circulates as a cysteine-rich homodimer with a molecular mass of 24.5 kDa. Human wild-type MIC-1 has a short half-life, meaning that treatment with wt-MIC-1 requires daily administration to maintain efficacy.
  • Accumulating evidence support the therapeutic utility of MIC-1 in metabolic disorders such as obesity and diabetes. Data from patients with advanced cancer showed that weight loss correlated with circulating levels of MIC-1 (Johnen et al, Nat Med., November, 2007). Transgenic mice overexpressing MIC-1 gain less weight and body fat both on a normal low fat diet and on a high fat diet (Macia et al, PLoS One, April, 2012). Also, transgenic mice overexpressing MIC-1 fed both on a low and high fat diet, respectively, had improved glucose tolerance compared with wild type animals on a comparable diet.
  • WO 2005099746 concerns a method of modulating appetite and/or body weight by administering a MIC-1 modulating agent.
    • SUMMARY OF INVENTION
  • The present invention relates to MIC-1 compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension. In one aspect, the MIC-1 compounds of the invention comprise a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension, wherein the amino acid extension comprises 3 to 200 amino acid residues, and the MIC-1 polypeptide with the amino acid extension has a calculated pI lower than 6.5.
  • In some embodiments, the MIC-1 compounds of the invention have an N-terminal amino acid extension with one Cysteine residue, wherein the protractor is attached to the Cysteine residue. In these embodiments the protractor comprises, or consists of at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
      • wherein Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)x—CO—*,  Chem. 1A:

  • HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

  • HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

  • (1H-tetrazol-5-yl)-(CH2)x—CO—*,  Chem. 1D:
      • wherein x is an integer in the range of 12-20,
      • wherein y is an integer in the range of 5-15;
      • wherein Chem. 2 is selected from the group consisting of:

  • *—(NH—CH(COOH)—(CH2)m-CO)k*,  Chem. 2A:

  • *—(NH—S(═O)2—(CH2)m-CO)k*, and  Chem. 2B:

  • *—(NH—(CH2)m-cyclohexane-CO)k—*,  Chem. 2C:
      • wherein m of Chem. 2 is an integer in the range of 1-5, and
      • k of Chem. 2 is an integer in the range of 0-4;
      • wherein Chem. 3 is

  • *(NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*)l,
      • wherein k of Chem. 3 is an integer in the range of 1-10,
      • n is an integer in the range of 1-5, and
      • l is an integer in the range of 0-5;
      • wherein Chem. 4 is selected from

  • *—NH—(CH2)m—NH—CO—CH2—*  Chem. 4A:

  • *—NH—CH(COOH)—(CH2)m—NH—CO—CH2—*,  Chem. 4B:

  • *—NH—(CH2)m—CH(COOH)—NH—CO—CH2—*, and  Chem. 4C:
  • Figure US20230364248A1-20231116-C00001
      • Chem. 4D:
      • wherein m of Chem. 4 is an integer in the range of 1-5, and n is an integer in the range 2-6; and
      • wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem., and wherein Chem. 4 is connected to the sulphur atom of the Cysteine residue of the amino acid extension.
  • An asterisk (*) in a chemical formula designates a point of attachment.
  • In some embodiments, the MIC-1 compounds of the invention comprise an N-terminal extension that has surplus of acidic amino acid residues (Aspartic acid and/or Glutamic acid) of at least 3, 4, 5 or 6 compared to the number of basic amino acid residues (Lysine, Arginine and/or Histidine).
  • In some embodiments of the invention the MIC-1 compounds comprise N-terminal extensions composed of amino acid residues selected among the group consisting of A, C, E, G, P, S, T, Q, N and D, wherein the amino acid extension comprises at least three E and/or D amino acid residues.
  • In some embodiments the MIC-1 compounds of the invention comprise an MIC-1 polypeptide that display at least 85%, 90%, 95% or 98% sequence identity to MIC-1 of SEQ ID NO:1.
  • In some embodiments the MIC-1 compounds of the invention comprise an MIC-1 polypeptide that comprises a deletion of the first three residues (MIC-1-A1-3) or a deletion of Asparagine 3 (des-N3) compared to MIC-1 of SEQ ID NO: 1.
  • In a particular embodiment of the invention the MIC-1 compound comprises a MIC-1 polypeptide and an N-terminal amino acid extension with an amino acid sequence according to SEQ ID NO: 87, 90, 92, 93, 94, 97, 98, 99, 100, 101, 102, 108, 109, 111, 112, 113, 114, 115, 116, 117, 164, 288, 289, 290, 291 or 292.
  • In one aspect, the MIC-1 compounds of the invention have retained MIC-1 receptor potency and in vivo efficacy on lowering food intake and body weight. These MIC-1 compounds can therefore be used for treatment of metabolic disorders such as obesity, diabetes, cardiovascular diseases like dyslipidaemia and arteriosclerosis and other disorders such as steatohepatitis and diabetic nephropathy.
  • In one aspect, the invention provides a pharmaceutical composition comprising the MIC-1 compound of the invention or a pharmaceutically acceptable salt, amide or ester thereof, and one or more pharmaceutically acceptable excipients.
  • In one aspect, the invention provides a MIC-1 compound for use in the prevention and/or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, type 2 diabetes, dyslipidemia, or diabetic nephropathy.
  • In one aspect, the invention provides a MIC-1 compound for use in the prevention and/or treatment of dyslipidaemia, arteriosclerosis, non-alcoholic steatohepatitis, or diabetic nephropathy.
  • In one aspect, the MIC-1 compounds of the invention have a protracted plasma exposure, i.e. a prolonged half-life compared to human wild type MIC-1.
  • In one aspect the MIC-1 compounds of the invention have improved solubility. In one aspect, the MIC-1 compounds of the invention have improved chemical stability.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 : The expression of MIC-1 polypeptides with N-extensions with single 12-mer building blocks. All cells were grown in TB at 37° C. and proteins were induced to express by adding 0.5 mM IPTG after OD600 reached 1.0. Cells were harvested after overnight and the expression level was checked by loading the total lysate on SDS-PAGE. Wild type human MIC-1 (MIC-1) was loaded as the positive control.
  • FIG. 2 : The expression of MIC-1 polypeptides with N-extensions with double 12-mer building blocks. All cells were grown in TB at 37° C. and proteins were induced to express by adding 0.5 mM IPTG after OD600 reached 1.0. Cells were harvested after overnight and the expression level was checked by loading the total lysate on SDS-PAGE. MIC-1 was loaded as the positive control.
  • FIG. 3 : a) Comparison of expression levels among MIC-1 polypeptides with N-extensions initiating with 12 mer-(4+2+_), -(4+4+_) and -(4+3+_). It should be noticed that the group bearing 12 mer-(4+3_) and the construct indicated by the dot contain M57L in the MIC-1 polypeptide sequence. b) the effects of the extended 12 mers on the expression level. In addition, the lowest data point in the group of 3.6 is the MIC-1 polypeptide containing M57L. In this figure, “1.6 latter” represents TSTEEG, “2.6” represents TSESAT, “3.6” represents TSTEPS and “4.6” represents SEPATS.
  • FIG. 4 : SDS-PAGE of representatives bearing 12 mer-(4+2+_), 12 mer-(4+3+_)+M57L, 12 mer-(three repeats) and 12 mer-(four repeats). T: total protein, S: soluble fraction, P: cell pellet (inclusion body).
  • FIG. 5 : MIC-1 polypeptides with in-sequence mutations. In this figure, the MIC-1 polypeptide sequence is MIC-1 A1-3. T: total protein, S: soluble fraction, P: cell pellet (inclusion body).
  • FIG. 6 : Body weight change over time during Pharmacodynamic (PD) study in pigs. 01: Compound 01; 05: Compound 05
    •  DETAILED DESCRIPTION
  • The invention relates to MIC-1 compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension.
  • In one aspect, the MIC-1 compounds of the invention comprise a MIC-1 polypeptide an N-terminal amino acid extension and a protractor attached to the amino acid extension, wherein the amino acid extension comprises 3 to 200 amino acid residues, and the MIC-1 polypeptide and the amino acid extension together have a calculated pI lower than 6.5.
  • The MIC-1 compounds of the invention are biologically active. For example, they are potent, retain full efficacy compared to MIC-1 and also, they have a protracted plasma exposure profile, i.e. have a pronged half-life. The particular combination of potency and long half-life is desirable.
    • MIC-1
  • The term “MIC-1” as used herein means Macrophage Inhibitory Cytokine-1 (MIC-1), also known as Growth Differentiation Factor 15 (GDF-15), placental bone morphogenetic protein (PLAB) and nonsteroidal anti-inflammatory drug-activated gene (NAG-1). MIC-1 is synthesized as a 62 kDa intracellular homodimer precursor protein which subsequently is cleaved by a furin-like protease into a 24.5 kDa homodimer. The sequence of the full length wild type human MIC-1 is available from the UNIPROT database with accession no. Q99988. The 308 amino acid precursor sequence includes a signal peptide (amino acids 1-29), a propeptide (amino acids 30-196) and a MIC-1 monomer sequence (amino acids 197-308). The 112 amino acid MIC-1 monomer sequence is included herein as SEQ ID NO:1. MIC-1 monomer contains nine cysteine residues which give rise to the formation of 4 intrachain disulphide bonds and one interchain disulphide bond to create a covalently linked 24.5 kDa homodimer. A naturally occurring mutation corresponding to H6D in the MIC-1 monomer sequence (SEQ ID NO:1) has been described.
  • The term “MIC-1 compound”, as used herein, refers to a compound comprising a MIC-1 polypeptide, an N-terminal amino acid extension, and a protractor. The MIC-1 compound is typically in the form of a homodimer.
  • The terms “MIC-1 polypeptide” as used herein refer to the human MIC-1 monomer sequence of SEQ ID NO:1 or an analogue thereof. Numerical references to particular MIC-1 residues, if not stated otherwise, refer to the 112 amino acid monomer sequence (i.e., residue 1 is Alanine (Al), and residue 112 is Isoleucine (I112).
  • The term “MIC-1 analogue”, or “analogue of MIC-1” as used herein refers to a MIC-1 polypeptide, which is an amino acid variant of the monomer MIC-1 sequence of SEQ ID NO: 1. In other words, a MIC-1 analogue is a MIC-1 polypeptide in which a number of amino acid residues have been changed when compared to human MIC-1 (SEQ ID NO: 1). These changes may represent, independently, one or more amino acid substitutions, additions, and/or deletions.
  • MIC-1 analogues may be described by reference to the amino acid residue which is changed, the number of the amino acid residue (i.e. the corresponding position in the MIC-1 monomer sequence (SEQ ID NO:1)), and the change (e.g. the amino acid residue change to).
  • In one aspect, the MIC-1 analogue is a functional variant of the MIC-1 of SEQ ID NO:1. In one aspect of the invention, the MIC-1 analogues display at least 85%, 90% or 95% sequence identity to MIC-1 of SEQ ID NO: 1. As an example of a method for determination of the sequence identity between two analogues the two peptides H6D MIC-1 and MIC-1 of SEQ ID NO:1 are aligned. The sequence identity of the H6D MIC-1 analogue relative to MIC-1 of SEQ ID NO:1 is given by the number of aligned identical residues divided by the total number of aligned residues in MIC-1 of SEQ ID NO: 1. Accordingly, in the example the sequence identity in percentage is (112-1)/112×100. In the determination of the sequence identity of a MIC-1 analogue, the N-terminal amino acid extension is not included. A suitable alignment program can be tested with a suitable alignment program “needle”, which is a Needleman-Wunsch alignment. The algorithm for this alignment program is described in Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48: 443-453.
  • In another aspect of the invention, the MIC-1 analogues comprise less than 15, 10 or 5, amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to human MIC-1 of SEQ ID NO:1. The term “amino acid modification” used throughout this application is used in the meaning of a modification to an amino acid as compared to monomer MIC-1 (SEQ ID NO:1). This modification can be the result of a deletion of an amino acid, addition of an amino acid, substitution of one amino acid with another or a substituent covalently attached to an amino acid of the peptide.
  • Substitutions:
  • In one aspect amino acids may be substituted by conservative substitution. The term “conservative substitution” as used herein denotes that one or more amino acids are replaced by another, biologically similar residue. Examples include substitution of amino acid residues with similar characteristics, e.g. small amino acids, acidic amino acids, polar amino acids, basic amino acids, hydrophobic amino acids and aromatic amino acids.
  • In one aspect amino acids may be substituted by non-conservative substitution.
  • The term “non-conservative substitution” as used herein denotes that one or more amino acids are replaced by another amino acid having different characteristics. Examples include substitution of a basic amino acid residue with an acidic amino acid residue, substitution of a polar amino acid residue with an aromatic amino acid residue, etc. In one aspect, the non-conservative substitution is substitution of a coded amino acid to another coded amino acid having different characteristics. In one aspect, the MIC-1 analogues may comprise substitutions of one or more unnatural and/or non-amino acids, e.g., amino acid mimetics, into the sequence of MIC-1.
  • In one aspect of the invention, the asparagine in the position corresponding to position 3 of monomer MIC-1 sequence (SEQ ID NO:1) is substituted to Serine (N3S), Glutamic acid (N3E), Alanine (N3A), or Glutamine (N3Q). In one aspect of the invention, the asparagine in the position corresponding to position 3 of human MIC-1 monomer sequence (SEQ ID NO:1) is substituted to Glutamic acid (N3E).
  • In one aspect of the invention, the arginine in the position corresponding to position 2 of human MIC-1 monomer sequence (SEQ ID NO: 1) has been substituted to alanine (R2A), and the asparagine in the position corresponding to position 3 of human MIC-1 monomer sequence (SEQ ID NO:1) has been substituted to Glutamic acid (N3E).
  • In one aspect of the invention, the arginine in the position corresponding to position 2 of human MIC-1 monomer sequence (SEQ ID NO: 1) has been substituted to Glutamic acid (R2E), and the asparagine in the position corresponding to position 3 of human MIC-1 monomer sequence (SEQ ID NO: 1) has been substituted to Serine (N3S).
  • Deletions and Truncations:
  • In one aspect, the MIC-1 analogues of the invention may have one or more amino acid residues deleted from the amino acid sequence of MIC-1 (SEQ ID NO:1), alone or in combination with one or more insertions or substitutions.
  • MIC-1 analogues with amino acid deletions may be described by “des”, reference to the amino acid residue which is deleted, and followed by the number of the deleted amino acid (i.e. the corresponding position in the monomer MIC-1 (SEQ ID NO:1)). In some embodiments of the invention, the asparagine in the position corresponding to position 3 of human monomer MIC-1 (SEQ ID NO:1) is deleted (MIC-1 des-N3, SEQ ID NO:2). In some embodiments of the invention, the alanine in the position corresponding to position 1 of human monomer MIC-1 (SEQ ID NO:1) is deleted (MIC-1, des-A1).
  • MIC-1 analogues with a truncation of one or more amino acid residues at the N or C terminal may be described by “MIC-1-A” and reference to the number(s) of the deleted amino acid residues (i.e. the corresponding position in the monomer MIC-1 (SEQ ID NO: 1)). In some embodiments of the invention, the first three residues (A1, R2, N3) at the N terminal are deleted (MIC-1-A1-3, SEQ ID NO:3).
  • Insertions:
  • In one aspect, the MIC-1 analogues of the invention have one or more amino acid residues inserted into the amino acid sequence of human MIC-1, alone or in combination with one or more deletions and/or substitutions.
  • In one aspect, the MIC-1 analogues of the invention include insertions of one or more unnatural amino acids and/or non-amino acids into the sequence of MIC-1.
  • The term “protein” or “polypeptide”, as e.g. used herein, refers to a compound which comprises a series of amino acids interconnected by amide (or peptide) bonds. Amino acids are molecules containing an amine group and a carboxylic acid group, and, optionally, one or more additional groups, often referred to as a side chain.
  • The term “amino acid” includes coded (or proteinogenic or natural) amino acids (amongst those the 20 standard amino acids), as well as non-coded (or non-proteinogenic or non-natural) amino acids. Coded amino acids are those which are naturally incorporated into proteins. The standard amino acids are those encoded by the genetic code. Non-coded amino acids are either not found in proteins, or not produced by standard cellular machinery (e.g., they may have been subject to post-translational modification). In what follows, all amino acids of the MIC-1 proteins for which the optical isomer is not stated is to be understood to mean the L-isomer (unless otherwise specified).
  • As is apparent from the above, amino acid residues may be identified by their full name, their one-letter code, and/or their three-letter code. These three ways are fully equivalent. For the reader's convenience, the single and three letter amino acid codes are provided below:
  • Glycine: G and Gly; Proline: P and Pro; Alanine: A and Ala; Valine: V and Val; Leucine: L and Leu; Isoleucine: I and Ile; Methionine: M and Met; Cysteine: C and Cys; Phenylalanine: F and Phe; Tyrosine: Y and Tyr; Tryptophan: W and Trp; Histidine: H and His; Lysine: K and Lys; Arginine: R and Arg; Glutamine: Q and Gin; Asparagine: N and Asn; Glutamic Acid: E and Glu; Aspartic Acid: D and Asp; Serine: S and Ser; and Threonine: T and Thr.
    • N-Terminal Amino Acid Extension
  • The MIC-1 compounds of the invention comprise an N-terminal amino acid extension.
  • The term “N-terminal amino acid extension” as used herein, means that the N-terminal of the MIC-1 polypeptide is attached to the C-terminal of the N-terminal amino acid extension via a peptide bond. The terms “N-terminal amino acid extension”, “N-terminal extension”, and “N-extension” herein means the same thing and are used interchangeably. In one embodiment, the compound of the invention comprises human MIC-1 monomer sequence (SEQ ID NO: 1) with an amino acid extension attached at the N-terminal, i.e. the Alanine at positon 1 (A1) via a peptide bond.
  • In some embodiments of the invention, the N-terminal amino acid extension is up to 200 amino acid residues long. In a particular embodiment of the invention the N-terminal amino acid extension has from 3 to 36 amino acid residues.
  • In one aspect of the invention, the N-terminal amino acid extension has a surplus of acidic amino acid residues (Aspartic acid and/or Glutamic acid) of at least 3, 4, 5 or 6 compared to the number of basic amino acid residues (Lysine, Arginine and/or Histidine). A “surplus” of acidic amino acid residues means that the number of acidic residues exceeds the number of basic residues. A defined value of the surplus of acidic amino acid residues is calculated as the number of acidic residues minus the number of basic residues.
  • Methionine is the initial amino acid for protein expression in prokaryotic cells (e.g. bacteria, for instance, E. coli). In some embodiments of the invention, the initial Methionine is removed from the protein during the protein expression. Therefore, the initial Methionine is not included in the sequence of the N-extension of MIC-1 compound. However, a person skilled in the art knows that the start codon, coding the initial Methionine, is required for the protein translation initiation and should be incorporated right in front of the nucleotide sequence for protein expression without exception.
  • Meanwhile, it can be understood that those MIC-1 compounds with N-extensions having the initial Methionine also fall into the scope of the invention.
    • Protractor
  • The MIC-1 compounds of the invention comprise a protractor. The protractor is covalently attached to a specific amino acid residue of the MIC-1 polypeptide or N-terminal amino acid extension.
  • The term “protractor” relates to the properties of conveying extended plasma exposure (“half-life extending moiety”) and is herein understood to refer to a chemical group attached to an amino acid site chain functionalities such as —SH, —OH, —COOH, —CONH2, —NH2 that can increase in vivo circulatory half-life of MIC-1 when conjugated to the MIC-1. Examples of protractors include but are not limited to: fatty acids and derivatives thereof, Hydroxy Alkyl Starch (HAS) e.g. Hydroxy Ethyl Starch (HES), Poly Ethylen Glycol (PEG), Poly (Glyx-Sery)n (HAP), Hyaluronic acid (HA), Heparosan polymers (HEP), Phosphorylcholine-based polymers (PC polymer), Fleximers, Dextran, Poly-sialic acids (PSA), an Fc domain, Transferrin, Albumin, Elastin like peptides, unstructured and repeated amino sequences (e.g. XTEN polymers), Albumin binding peptides, a CTP peptide, and any combination thereof.
  • In some embodiments of the invention, the protractor is capable of forming non-covalent associations with albumin, thereby increasing the blood/plasma exposure time of the MIC-1 compound, and also having the effect of protracting the time of action of the MIC-1 compound, due to the fact that the association of the MIC-1 compound and albumin is only slowly disintegrated to release the active pharmaceutical ingredient.
  • In some embodiments, the fatty acid comprising protractors of the invention are capable of forming non-covalent associations with albumin and thereby prolonging plasma half-life of the MIC-1 compound compared to human wide type MIC-1.
  • In some embodiments of the invention, the protractor is covalently attached to a cysteine residue of the N-terminal amino acid extension of the MIC-1 polypeptide. In an embodiment, the protractor comprises a haloacetamide group, which reacts with the thiol group of a cysteine residue, under formation of a covalent sulfur-carbon bond (this process being referred to as Cys-alkylation) which is also referred to as a thio-ether bond. In another embodiment, the protractor comprises a maleimide group, which reacts with the thiol group of a cysteine residue, under formation of a covalent sulfur-carbon bond.
  • In some embodiments of the invention, the protractor is covalently attached the N-terminal amino acid of the N-terminal amino acid extension.
    • Fatty Acid Comprising Protractor
  • In an aspect of the invention, the protractor comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3, and Chem. 4:
      • wherein Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)x—CO—*,  Chem. 1A:

  • HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

  • HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

  • (1H-tetrazol-5-yl)-(CH2)x—CO—*,  Chem. 1D:
      • wherein x is an integer in the range of 12-20,
      • wherein y is an integer in the range of 5-15;
      • wherein Chem. 2 is selected from the group consisting of:

  • *—NH—CH(COOH)—(CH2)m—CO—*,  Chem. 2A:

  • *—NH—S(═O)2—(CH2)m—CO—*, and  Chem. 2B:

  • *—NH—(CH2)m-cyclohexane-CO—*,  Chem. 2C:
      • wherein m of Chem. 2 is an integer in the range of 1-5;
      • wherein Chem. 3 is

  • *NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*,
      • wherein k of Chem. 3 is an integer in the range of 1-10,
      • n is an integer in the range of 1-5; and
      • wherein Chem. 4 is selected from

  • *—NH—(CH2)m—NH—CO—CH2—*  Chem. 4A:

  • *—NH—CH(COOH)—(CH2)m—NH—CO—CH2—*,  Chem. 4B:

  • *—NH—(CH2)m—CH(COOH)—NH—CO—CH2—*, and  Chem. 4C:
      • Chem. 4D:
  • Figure US20230364248A1-20231116-C00002
      • wherein m of Chem. 4 is an integer in the range of 1-5 and n is an integer in the range of 2-6 or
      • wherein Chem. 4 is selected from the group consisting of Formula I, II or III:
  • Figure US20230364248A1-20231116-C00003
      • wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem.
  • In some embodiments, the protractor of the invention comprises one Chem. 1, one Chem. 4, and one or more of Chem. 2 and Chem. 3. As a non-limiting example, the protractor consists of one Chem. 1 element, two Chem. 2 elements, two Chem. 3 elements, and one Chem. 4 element.
  • The elements Chem. 2 and Chem. 3 both hold a —NH— and CO— end allowing them to be linked by amide bonds to each other and to either —CO— or —NH— of Chem. 1 or Chem. 4. Chem. 4 has a —NH— end (capable of forming an amide bond with Chem. 2 or Chem. 3). Chem. 4 further has either a —NH—CO—CH2— end, which in the unreacted form is a haloacetamide capable of reacting with the thiol group of a cysteine residue, or a (—N*—CO—CH2—CH**—CO)-end, the parenthesis representing a cyclic structure, which in the unreacted form is a maleimide capable of reacting with the thiol group of the cysteine; or an aldehyde capable of reacting with the N-terminal amino group in a reductive alkylation reaction.
  • The length of the carbon chain of Chem.1 defined by x or y may vary from 12-20 for x and 5-15 for y. Shorter or longer versions may be favoured for different types of protractors. In a particular embodiment of Chem. 1A, *—(CH2)x* refers to straight alkylene in which x is an integer in the range of 12-20, such as 14-18 or such as 16.
  • This Chem. 1 may be briefly referred to as C18 diacid, i.e. a fatty di-carboxylic acid with 18 carbon atoms. When x=16 the structure of this linker element corresponds to Chem. 1a: HOOC—(CH2)16—CO—*.
  • In further embodiments Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)16—CO—*,  Chem. 1a:

  • HO—S(═O)2—(CH2)15—CO—*  Chem. 1b:

  • HOOC-benzene-O—(CH2)9—CO—*, and  Chem. 1c:

  • (1H-tetrazol-5-yl)-(CH2)15—CO—*,  Chem. 1d:
  • In further embodiments Chem. 2 is selected from the group consisting of:

  • *—NH—CH(COOH)—(CH2)2—CO—*,  Chem. 2a:

  • *—NH—S(═O)2—(CH2)3—CO—* and  Chem. 2b:

  • *—NH—CH2-cyclohexane-CO—*.  Chem. 2c:
  • In an aspect of the invention, protractor is attached to a Cysteine residue; and the protractor comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
      • wherein Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)x—CO—*,  Chem. 1A:

  • HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

  • HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

  • (1H-tetrazol-5-yl)-(CH2)x—CO—*,  Chem. 1D:
      • wherein x is an integer in the range of 12-20,
      • wherein y is an integer in the range of 5-15;
      • wherein Chem. 2 is selected from the group consisting of:

  • *—(NH—CH(COOH)—(CH2)m—CO)k*,  Chem. 2A:

  • *—(NH—S(═O)2—(CH2)m—CO)k*, and  Chem. 2B:

  • *—(NH—(CH2)m-cyclohexane-CO)k—*,  Chem. 2C:
      • wherein m of Chem. 2 is an integer in the range of 1-5, and
      • k is an integer in the range of 0-4;
      • wherein Chem. 3 is

  • *(NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*)l,
      • wherein k of Chem. 3 is an integer in the range of 1-10,
      • n is an integer in the range of 1-5, and
      • l is an integer in the range of 0-5;
      • wherein Chem. 4 is selected from

  • *—NH—(CH2)m—NH—CO—CH2—*, and  Chem. 4A:

  • *—NH—CH(COOH)—(CH2)m—NH—CO—CH2—*,  Chem. 4B:
      • wherein m of Chem. 4 is an integer in the range of 1-5; and
      • wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem., and wherein the CH2—* end of Chem. 4 is connected to the sulphur atom of the Cysteine residue of the amino acid extension.
  • In an aspect of the invention, the protractor is attached to an N-terminal amino acid, and comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
      • wherein Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)x—CO—*,  Chem. 1A:

  • HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

  • HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

  • (1H-tetrazol-5-yl)-(CH2)x—CO—*  Chem. 1D:
  • wherein x is an integer in the range of 12-20, wherein y is an integer in the range of 5-15;
      • wherein Chem. 2 is selected from the group consisting of:

  • *—(NH—CH(COOH)—(CH2)m—CO)k*,  Chem. 2A:

  • *—(NH—S(═O)2—(CH2)m—CO)k*, and  Chem. 2B:

  • *—(NH—(CH2)m-cyclohexane-CO)k—*,  Chem. 2C:
      • wherein m of Chem. 2 is an integer in the range of 1-5, and
      • k is an integer in the range of 0-4;
      • wherein Chem. 3 is

  • *(NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*)l,
      • wherein k of Chem. 3 is an integer in the range of 1-10,
      • n is an integer in the range of 1-5, and
      • l is an integer in the range of 0-5;
      • wherein Chem. 4 is selected from the group consisting of Formula I, II or III:
  • Figure US20230364248A1-20231116-C00004
      • wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem., and wherein the CH2—* end of Chem. 4 is connected to the alpha-amino group of the N-terminal of the amino acid extension.
  • The nomenclature is as is usual in the art, for example in the above formulas *—CO—* refers to carbonyl (*—C(═O)—*). Benzene refers to the ring structure which in Chem. 1C is substituted at C1 and C3 or C4 by —O—(CH2)x—* and —COOH, respectively. HO—S(═O)2—* describes a sulfonic acid group.
  • The compounds/protractors of the invention may exist in different stereo-isomeric forms having the same molecular formula and sequence of bonded atoms, but differing only in the three-dimensional orientation of their atoms in space. The stereoisomerism of the exemplified compounds/protractors of the invention is indicated in the experimental section, in the names as well as the structures, using standard nomenclature. Unless otherwise stated the invention relates to all stereoisomeric forms of the claimed compounds/protractors.
    • Isoelectric Point (pI)
  • The calculated pI of the MIC-1 polypeptide with an N-terminal amino acid extension is defined as the pH at which the net calculated charge of the MIC-1 polypeptide with the N-extension is zero. The calculated charge of the MIC-1 polypeptide with the N-extension as a function of pH is obtained using the pKa values of the amino acid residues described in Table 1 and the method described by B. Skoog and A. Wichman (Trends in Analytical Chemistry, 1986, vol. 5, pp. 82-83). The side chain pKa of cysteine (Cys) is only included in the charge calculation for cysteines with a free sulfhydryl group. As an example the calculated pI value of human wild type MIC-1 as the homodimer is 8.8.
  • As described herein, pI calculations on MIC-1 polypeptides with N-extensions are made on homodimers.
  • TABLE 1
    pKa of amino acid residues used for calculating pI. The pKa values
    are those described in “Correlation of Electrophoretic Mobilities
    from Capillary Electrophoresis with Physicochemical Properties
    of Proteins and Peptides by Rickard EC, Strohl MM, Nielsen RG.
    Analytical Biochemistry 1991, vol 197, pp 197-207”.
    N-terminus C-Terminus Side chain
    Asp 8.6 2.75  3.5
    Asn 7.3 2.75 —
    Thr 8.2 3.2 —
    Ser 7.3 3.2 —
    Glu 8.2 3.2  4.5
    Gln 7.7 3.2 —
    Pro 9 3.2 —
    Gly 8.2 3.2 —
    Ala 8.2 3.2 —
    Val 8.2 3.2 —
    Cys 7.3 2.75 10.3
    Met 9.2 3.2 —
    Ile 8.2 3.2 —
    Leu 8.2 3.2 —
    Tyr 7.7 3.2 10.3
    Phe 7.7 3.2 —
    Lys 7.7 3.2 10.3
    His 8.2 3.2  6.2
    Trp 8.2 3.2 —
    Arg 8.2 3.2 12.5
    • Functional Properties
  • In one aspect, the MIC-1 compounds of the invention have good biophysical properties.
  • The MIC-1 compounds of the invention are biologically active. For example they are potent, binds to and activate the MIC-1 receptor complex. Also MIC-1 compounds exhibit protracted plasma exposure defined as longer half-life. For example MIC-1 compounds have a markedly longer plasma half-life when administered i.v. to rat and/or mini pigs compared to MIC-1 (SEQ ID 1). The particular combination of retained receptor potency and long plasma half-life may be highly desirable.
    • In Vitro Activity
  • In one aspect, the compounds of the invention have retained MIC-1 receptor potency relative to human MIC-1 (SEQ ID NO:1). Receptor potency and efficacy can be measured in mammalian cells transfected with human MIC-1 receptor (hGFRAL, GDNF family receptor alpha like) and its signalling co-receptor hRET (proto-oncogene tyrosine-protein kinase receptor Ret). MIC-1 compounds activation of the receptor complex is measured by phosphorylation of extracellular signal-regulated kinases (ERKs) as described in Example 6.
  • As described herein receptor potency and efficacy is measured on MIC-1 compounds as homodimers.
    • In Vivo Biological Activity
  • In one aspect the compounds of the invention are potent in vivo, which may be determined as is known in the art in any suitable animal model.
  • The non-obese Sprague Dawley rat is one example of a suitable animal model, and the changes in food intake may be determined in such rats in vivo, e.g. as described in Example 14. In one aspect the compounds of the invention inhibits in vivo food intake in non-obese Sprague Dawley rats.
    • In Vivo Plasma Half-Life
  • In one aspect the MIC-1 compounds of the invention are protracted and have an extended in vivo plasma half-life, which can be determined in a suitable pharmacokinetic in vivo study.
  • Extended plasma exposure may be determined as plasma half-life (T½) after i.v. administration to animals such as rats or mini pigs.
  • In some embodiments, the MIC-1 compounds of the invention have a plasma half-life after i.v. administration to rat of at least 10 hour, more preferably between 25-50 hours, or most preferably at least 50 hours, determined as described in Example 16.
  • In some embodiments, the MIC-1 compounds of the invention have a plasma half-life after i.v. administration to mini pigs of at least 50 hours, more preferably between 50-200 hours, even more preferably at least 200 hours or most preferably at least 300 hours, determined as described in Example 17.
  • According to a third aspect, the compounds of the invention are protracted and at the same time retain in vivo potency. The particular combination of retained potency and long plasma half-life may be highly desirable.
    • Solubility
  • The human wild type MIC-1 is a hydrophobic protein, with a calculated pI 8.8 based on the homodimer. Consequently, wild type MIC-1 can only be solubilized to around 0.5 mg/ml in neutral pH aqueous buffer systems. The low solubility of MIC-1 significantly hampers its pharmaceutical formulation properties and therapeutic use, so developing a MIC-1 compound with improved solubility would greatly improve the therapeutic utility.
  • In one aspect, the MIC-1 polypeptides with an N-extension of the invention have improved solubility (i.e. are more soluble) relative to human MIC-1 of SEQ ID NO:1.
  • As described herein, solubility is measured as described in Example 4.
  • In certain embodiments, the MIC-1 polypeptides with an N-extension of the invention have a solubility of at least 1 mg/ml in Tris buffer at pH 8.0. In other embodiments, the MIC-1 polypeptides with an N-extension of the invention have a solubility of at least 5 mg/ml, at least 10 mg/ml, at least 30 mg/ml, or at least 40 mg/ml in Tris buffer at pH 8.0.
  • Adding a protractor to make a MIC-1 compound do not markedly alter the improved solubility of measured for the corresponding MIC-1 polypeptides with an N-extension (Example 12).
  • As described herein, solubility is measured on MIC-1 compounds and MIC-1 polypeptides with an N-extension as homodimers.
    • Stability
  • The human wild type MIC-1 sequence is chemically unstable and several residues of the amino acid sequence could be modified during storage, including deamidation on Asparagine at position 3 (N3) and oxidation of methionines M43, M57 and M86. Chemical instability of certain residues could impact pharmaceutical properties so developing chemical stable MIC-1 compounds would be another important part of making a MIC-1 therapeutic compound.
  • In one aspect, the compounds of the invention have improved chemical stability relative to human MIC-1 of SEQ ID NO:1.
  • The term “chemical stability” refers to chemical changes in the polypeptide structure leading to formation of chemical degradation products potentially having a reduced biological activity, decreased solubility, and/or increased immunogenic effect as compared to the intact polypeptide. The chemical stability can be evaluated by measuring the amount of chemical degradation products at various time-points after exposure to different environmental conditions, e.g. by SEC-HPLC, and/or RP-HPLC.
  • In some embodiments of the invention, certain residues of the MIC-1 monomer sequence (SEQ ID NO:1) is modified, e.g. by substitution to increase the chemical stability of the MIC-1 compounds. To avoid deamidation, N3 is deleted or substituted with other amino acids, e.g. E or Q. To decrease oxidation, Methionine is substituted with other amino acids, e.g. E or L.
    • Immunogenicity
  • In one aspect, the MIC-1 compounds of the invention have low immunogenicity risk.
    • Production Processes
  • MIC-1 polypeptides with an N-terminal amino acid extension of the present invention may be produced by means of recombinant protein technology known to persons skilled in the art. In general, nucleic acid sequences encoding the proteins of interest or functional variants thereof are modified to encode the desired MIC-1 polypeptide with an N-extension. This modified sequence is then inserted into an expression vector, which is in turn transformed or transfected into the expression host cells.
  • The nucleic acid construct encoding the MIC-1 polypeptide with an N-extension may suitably be of genomic, cDNA or synthetic origin. Amino acid sequence alterations are accomplished by modification of the genetic code by well-known techniques.
  • The DNA sequence encoding the MIC-1 polypeptide with an N-extension is usually inserted into a recombinant vector which may be any vector, which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector, which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • The vector is preferably an expression vector in which the DNA sequence encoding the MIC-1 polypeptide with an N-extension is operably linked to additional segments required for transcription of the DNA. The term, “operably linked” indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence coding for the polypeptide until it terminates within a terminator.
  • Thus, expression vectors for use in expressing the MIC-1 polypeptide with an N-extension will comprise a promoter capable of initiating and directing the transcription of a cloned gene or cDNA. The promoter may be any DNA sequence, which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • Additionally, expression vectors for expression of the MIC-1 polypeptide with an N-extension will also comprise a terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3′ terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
  • Expression of the MIC-1 polypeptide with an N-extension can be aimed for either intracellular expression in the cytosol of the host cell or be directed into the secretory pathway for extracellular expression into the growth medium.
  • Intracellular expression is the default pathway and requires an expression vector with a DNA sequence comprising a promoter followed by the DNA sequence encoding the MIC-1 polypeptide with an N-extension followed by a terminator.
  • To direct the sequence of the MIC-1 polypeptide with an N-extension into the secretory pathway of the host cells, a secretory signal sequence (also known as signal peptide or a pre sequence) is needed as an extension of the MIC-1 sequence. A DNA sequence encoding the signal peptide is joined to the 5′ end of the DNA sequence encoding the MIC-1 polypeptide with an N-extension in the correct reading frame. The signal peptide may be that normally associated with the protein or may be from a gene encoding another secreted protein.
  • The procedures used to ligate the DNA sequences coding for the MIC-1 polypeptide with an N-extension, the promoter, the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989).
  • The host cell into which the DNA sequence encoding the MIC-1 polypeptide with an N-extension is introduced may be any cell that is capable of expressing the MIC-1 polypeptide with an N-extension either intracellularly or extracellularly. The MIC-1 polypeptide with an N-extension may be produced by culturing a host cell containing a DNA sequence encoding the MIC-1 polypeptide with an N-extension and capable of expressing the MIC-1 polypeptide with an N-extension in a suitable nutrient medium under conditions permitting the expression of the MIC-1 polypeptide with an N-extension. Non-limiting examples of host cells suitable for expression of MIC-1 polypeptide with N-extension are: Escherichia coli, Saccharomyces cerevisiae, as well as human embryonic kidney (HEK), Baby Hamster Kidney (BHK) or Chinese hamster ovary (CHO) cell lines. If posttranslational modifications are needed, suitable host cells include yeast, fungi, insects and higher eukaryotic cells such as mammalian cells.
  • Once the MIC-1 polypeptide with an N-extension has been expressed in a host organism it may be recovered and purified to the required quality by conventional techniques. Non-limiting examples of such conventional recovery and purification techniques are centrifugation, solubilization, filtration, precipitation, ion-exchange chromatography, immobilized metal affinity chromatography (IMAC), Reversed phase—High Performance Liquid Chromatography (RP-HPLC), gel-filtration and freeze drying.
  • Examples of recombinant expression and purification of MIC-1 proteins may be found in e.g. Cordingley et al., J. Virol. 1989, 63, pp 5037-5045; Birch et al., Protein Expr Purif., 1995, 6, pp 609-618 and in WO2008/043847.
  • Examples of microbial expression and purification of MIC-1 proteins may be found in e.g. Chich et al, Anal. Biochem, 1995, 224, pp 245-249 and Xin et al., Protein Expr. Purif. 2002, 24, pp 530-538.
  • Specific examples of methods of preparing a number of the MIC-1 polypeptides with an N-extension of the invention are included in the experimental part.
    • Inclusion Body and Protein Expression
  • MIC-1 polypeptides with an N-terminal amino acid extension can be expressed in bacteria such as E. coli. In the context of the present invention, large scale protein production of the MIC-1 polypeptides with an N-extension could take of using Inclusion Bodies (IB) as this represent an advantageous approach to controlling process recovery, protein purity, protease degradation and general protein stability. This becomes particular important for large scale protein production. Of critical importance for the quality of IB is the balance of MIC-1 polypeptides with an N-extension solubility partly controlled by the calculated pI and IB formation.
    • Mode of Administration
  • The route of administration may be any route which effectively transports a compound of this invention to the desired or appropriate place in the body, such as parenterally, for example, subcutaneously, intramuscularly or intraveneously. Alternatively, a compound of this invention can be administered orally, pulmonary, rectally, transdermally, buccally, sublingually, or nasally.
  • The amount of a compound of this invention to be administered, the determination of how frequently to administer a compound of this invention, and the election of which compound or compounds of this invention to administer, optionally together with another pharmaceutically active agent, is decided in consultation with a practitioner who is familiar with the treatment of obesity and related disorders.
    • Pharmaceutical Compositions
  • Pharmaceutical compositions comprising a compound of the invention or a pharmaceutically acceptable salt, amide, or ester thereof, and a pharmaceutically acceptable excipient may be prepared as is known in the art.
  • The term “excipient” broadly refers to any component other than the active therapeutic ingredient(s). The excipient may be an inert substance, an inactive substance, and/or a not medicinally active substance.
  • The excipient may serve various purposes, e.g. as a carrier, vehicle, diluent, tablet aid, and/or to improve administration, and/or absorption of the active substance.
  • The formulation of pharmaceutically active ingredients with various excipients is known in the art, see e.g. Remington: The Science and Practice of Pharmacy (e.g. 19th edition (1995), and any later editions).
    • Combination Treatment
  • The treatment with a compound according to the present invention may also be combined with one or more pharmacologically active substances, e.g., selected from antiobesity agents, appetite regulating agents, and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
    • Pharmaceutical Indications
  • In one aspect, the present invention relates to a compound of the invention, for use as a medicament.
  • In particular embodiments, the compound of the invention may be used for the following medical treatments:
      • (i) Prevention and/or treatment of eating disorders, such as obesity, e.g. by decreasing food intake, reducing body weight, suppressing appetite and/or inducing satiety.
      • (ii) Prevention and/or treatment of hyperglycemia, insulin resistance and/or impaired glucose tolerance.
      • (iii) Prevention and/or treatment of dyslipidaemia.
  • In some embodiments the invention relates to a method for weight management. In some embodiments the invention relates to a method for reduction of appetite. In some embodiments the invention relates to a method for reduction of food intake.
  • Generally, all subjects suffering from obesity are also considered to be suffering from overweight. In some embodiments the invention relates to a method for treatment or prevention of obesity. In some embodiments the invention relates to use of the MIC-1 compounds of the invention for treatment or prevention of obesity. In some embodiments the subject suffering from obesity is human, such as an adult human or a paediatric human (including infants, children, and adolescents). Body mass index (BMI) is a measure of body fat based on height and weight. The formula for calculation is BMI=weight in kilograms/height in meters2. A human subject suffering from obesity has a BMI of ≥30; this subject may also be referred to as obese. In some embodiments the human subject suffering from obesity has a BMI of ≥35 or a BMI in the range of ≥30 to <40. In some embodiments the obesity is severe obesity or morbid obesity, wherein the human subject has a BMI of ≥40.
  • In some embodiments the invention relates to a method for treatment or prevention of overweight, optionally in the presence of at least one weight-related comorbidity. In some embodiments the invention relates to use of the MIC-1 compounds of the invention for treatment or prevention of overweight, optionally in the presence of at least one weight-related comorbidity.
  • In some embodiments the subject suffering from overweight is human, such as an adult human or a paediatric human (including infants, children, and adolescents). In some embodiments a human subject suffering from overweight has a BMI of ≥25, such as a BMI of ≥27. In some embodiments a human subject suffering from overweight has a BMI in the range of 25 to <30 or in the range of 27 to <30. In some embodiments the weight-related comorbidity is selected from the group consisting of hypertension, diabetes (such as type 2 diabetes), dyslipidaemia, high cholesterol, and obstructive sleep apnoea.
  • In some embodiments the invention relates to a method for reduction of body weight. In some embodiments the invention relates to use of the MIC-1 compounds of the invention for reduction of body weight. A human to be subjected to reduction of body weight according to the present invention has a BMI of ≥25, such as a BMI of ≥27 or a BMI of ≥30. In some embodiments the human to be subjected to reduction of body weight according to the present invention has a BMI of ≥35 or a BMI of ≥40.
  • In some embodiments the invention relates to a method for treatment or prevention of cardiovascular diseases like arteriosclerosis and other disorders such as steatohepatitis, and diabetic nephropathy.
  • The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “a MIC-1 polypeptide” means one MIC-1 polypeptide or more than one MIC-1 polypeptide.
  • An asterisk (*) in a chemical formula designates a point of attachment.
    • PARTICULAR EMBODIMENTS
  • The invention is further described by the following non-limiting embodiments of the invention:
      • 1. A MIC-1 compound comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor, wherein the protractor is attached to the amino acid extension.
      • 2. The MIC-1 compound according to embodiment 1, wherein the compound is a homodimer.
      • 3. The MIC-1 compound according to embodiments 1 or 2, wherein the N-terminal amino acid extension comprises a cysteine residue, and wherein the protractor is attached to the amino acid extension at the Cysteine residue.
      • 4. The MIC-1 compound according to embodiment 3, wherein the protractor comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4; wherein Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)x—CO—*,  Chem. 1A:

  • HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

  • HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

  • (1H-tetrazol-5-yl)-(CH2)x—CO—*,  Chem. 1D:
      • wherein x is an integer in the range of 12-20,
      • wherein y is an integer in the range of 5-15;
      • wherein Chem. 2 is selected from the group consisting of:

  • *—(NH—CH(COOH)—(CH2)m—CO)k*,  Chem. 2A:

  • *—(NH—S(═O)2—(CH2)m—CO)k*, and  Chem. 2B:

  • *—(NH—(CH2)m-cyclohexane-CO)k—*,  Chem. 2C:
      • wherein m of Chem. 2 is an integer in the range of 1-5, and
      • k is an integer in the range of 0-4;
      • wherein Chem. 3 is

  • *(NH—(CH2)2—[O—(CH2)2]—O—[CH2]—CO—*)l,
      • wherein k of Chem. 3 is an integer in the range of 1-10,
      • n is an integer in the range of 1-5, and
      • l is an integer in the range of 0-5;
      • wherein Chem. 4 is selected from

  • *—NH—(CH2)m—NH—CO—CH2—*, and  Chem. 4A:

  • *—NH—CH(COOH)—(CH2)m—NH—CO—CH2—*,  Chem. 4B:

  • *—NH—(CH2)m—CH(COOH)—NH—CO—CH2—*, and  Chem. 4C:
      • Chem. 4D:
  • Figure US20230364248A1-20231116-C00005
      • wherein m of Chem. 4 is an integer in the range of 1-5 and n is an integer in the range of 2-6; and
      • wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem., and wherein the CH2—* end of Chem. 4 is connected to a sulfur atom of the Cysteine residue of the amino acid extension.
      • 5. The MIC-1 compound according to embodiments 1 or 2, and wherein the protractor is attached to the N-terminal amino acid of the amino acid extension.
      • 6. The MIC-1 compound according to embodiment 5, wherein the protractor comprises, or consists of, at least one of each of Chem. 1, Chem. 2, Chem. 3 and Chem. 4; wherein Chem. 1 is selected from the group consisting of:

  • HOOC—(CH2)x—CO—*,  Chem. 1A:

  • HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

  • HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

  • (1H-tetrazol-5-yl)-(CH2)x—CO—*  Chem. 1D:
      • wherein x is an integer in the range of 12-20,
      • wherein y is an integer in the range of 5-15;
      • wherein Chem. 2 is selected from the group consisting of:

  • *—(NH—CH(COOH)—(CH2)m—CO)k*,  Chem. 2A:

  • *—(NH—S(═O)2—(CH2)m—CO)k*, and  Chem. 2B:

  • *—(NH—(CH2)m-cyclohexane-CO)k—*,  Chem. 2C:
      • wherein m of Chem. 2 is an integer in the range of 1-5, and
      • k is an integer in the range of 0-4;
      • wherein Chem. 3 is

  • *(NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*)|,
      • wherein k of Chem. 3 is an integer in the range of 1-10,
      • n is an integer in the range of 1-5, and
      • l is an integer in the range of 0-5;
      • wherein Chem. 4 is selected from the group consisting of Formula I, II or III:
  • Figure US20230364248A1-20231116-C00006
      • wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem., and wherein the CH2—* end of Chem. 4 is connected to amino group of the N-terminal of the amino acid extension.
      • 7. The MIC-1 compound according to any one of embodiments 4 and 6, wherein Chem. 1 is selected from the group consisting of: Chem. la: HOOC—(CH2)16—CO—*,

  • HO—S(═O)2—(CH2)15—CO—*  Chem. 1b:

  • HOOC-benzene-O—(CH2)9—CO—*, and  Chem. 1c:

  • (1H-tetrazol-5-yl)-(CH2)15—CO—*.  Chem. 1d:
      • 8. The MIC-1 compound according to any one of embodiments 4, 6 and 7 wherein Chem.
      • 2 is selected from the group consisting of:

  • *—NH—CH(COOH)—(CH2)2—CO—*,  Chem. 2a:

  • *—NH—S(═O)2—(CH2)3—CO—* and  Chem. 2b:

  • *—NH—CH2-cyclohexane-CO—*.  Chem. 2c:
      • 9. The MIC-1 compound according to any one of embodiments 4, 6 and 7, wherein Chem. 2-Chem. 3 is the following Formula IV:
  • Figure US20230364248A1-20231116-C00007
      • where n is of 0-3 and m is 0-3
      • 10. The MIC-1 compound according to any one of embodiments 4 and 7-9, wherein Chem. 4 is selected from the group consisting of:

  • *—NH—(CH2)2—NH—CO—CH2—* and  Chem. 4a:

  • *—NH—CH(COOH)—(CH2)4—NH—CO—CH2—*.  Chem. 4b:
      • 11. The MIC-1 compound according to any one of embodiments 4 and 7-9, wherein Chem. 4 is selected from the group consisting of Formula V, VI or VII:
  • Figure US20230364248A1-20231116-C00008
      • where n is 1-4.
      • 12. The MIC-1 compound according to any one of embodiments 4 and 7-9, wherein Chem. 4 is the following Formula VIII:
  • Figure US20230364248A1-20231116-C00009
      • where p is 1-5, and q is 1-5.
      • 13. The MIC-1 compound according to any one of embodiments 1-3 and 5, wherein the protractor is selected from the group consisting of Formula IX, Formula X, Formula XI, Formula XII and Formula XIII:
  • Figure US20230364248A1-20231116-C00010
      • 14. The MIC-1 compound according to any one of embodiments 1-3 and 5, wherein the protractor is selected from the group consisting of: Biocompatible fatty acids and derivatives thereof, Hydroxy Alkyl Starch (HAS) e.g. Hydroxy Ethyl Starch (HES), Poly Ethylen Glycol (PEG), Poly (Glyx-Sery)n (HAP), Hyaluronic acid (HA), Heparosan polymers (HEP), Phosphorylcholine-based polymers (PC polymer), Fleximers, Dextran, Poly-sialic acids (PSA), an Fc domain, Transferrin, Albumin, Elastin like peptides, XTEN polymers, Albumin binding peptides, a CTP peptide, and any combination thereof.
      • 15. The MIC-1 compound according to any one of the preceding embodiments, wherein the MIC-1 polypeptide with the amino acid extension has a calculated pI lower than 6.5.
      • 16. The MIC-1 compound according to embodiment 15, wherein the calculated pI is lower than 6.1.
      • 17. The MIC-1 compound according to embodiment 15, wherein the calculated pI is lower than 6.0.
      • 18. The MIC-1 compound according to embodiment 15, wherein the calculated pI is lower than 6.4, 6.3, 6.2, 6.1, 6.0, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, or 5.2, 5.1, or 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1 or 4.0.
      • 19. The MIC-1 compound according to embodiment 15, wherein the calculated pI is higher than 4.7.
      • 20. The MIC-1 compound according to embodiment 15, wherein the calculated pI is higher than 4.8.
      • 21. The MIC-1 compound according to embodiment 15, wherein the calculated pI is higher than 4.9.
      • 22. The MIC-1 compound according to embodiment 15, wherein the calculated pI is higher than 5.0.
      • 23. The MIC-1 compound according to embodiment 15, wherein the calculated pI is higher than 5.1.
      • 24. The MIC-1 compound according to embodiment 15, wherein the calculated pI is in the range of 6.5-3.0, 6.5-3.5, 6.5-4.0, 6.1-3.0, 6.1-3.5, 6.1-4.0, 6.1-4.7, 6.1-4.9, 6.1-5.0, 6.1-5.1, 6.0-3.0, 6.0-3.5, 6.0-4.0, 5.9-3.0, 5.9-3.5, 5.9-4.0, 5.9-5.0, 5.9-5.1, 5.8-3.0, 5.8-3.5, 5.8-4.0, 5.8-5.1, 5.8-5.2, 5.5-3.0, 5.5-3.5, 5.5-4.0, or 5.0-4.0.
      • 25. The MIC-1 compound according embodiment 15, wherein the calculated pI is in the range of 5.8-5.2.
      • 26. The MIC-1 compound according to any of the preceding embodiments, wherein the amino acid extension comprises 3 to 200 amino acid residues.
      • 27. The MIC-1 compound according to any of the preceding embodiments, wherein the amino acid extension is in the range of 3-100, 3-50, 3-40, 3-30, 5-100, 5-50, 5-40, 5-30, 10-100, 10-50, 10-40, 10-30, 3-36, 3-30, 3-25, 3-24, 3-12, 4-36, 4-30, 4-24, 4-12, 5-36, 5-30, 5-24, 5-12, 6-36, 6-30, 6-24, 6-12, 7-36, 7-30, 7-24, 7-12, 8-36, 8-30, 8-24, 8-12, 30-36, 32-36, 30-34, or 30-32 amino acid residues in length.
      • 28. The MIC-1 compound according to any of the preceding embodiments, wherein the amino acid extension is in the range of 3-36 or 30-32 amino acid residues in length.
      • 29. The MIC-1 compound according to any of the preceding embodiments, wherein the amino acid extension has a surplus of acidic amino acid residues (Aspartic acid or Glutamic acid) of at least 3, 4, 5, 6, 7, 8, 9 or 10 compared to the number of basic amino acid residues (Lysine, Arginine or Histidine).
      • 30. The MIC-1 compound according to any of the preceding embodiments, wherein the amino acid extension comprise at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70% or 75% surplus of acidic amino acid residues (Aspartic acid or Glutamic acid) compared to number of basic amino acid residues (Lysine or Arginine or Histidine).
      • 31. The MIC-1 compound according to embodiment 30, wherein the amino acid extension comprise at least 10% acidic amino acid residues.
      • 32. The MIC-1 compound according to embodiment 30, wherein the amino acid extension comprise at least 15% acidic amino acid residues.
      • 33. The MIC-1 compound according to embodiment 11, wherein the amino acid extension comprise at least 25% acidic amino acid residues.
      • 34. The MIC-1 compound according to any one of embodiments 1-33, wherein the amino acid extension is composed of amino acid residues selected among the group consisting of A, C, E, G, P, S, T, Q, N and D and wherein the amino acid extension comprises at least three E and/or D amino acid residues.
      • 35. The MIC-1 compound according to embodiment 34, wherein the amino acid extension is composed of amino acid residues A, C, E, G, P, S and T.
      • 36. The MIC-1 compound according to embodiment 35, wherein the amino acid extension comprises at least three E and at least one P.
      • 37. The MIC-1 compound according to embodiment 36, wherein the amino acid extension comprises at least 6 Ser, 4 Pro, 4 Gly, 4 Thr, 4 Glu and 2 Ala.
      • 38. The MIC-1 compound according to embodiment 37, wherein the amino acid extension comprises two of sequences selected from the group consisting of SPAGSPTSTEEG (SEQ ID NO: 166), TSESATPESGPG (SEQ ID NO: 167), TSTEPSEGSAPG (SEQ ID NO: 168) and SEPATSGSETPG (SEQ ID NO: 169), and wherein one of the amino acid of the amino acid extension is replaced with Cysteine.
      • 39. The MIC-1 compound according to embodiment 38, wherein the amino acid extension further comprises 6-8 consecutive amino acids of SPAGSPTSTEEG (SEQ ID NO: 166), TSESATPESGPG (SEQ ID NO: 167), TSTEPSEGSAPG (SEQ ID NO: 168) or SEPATSGSETPG(SEQ ID NO: 169), such as the first 6-8 amino acid residues, the last 6-8 residues or the internal 6-8 residues, and wherein one of the amino acid of the amino acid extension is replaced with Cysteine.
      • 40. The MIC-1 compound according to any one of embodiments 3-39, wherein Cysteine locates in any position of the N-terminal amino acid extension.
      • 41. The MIC-1 compound according to embodiment 40, wherein the distance between the Cysteine residue of the N-terminal extension and the N-terminal amino acid of the MIC-1 polypeptide is at least 1, 3, 5, 10, 15, 19, 23, 26, 29, or 32 amino acids (including Cysteine residue of the N-terminal extension, but not including N-terminal amino acid of MIC-1 polypeptide).
      • 42. The MIC-1 compound according to embodiment 40, wherein the distance between Cysteine residue of the N-terminal extension and the N-terminal amino acid of the MIC-1 polypeptide is at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32 amino acids (including Cysteine residue of the N-terminal extension, but not including N-terminal amino acid of MIC-1 polypeptide).
      • 43. The MIC-1 compound according to embodiment 42, wherein the distance between Cysteine residue of the N-terminal extension and the N-terminal amino acid of the MIC-1 polypeptide is 26-29 amino acids (including Cysteine residue of the N-terminal extension, but not including N-terminal amino acid of MIC-1 polypeptide).
      • 44. The MIC-1 compound according to any one of the preceding embodiments, wherein the amino acid extension starts with S.
      • 45. The MIC-1 compound according to any one of the preceding embodiments, wherein the amino acid extension starts with SE.
      • 46. The MIC-1 compound according to any one of the preceding embodiments, wherein the amino acid extension starts with SEP.
      • 47. The MIC-1 compound according to any one of the preceding embodiments, wherein the amino acid extension comprises one or more of the following sequences
  • (SEQ ID NO: 223)
    SEPATCGSETPGTSESATPESGPGTSTEPS,
    (SEQ ID NO: 224)
    SEPATSGCETPGTSESATPESGPGTSTEPS,
    (SEQ ID NO: 225)
    SEPCTSGSETPGTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 240)
    SEPCTSGSETPGTSESATPESGPGTSTEPS,
    (SEQ ID NO: 241)
    SEPCTSGSETPGTSESATPESGPGTSTE,
    (SEQ ID NO: 242)
    SEPCTSGSETPGTSESATPESGPG,
    (SEQ ID NO: 243)
    SEPCTSGSETPGTSESATPES,
    (SEQ ID NO: 244)
    SEPCTSGSETPG,
    (SEQ ID NO: 245)
    SEPCTSGSETPGSPAGSPTSTEEGSPAGSP,
    (SEQ ID NO: 246)
    SEPCTSGSETPGTSESATPESGPGSPAGSP,
    (SEQ ID NO: 247)
    SEPCTSGSETPGTSTEPESGSAPGSPAGSP,
    (SEQ ID NO: 248)
    SEPCTSGSETPGSPAGSPTSTEEGTSESAT,
    (SEQ ID NO: 249)
    SEPCTSGSETPGTSESATPESGPGTSESAT,
    (SEQ ID NO: 250)
    SEPCTSGSETPGTSTEPESGSAPGTSESAT,
    (SEQ ID NO: 251)
    SEPCTSGSETPGSPAGSPTSTEEGTSTEPE,
    (SEQ ID NO: 252)
    SEPCTSGSETPGTSESATPESGPGTSTEPE,
    (SEQ ID NO: 253)
    SEPCTSGSETPGTSTEPESGSAPGTSTEPE,
    (SEQ ID NO: 254)
    SEPCTSGSETPGSPAGSPTSTEEGSEPATS,
    (SEQ ID NO: 255)
    SEPCTSGSETPGTSESATPESGPGSEPATS,
    (SEQ ID NO: 256)
    SEPCTSGSETPGTSTEPESGSAPGSEPATS,
    (SEQ ID NO: 257)
    SEPCTSGSETPGSPAGSPTSTEEGTSTEEG,
    (SEQ ID NO: 258)
    SEPCTSGSETPGTSESATPESGPGTSTEEG,
    (SEQ ID NO: 259)
    SEPCTSGSETPGTSTEPESGSAPGTSTEEG,
    (SEQ ID NO: 260)
    SEPCTSGSETPGSPAGSPTSTEEGPESGPG,
    (SEQ ID NO: 261)
    SEPCTSGSETPGTSESATPESGPGPESGPG,
    (SEQ ID NO: 262)
    SEPCTSGSETPGTSTEPESGSAPGPESGPG,
    (SEQ ID NO: 263)
    SEPCTSGSETPGSPAGSPTSTEEGSGSAPG,
    (SEQ ID NO: 264)
    SEPCTSGSETPGTSESATPESGPGSGSAPG,
    (SEQ ID NO: 265)
    SEPCTSGSETPGTSTEPESGSAPGSGSAPG,
    (SEQ ID NO: 266)
    SEPCTSGSETPGSPAGSPTSTEEGGSETPG,
    (SEQ ID NO: 267)
    SEPCTSGSETPGTSESATPESGPGGSETPG,
    (SEQ ID NO: 268)
    SEPCTSGSETPGTSTEPESGSAPGGSETPG,
    (SEQ ID NO: 269)
    SEPCTSGSETPGSPAGSPTSTEEGTSESATPESGPG,
    (SEQ ID NO: 270)
    SEPCTSGSETPGSPAGSPTSTEEGSPAGSPTSTEEG,
    (SEQ ID NO: 271)
    SEPCTSGSETPGSPAGSPTSTEEGTSTEPESGSAPG,
    (SEQ ID NO: 272)
    SEPCTSGSETPGTSESATPESGPGSPAGSPTSTEEG,
    (SEQ ID NO: 273)
    SEPCTSGSETPGTSESATPESGPGTSESATPESGPG,
    (SEQ ID NO: 274)
    SEPCTSGSETPGTSESATPESGPGTSTEPESGSAPG,
    (SEQ ID NO: 275)
    SEPCTSGSETPGTSESATPESGPGSEPATSGSETPG,
    (SEQ ID NO: 276)
    SEPCTSGSETPGTSTEPESGSAPGSPAGSPTSTEEG,
    (SEQ ID NO: 277)
    SEPCTSGSETPGTSTEPESGSAPGTSESATPESGPG,
    (SEQ ID NO: 278)
    SEPCTSGSETPGTSTEPESGSAPGTSTEPESGSAPG,
    (SEQ ID NO: 279)
    SEPCTSGSETPGTSTEPESGSAPGSEPATSGSETPG,
    (SEQ ID NO: 280)
    SEPCTSGSETPGSEPATSGSETPGSPAGSPTSTEEG,
    (SEQ ID NO: 281)
    SEPCTSGSETPGSEPATSGSETPGTSESATPESGPG,
    (SEQ ID NO: 282)
    SEPCTSGSETPGSEPATSGSETPGTSTEPESGSAPG,
    (SEQ ID NO: 283)
    SEPCTSGSETPGSEPATSGSETPGSEPATSGSETPG,
    (SEQ ID NO: 284)
    GPCEGPSEGPSEGPSEGPSEGPSEGPSE,
    (SEQ ID NO: 285)
    GECPGEQPGEQPGEQPGEQPGEQPGEQP,
    (SEQ ID NO: 286)
    PACEEEDDPDGGGSGGGSGGGS,
    (SEQ ID NO: 287)
    PDECTEEETEGGGSGGGSGGGS,
    (SEQ ID NO: 226)
    SEPATCGSETPGTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 227)
    SEPATSCSETPGTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 229)
    SEPACSGSETPGTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 230)
    SEPATSGCETPGTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 231)
    SEPATSGSECPGTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 232)
    SEPATSGSETPCTSESATPESGPGTSTEPSEG,
    (SEQ ID NO: 233)
    SEPATSGSETPGTCESATPESGPGTSTEPSEG,
    (SEQ ID NO: 234)
    SEPATSGSETPGTSECATPESGPGTSTEPSEG,
    (SEQ ID NO: 235)
    SEPATSGSETPGTSESACPESGPGTSTEPSEG,
    (SEQ ID NO: 236)
    SEPATSGSETPGTSESATPECGPGTSTEPSEG,
    (SEQ ID NO: 237)
    SEPATSGSETPGTSESATPESCPGTSTEPSEG,
    (SEQ ID NO: 238)
    SEPATSGSETPGTSESATPESGPGTSCEPSEG,
    (SEQ ID NO: 239)
    SEPATSGSETPGTSESATPESGPGTSTEPCEG.
      • 48. The MIC-1 compound according to any one of embodiments 1-2 and 5-33 wherein the amino acid extension is composed of amino acid residues selected among the group consisting of A, E, G, P, S, T, D, N, and Q wherein the amino acid extension comprises at least three E and/or D amino acid residues.
      • 49. The MIC-1 compound according to any of the preceding embodiments, wherein the amino acid extension is composed of amino acid residues selected among the group consisting of A, E, G, P, S, T, Q and D, wherein the amino acid extension comprises at least three E and/or D amino acid residues.
      • 50. The MIC-1 compound according to embodiment 48 or 49, wherein the amino acid extension comprises at least three E and at least one P.
      • 51. The MIC-1 compound according to embodiment 50, wherein the amino acid extension further comprises S, G, T and A.
      • 52. The MIC-1 compound according to embodiment 51, wherein the amino acid extension comprises 6 Ser, 4 Pro, 4 Gly, 4 Thr, 4 Glu and 2 Ala.
      • 53. The MIC-1 compound according to embodiment 51, wherein the amino acid extension comprises two of sequences selected from the group consisting of SPAGSPTSTEEG (SEQ ID NO: 166), TSESATPESGPG (SEQ ID NO: 167), TSTEPSEGSAPG (SEQ ID NO: 168) and SEPATSGSETPG (SEQ ID NO: 169).
      • 54. The MIC-1 compound according to embodiment 53, wherein the amino acid extension further comprises 6-8 consecutive amino acids of SPAGSPTSTEEG (SEQ ID NO: 166), TSESATPESGPG (SEQ ID NO: 167), TSTEPSEGSAPG (SEQ ID NO: 168) or SEPATSGSETPG (SEQ ID NO: 169), such as the first 6-8 amino acid residues, the last 6-8 residues or the internal 6-8 residues.
      • 55. The MIC-1 compound according to any one of embodiments 48 to 54, wherein the amino acid extension starts with S.
      • 56. The MIC-1 compound according embodiment 55, wherein the amino acid extension starts with SE.
      • 57. The MIC-1 compound according to embodiment 56, wherein the amino acid extension starts with SEP.
      • 58. The MIC-1 compound according to any one of embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences SPAGSP (SEQ ID NO:4), TSESAT (SEQ ID NO:5), TSTEPE (SEQ ID NO:6), SEPATS (SEQ ID NO:7), TSTEEG (SEQ ID NO:8), PESGPG (SEQ ID NO:9), SGSAPG (SEQ ID NO:10), GSETPG (SEQ ID NO:11), SEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO:12), SEPATSGSETPGTSESATPESGPG (SEQ ID NO: 13), SEPATSGSETPGTSTEPESGSAPG (SEQ ID NO:14), SEPATSGSETPGSPAGSPTSTEEGSPAGSP (SEQ ID NO:15), SEPATSGSETPGTSESATPESGPGSPAGSP (SEQ ID NO:16), SEPATSGSETPGTSTEPESGSAPGSPAGSP (SEQ ID NO:17), SEPATSGSETPGSPAGSPTSTEEGTSESAT (SEQ ID NO:18), SEPATSGSETPGTSESATPESGPGTSESAT (SEQ ID NO:19), SEPATSGSETPGTSTEPESGSAPGTSESAT (SEQ ID NO:20), SEPATSGSETPGSPAGSPTSTEEGTSTEPE (SEQ ID NO:21), SEPATSGSETPGTSESATPESGPGTSTEPE (SEQ ID NO:22), SEPATSGSETPGTSTEPESGSAPGTSTEPE (SEQ ID NO:23), SEPATSGSETPGSPAGSPTSTEEGSEPATS (SEQ ID NO:24), SEPATSGSETPGTSESATPESGPGSEPATS (SEQ ID NO:25), SEPATSGSETPGTSTEPESGSAPGSEPATS (SEQ ID NO:26), SEPATSGSETPGSPAGSPTSTEEGTSTEEG (SEQ ID NO:27), SEPATSGSETPGTSESATPESGPGTSTEEG (SEQ ID NO:28), SEPATSGSETPGTSTEPESGSAPGTSTEEG (SEQ ID NO:29), SEPATSGSETPGSPAGSPTSTEEGPESGPG (SEQ ID NO:30), SEPATSGSETPGTSESATPESGPGPESGPG (SEQ ID NO:31), SEPATSGSETPGTSTEPESGSAPGPESGPG (SEQ ID NO:32), SEPATSGSETPGSPAGSPTSTEEGSGSAPG (SEQ ID NO:33), SEPATSGSETPGTSESATPESGPGSGSAPG (SEQ ID NO:34), SEPATSGSETPGTSTEPESGSAPGSGSAPG (SEQ ID NO:35), SEPATSGSETPGSPAGSPTSTEEGGSETPG (SEQ ID NO:36), SEPATSGSETPGTSESATPESGPGGSETPG (SEQ ID NO:37), SEPATSGSETPGTSTEPESGSAPGGSETPG (SEQ ID NO:38), SEPATSGSETPGTSESATPESGPGTSTEPS (SEQ ID NO:70), SEPATSGSETPGTSESATPESGPGTSTEPSEG (SEQ ID NO:71), SEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG (SEQ ID NO:39), SEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEG (SEQ ID NO:40), SEPATSGSETPGSPAGSPTSTEEGTSTEPESGSAPG (SEQ ID NO:41), SEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG (SEQ ID NO:42), SEPATSGSETPGTSESATPESGPGTSESATPESGPG (SEQ ID NO:43), SEPATSGSETPGTSESATPESGPGTSTEPESGSAPG (SEQ ID NO:44), SEPATSGSETPGTSESATPESGPGSEPATSGSETPG (SEQ ID NO:45), SEPATSGSETPGTSTEPESGSAPGSPAGSPTSTEEG (SEQ ID NO:46), SEPATSGSETPGTSTEPESGSAPGTSESATPESGPG (SEQ ID NO:47), SEPATSGSETPGTSTEPESGSAPGTSTEPESGSAPG (SEQ ID NO:48), SEPATSGSETPGTSTEPESGSAPGSEPATSGSETPG (SEQ ID NO:49), SEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO:50), SEPATSGSETPGSEPATSGSETPGTSESATPESGPG (SEQ ID NO:51), SEPATSGSETPGSEPATSGSETPGTSTEPESGSAPG (SEQ ID NO:52), SEPATSGSETPGSEPATSGSETPGSEPATSGSETPG (SEQ ID NO: 53), GEPS (SEQ ID NO:118), GPSE (SEQ ID NO:119), GPES (SEQ ID NO:120), GSPE (SEQ ID NO: 121), GSEP (SEQ ID NO:122), GEPQ (SEQ ID NO: 123), GEQP (SEQ ID NO:124), GPEQ (SEQ ID NO: 125), GPQE (SEQ ID NO: 126), GQEP (SEQ ID NO:127) or GQPE (SEQ ID NO:128), PEDEETPEQE (SEQ ID NO:129), PDEGTEEETE (SEQ ID NO:130), PAAEEEDDPD (SEQ ID NO:131), AEPDEDPQSED (SEQ ID NO: 132), AEPDEDPQSE (SEQ ID NO: 133), AEPEEQEED (SEQ ID NO:134), AEPEEQEE (SEQ ID NO: 135), GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO:137), GGSS (SEQ ID NO:138) and SSSG (SEQ ID NO:139).
      • 59. The MIC-1 compound according to any one of embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences SPAGSP (SEQ ID NO:4), TSESAT (SEQ ID NO:5), TSTEPE (SEQ ID NO:6), SEPATS, (SEQ ID NO:7) TSTEEG (SEQ ID NO:8), PESGPG (SEQ ID NO:9), SGSAPG (SEQ ID NO:10), GSETPG (SEQ ID NO:11), SEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO:12), SEPATSGSETPGTSESATPESGPG (SEQ ID NO:13), SEPATSGSETPGTSTEPESGSAPG (SEQ ID NO:14), SEPATSGSETPGSPAGSPTSTEEGSPAGSP (SEQ ID NO:15), SEPATSGSETPGTSESATPESGPGSPAGSP (SEQ ID NO:16), SEPATSGSETPGTSTEPESGSAPGSPAGSP (SEQ ID NO:17), SEPATSGSETPGSPAGSPTSTEEGTSESAT (SEQ ID NO:18), SEPATSGSETPGTSESATPESGPGTSESAT (SEQ ID NO:19), SEPATSGSETPGTSTEPESGSAPGTSESAT (SEQ ID NO:20), SEPATSGSETPGSPAGSPTSTEEGTSTEPE (SEQ ID NO:21), SEPATSGSETPGTSESATPESGPGTSTEPE (SEQ ID NO:22), SEPATSGSETPGTSTEPESGSAPGTSTEPE (SEQ ID NO:23), SEPATSGSETPGSPAGSPTSTEEGSEPATS (SEQ ID NO:24), SEPATSGSETPGTSESATPESGPGSEPATS (SEQ ID NO:25), SEPATSGSETPGTSTEPESGSAPGSEPATS (SEQ ID NO:26), SEPATSGSETPGSPAGSPTSTEEGTSTEEG (SEQ ID NO:27), SEPATSGSETPGTSESATPESGPGTSTEEG (SEQ ID NO:28), SEPATSGSETPGTSTEPESGSAPGTSTEEG (SEQ ID NO:29), SEPATSGSETPGSPAGSPTSTEEGPESGPG (SEQ ID NO:30), SEPATSGSETPGTSESATPESGPGPESGPG (SEQ ID NO:31), SEPATSGSETPGTSTEPESGSAPGPESGPG (SEQ ID NO:32), SEPATSGSETPGSPAGSPTSTEEGSGSAPG (SEQ ID NO:33), SEPATSGSETPGTSESATPESGPGSGSAPG (SEQ ID NO:34), SEPATSGSETPGTSTEPESGSAPGSGSAPG (SEQ ID NO:35), SEPATSGSETPGSPAGSPTSTEEGGSETPG (SEQ ID NO:36), SEPATSGSETPGTSESATPESGPGGSETPG (SEQ ID NO:37), SEPATSGSETPGTSTEPESGSAPGGSETPG (SEQ ID NO:38) SEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG (SEQ ID NO:39), SEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEG (SEQ ID NO:40), SEPATSGSETPGSPAGSPTSTEEGTSTEPESGSAPG (SEQ ID NO:41), SEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG (SEQ ID NO:42), SEPATSGSETPGTSESATPESGPGTSESATPESGPG (SEQ ID NO:43), SEPATSGSETPGTSESATPESGPGTSTEPESGSAPG (SEQ ID NO:44), SEPATSGSETPGTSESATPESGPGSEPATSGSETPG (SEQ ID NO:45), SEPATSGSETPGTSTEPESGSAPGSPAGSPTSTEEG (SEQ ID NO:46), SEPATSGSETPGTSTEPESGSAPGTSESATPESGPG (SEQ ID NO:47), SEPATSGSETPGTSTEPESGSAPGTSTEPESGSAPG (SEQ ID NO:48), SEPATSGSETPGTSTEPESGSAPGSEPATSGSETPG (SEQ ID NO:49), SEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO:50), SEPATSGSETPGSEPATSGSETPGTSESATPESGPG (SEQ ID NO:51), SEPATSGSETPGSEPATSGSETPGTSTEPESGSAPG (SEQ ID NO:52), SEPATSGSETPGSEPATSGSETPGSEPATSGSETPG (SEQ ID NO:53), GEPQ (SEQ ID NO:123), GEPS (SEQ ID NO:118), GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO:137), GGSS (SEQ ID NO: 138), and SSSG (SEQ ID NO:139).
      • 60. The MIC-1 compound according to any one of embodiments 1-2 and 5-33, wherein the amino acid extension comprises any combination of any 2-6 of the following sequences SPAGSP (SEQ ID NO:4), TSESAT (SEQ ID NO:5), TSTEPE (SEQ ID NO:6), SEPATS (SEQ ID NO:7), TSTEEG (SEQ ID NO:8), PESGPG (SEQ ID NO:9), SGSAPG (SEQ ID NO:10), GSETPG (SEQ ID NO:11), GEPQ (SEQ ID NO:123), GEPS (SEQ ID NO:118), GGGS (SEQ ID NO:136), GSGS (SEQ ID NO:137), GGSS (SEQ ID NO:138), and SSSG (SEQ ID NO:139).
      • 61. The MIC-1 compound according to any one of embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences GEPS (SEQ ID NO:118), GPSE (SEQ ID NO:119), GPES (SEQ ID NO: 120), GSPE (SEQ ID NO:121), GSEP (SEQ ID NO:122), GEPQ (SEQ ID NO:123), GEQP (SEQ ID NO:124), GPEQ (SEQ ID NO: 125), GPQE (SEQ ID NO:126), GQEP (SEQ ID NO: 127), GQPE (SEQ ID NO:128), GGGS (SEQ ID NO:136), GSGS (SEQ ID NO:137), GGSS (SEQ ID NO:138), and SSSG (SEQ ID NO:139).
      • 62. The MIC-1 compound according to embodiment 61, wherein the amino acid extension comprises any combination of 2-9 of the following sequences GEPS (SEQ ID NO:118), GPSE (SEQ ID NO:119), GPES (SEQ ID NO: 120), GSPE (SEQ ID NO:121), GSEP (SEQ ID NO: 122), GEPQ (SEQ ID NO:123), GEQP (SEQ ID NO: 124), GPEQ (SEQ ID NO:125), GPQE (SEQ ID NO:126), GQEP (SEQ ID NO:127), GQPE (SEQ ID NO:128), GGGS (SEQ ID NO:136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO: 138), and SSSG (SEQ ID NO: 139).
      • 63. The MIC-1 compound according to any one of embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences GEPS (SEQ ID NO:118), GPSE (SEQ ID NO:119), GPES (SEQ ID NO: 120), GSPE (SEQ ID NO:121), GSEP (SEQ ID NO:122), GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO:138), and SSSG (SEQ ID NO:139).
      • 64. The MIC-1 compound according to embodiment 63, wherein the amino acid extension comprises any combination of 2-9 of the following sequences GEPS (SEQ ID NO:118), GPSE (SEQ ID NO:119), GPES (SEQ ID NO: 120), GSPE (SEQ ID NO:121), GSEP (SEQ ID NO: 122), GGGS (SEQ ID NO:136), GSGS (SEQ ID NO:137), GGSS (SEQ ID NO: 138), and SSSG (SEQ ID NO: 139).
      • 65. The MIC-1 compound according to embodiment 64, wherein the amino acid extension comprises one or more of the following sequences GEPSGEPSGEPSGEPSGEPS (SEQ ID NO: 140), GPSEGPSEGPSEGPSEGPSE (SEQ ID NO:141), GPESGPESGPESGPESGPES (SEQ ID NO:142), GSPEGSPEGSPEGSPEGSPE (SEQ ID NO:143), and GSEPGSEPGSEPGSEPGSEP (SEQ ID NO:144).
      • 66. The MIC-1 compound according to any one of embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences GEPQ (SEQ ID NO:123), GEQP (SEQ ID NO: 124), GPEQ (SEQ ID NO: 125), GPQE (SEQ ID NO: 126), GQEP (SEQ ID NO:127), GQPE (SEQ ID NO:128), GGGS (SEQ ID NO:136), GSGS (SEQ ID NO:137), GGSS (SEQ ID NO: 138), and SSSG (SEQ ID NO:139).
      • 67. The MIC-1 compound according to embodiment 66, wherein the amino acid extension comprises any combination of 2-9 of the following sequences GEPQ (SEQ ID NO: 123), GEQP (SEQ ID NO:124), GPEQ (SEQ ID NO:125), GPQE (SEQ ID NO:126), GQEP (SEQ ID NO: 127), GQPE (SEQ ID NO:128), GGGS (SEQ ID NO:136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO:138), and SSSG.
      • 68. The MIC-1 compound according to embodiment 67, wherein the amino acid extension comprises one or more of the following sequences GEPQGEPQGEPQGEPQGEPQ (SEQ ID NO: 145), GEQPGEQPGEQPGEQPGEQP (SEQ ID NO: 146), GPEQGPEQGPEQGPEQGPEQ(SEQ ID NO: 147), GPQEGPQEGPQEGPQEGPQE (SEQ ID NO: 148), GQEPGQEPGQEPGQEPGQEP (SEQ ID NO: 149), and GQPEGQPEGQPEGQPEGQPE (SEQ ID NO:150).
      • 69. The MIC-1 compound according to any of the embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences PEDEETPEQE (SEQ ID NO:129), PDEGTEEETE (SEQ ID NO: 130), PAAEEEDDPD (SEQ ID NO: 131), AEPDEDPQSED (SEQ ID NO:132), AEPDEDPQSE (SEQ ID NO: 133), AEPEEQEED (SEQ ID NO: 134), and AEPEEQEE (SEQ ID NO:135), GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO:138) and SSSG (SEQ ID NO:139).
      • 70. The MIC-1 compound according to any of the embodiments 1-2 and 5-33, wherein the amino acid extension comprises any combination of two to three of the following sequences PEDEETPEQE (SEQ ID NO:129), PDEGTEEETE (SEQ ID NO:130), PAAEEEDDPD (SEQ ID NO:131), AEPDEDPQSED (SEQ ID NO: 132), AEPDEDPQSE (SEQ ID NO:133), AEPEEQEED (SEQ ID NO:134), AEPEEQEE (SEQ ID NO:135) and AEEAEEAEEAEEAEE (SEQ ID NO:151).
      • 71. The MIC-1 compound according to any of the embodiments 1-2 and 5-33, wherein the amino acid extension comprises one or more of the following sequences SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO: 187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO: 190, SEQ ID NO:191, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 194 and SEQ ID NO: 195.
      • 72. The MIC-1 compound according to any one of preceding embodiments, wherein the amino acid extension comprises 1-3 alanine amino acid residues N-terminally.
      • 73. The MIC-1 compound according to any one of preceding embodiments, wherein the amino acid extension comprises 1-4 Glycine and Serine amino acid residues C-terminally.
      • 74. The MIC-1 compound according to any one of preceding embodiments, wherein the amino acid extension comprises a (Gly-Ser)n or a (Ser-Gly)n sequence C-terminally, wherein n is an integer between 1-8.
      • 75. The MIC-1 compound according to any one of preceding embodiments, wherein the amino acid extension comprises GGGS (SEQ ID NO:136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO:138) or SSSG (SEQ ID NO: 139) C-terminally.
      • 76. The MIC-1 compound according to any of the preceding embodiments, wherein the MIC-1 polypeptide displays at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to wild type MIC-1 (SEQ ID NO: 1).
      • 77. The MIC-1 compound according to embodiment 70, wherein the MIC-1 polypeptide displays at least 95% sequence identity to wild type MIC-1 (SEQ ID NO: 1).
      • 78. The MIC-1 compound according to any one of embodiments 1-70, wherein the MIC-1 polypeptide has a maximum of 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid modifications compared to MIC-1 of SEQ ID NO:1.
      • 79. The MIC-1 compound according to any one of embodiments 1-72, wherein the MIC-1 polypeptide has a maximum of 7, 6, 5, 4, 3 or 2 amino acid modifications compared to MIC-1 of SEQ ID NO:1.
      • 80. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises one or more of the following substitutions P11E, H18E, R21E, A30E, M43L, M43E, A47E, R53E, A54E, M57E, M57L, H66E, R67E, L68E, K69E, A75E, A81E, P85E, M86F, M86L, Q90E, T92E, 105E, K107E, K69R, K107R and K91R compared to wild type MIC-1 (SEQ ID NO:1).
      • 81. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises one or more of the following substitutions R2S, R2A, R2E, N3S, N3E, N3A, N3T, N3P, N3G, N3V, N3H, N3Y or N3Q compared to MIC-1 of SEQ ID NO:1.
      • 82. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a deletion of N3 (des-N3) compared to MIC-1 of SEQ ID NO:1.
      • 83. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a M57E or M57L substitution compared to MIC-1 of SEQ ID NO:1.
      • 84. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a M86L or M86F substitution compared to MIC-1 of SEQ ID NO:1.
      • 85. The MIC-1 compound according to embodiment 84 wherein the MIC-1 polypeptide further comprises a Q90E or T92E substitution compared to MIC-1 of SEQ ID NO: 1.
      • 86. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a H66E substitution compared to MIC-1 of SEQ ID NO:1.
      • 87. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a R67E substitution compared to MIC-1 of SEQ ID NO:1.
      • 88. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a deletion of the first 3, 4, 5 or 6 residues compared to MIC-1 of SEQ ID NO:1.
      • 89. The MIC-1 compound according to any one of the preceding embodiments wherein the MIC-1 polypeptide comprises a deletion of the first 3 residues compared to MIC-1 of SEQ ID NO:1.
      • 90. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:154 (M43L/des-N3).
      • 91. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:155 (M43L/Δ1-3).
      • 92. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:156 (M57E/H66E/des-N3).
      • 93. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:157 (M57L/Δ1-3).
      • 94. Compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:158 (M57L/des-N3).
      • 95. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a according to SEQ ID NO:159 (M86L/Δ1-3).
      • 96. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:160 (M86L/des-N3) or SEQ ID NO:222 (M57L, M86L/des-N3).
      • 97. The MIC-1 compound according to any one of embodiments 1-75, wherein the MIC-1 polypeptide has a sequence according to SEQ ID NO:1.
      • 98. The MIC-1 compound according to any one of preceding embodiments, wherein the MIC-1 polypeptide and the N-terminal amino acid extension together comprises an amino acid sequence according to SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 164,
  • (SEQ ID NO: 288)
    SEPCTSGSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYD
    DLLAKDCHCI,
    (SEQ ID NO: 289)
    SEPATSCSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 290)
    SEPCTSGSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 291)
    SEPATCGSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYD
    DLLAKDCHCI,
    (SEQ ID NO: 292)
    SEPATSGSETPGTSESACPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 293)
    SEPATSGSETPGTSESATPESGPGTSTEPCEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 294)
    SEPATSGSETPGSEPATSGSETPGGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCI
    GACPSQFRAANEHAQIKTSLERLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI,
    (SEQ ID NO: 295)
    SEPATSGSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYD
    DLLAKDCHCI,
    (SEQ ID NO: 296)
    SEPATSGSETPGTSESATPESGPGTSTEPSARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPR
    EVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDDLL
    AKDCHCI,
    (SEQ ID NO: 297)
    SEPATSGSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYD
    DLLAKDCHCI,
    (SEQ ID NO: 298)
    SEPATSGSETPGTSESATPESGPGTSTEPSARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPR
    EVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDL
    LAKDCHCI,
    (SEQ ID NO: 299)
    SEPATSGSETPGSEPATSGSETPGTSTEPSARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPR
    EVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDL
    LAKDCHCI,
    (SEQ ID NO: 300)
    SAPATSGSATPGSAPATSGSATPGGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCI
    GACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI,
    (SEQ ID NO: 301)
    SEPCTSGSETPGTSESATPESGPGTSTEPSARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPR
    EVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDL
    LAKDCHCI,
    (SEQ ID NO: 302)
    SEPATCGSETPGTSESATPESGPGTSTEPSARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPR
    EVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDL
    LAKDCHCI,
    (SEQ ID NO: 303)
    SEPATSGCETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 304)
    SEPATSGSECPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 305)
    SEPATSGSETPCTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 306)
    SEPATSGSETPGTCESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 307)
    SEPATSGSETPGTSECATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 308)
    SEPATSGSETPGTSESATPECGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 309)
    SEPATSGSETPGTSESATPESCPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 310)
    SEPATSGSETPGTSESATPESGPGTSCEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLKPDTVPAPCCVPASYNPLVLIQKTDTGVSLQTYDD
    LLAKDCHCI,
    (SEQ ID NO: 311)
    EEAEADDDDKESGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCIGACPSQFRAAN
    MHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI,
    or
    (SEQ ID NO: 312)
    SEPATSGSETPGTSESATPESGPGTSTEPSEGARGDHCPLGPGRCCRLHTVRASLEDLGWADWVLS
    PREVQVTMCIGACPSQFRAANLHAQIKTSLHRLRPDTVPAPCCVPASYNPLVLIQRTDTGVSLQTYDD
    LLARDCHCI.
      • 99. MIC-1 compound according to embodiment 1 with one of the following Formulae:
  • Figure US20230364248A1-20231116-C00011
    Figure US20230364248A1-20231116-C00012
    Figure US20230364248A1-20231116-C00013
    Figure US20230364248A1-20231116-C00014
    Figure US20230364248A1-20231116-C00015
    Figure US20230364248A1-20231116-C00016
    Figure US20230364248A1-20231116-C00017
    Figure US20230364248A1-20231116-C00018
    Figure US20230364248A1-20231116-C00019
    Figure US20230364248A1-20231116-C00020
    Figure US20230364248A1-20231116-C00021
    Figure US20230364248A1-20231116-C00022
    Figure US20230364248A1-20231116-C00023
    Figure US20230364248A1-20231116-C00024
    Figure US20230364248A1-20231116-C00025
    Figure US20230364248A1-20231116-C00026
    Figure US20230364248A1-20231116-C00027
    Figure US20230364248A1-20231116-C00028
    Figure US20230364248A1-20231116-C00029
    Figure US20230364248A1-20231116-C00030
    Figure US20230364248A1-20231116-C00031
      • 100. The MIC-1 compound according to any one of the preceding embodiments, showing extended plasma half-life compared with MIC-1 of SEQ ID NO:1.
      • 101. The MIC-1 compound according to any one of the preceding embodiments, showing improved plasma half-life compared with MIC-1 of SEQ ID NO:1 as measured by administrating the compound to rat i.v. and estimate the terminal half-life from changes in plasma concentration of compound over time.
      • 102. The MIC-1 compound according to any one of the preceding embodiments, showing maintained potency compared with MIC-1 of SEQ ID NO: 1.
      • 103. The MIC-1 compound according to any one of the preceding embodiments, showing retained efficacy compared with MIC-1 of SEQ ID NO:1 as measured by administrating compound to rat s.c. and measure changes in daily food intake.
      • 104. The MIC-1 compound according to any one of the preceding embodiments, wherein the MIC-1 polypeptide with an amino acid extension has acceptable solubility compared with MIC-1 of SEQ ID NO:1.
      • 105. The MIC-1 compound according to any one of embodiments 1-99, wherein the MIC-1 polypeptide with an amino acid extension has a solubility of 0.5, 1.0, 5.0, 10, 30 or 50 mg/ml as measured at pH 8.0 in a Tris buffer system.
      • 106. The MIC-1 compound according to embodiments 1 or 2, wherein the MIC-1 polypeptide comprises a deletion of N3 (des-N3) compared to MIC-1 of SEQ ID NO: 1, wherein the amino acid extension has the following sequence SEPCTSGSETPGTSESATPESGPGTSTEPSEG (SEQ ID NO: 225), and wherein the protractor has the following formula:
  • Figure US20230364248A1-20231116-C00032
      • and wherein the protractor is attached to the Cysteine of the amino acid extension.
      • 107. Compound according to embodiments 1 or 2, wherein the MIC-1 polypeptide with an N-terminal amino acid extension has the sequence according to SEQ ID NO: 288, and the protractor has the following formula:
  • Figure US20230364248A1-20231116-C00033
      • and wherein the protractor is attached to the Cysteine of the amino acid extension.
      • 108. MIC-1 compound according to any one of embodiments 1-107 or a pharmaceutically acceptable salt, amide or ester thereof.
      • 109. The MIC-1 compound according to any of the preceding embodiments, wherein the compound has improved in vivo efficacy on lowering food intake and/or lowering body weight compared with MIC-1 of SEQ ID NO:1.
      • 110. MIC-1 compound according to any one of embodiments 1-109 and 132-152 for use as a medicament.
      • 111. MIC-1 compound according to any one of embodiments 1-109 and 132-152 for use in the prevention and/or treatment of a metabolic disorder.
      • 112. MIC-1 compound according to embodiment 111 for use in the prevention and/or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, type 2 diabetes, dyslipidemia, or diabetic nephropathy.
      • 113. MIC-1 compound according to any one of embodiments 1-109 and 132-152 for use in the prevention and/or treatment of eating disorders, such as obesity.
      • 114. MIC-1 compound according to embodiment 113 for use in the prevention and/or treatment of obesity by decreasing food intake, reducing body weight, suppressing appetite and/or inducing satiety.
      • 115. MIC-1 compound according to any one of embodiments 1-109 and 132-152 for use in the prevention and/or treatment of a cardiovascular disease.
      • 116. MIC-1 compound according to embodiment 115 for use in the prevention and/or treatment of dyslipidaemia, arteriosclerosis, steatohepatitis, or diabetic nephropathy.
      • 117. Pharmaceutical composition comprising the MIC-1 compound according to any one of embodiments 1-109 and 132-152 or a pharmaceutically acceptable salt, amide or ester thereof, and one or more pharmaceutically acceptable excipients.
      • 118. The use of a MIC-1 compound according to any one of embodiments 1-109 and 132-152 in the manufacture of a medicament for the prevention and/or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, type 2 diabetes, dyslipidemia, or diabetic nephropathy.
      • 119. The use of a MIC-1 compound according to any one of embodiments 1-109 and 132-152 in the manufacture of a medicament for the prevention and/or treatment of eating disorders.
      • 120. The use of a MIC-1 compound according to any one of embodiments 1-109 and 132-152 in the manufacture of a medicament for the prevention and/or treatment of obesity.
      • 121. The use of a MIC-1 compound according to any one of embodiments 1-109 and 132-152 in the manufacture of a medicament for the prevention and/or treatment of obesity by decreasing food intake, reducing body weight, suppressing appetite and/or inducing satiety.
      • 122. The use of a MIC-1 compound according to any one of embodiments 1-109 and 132-152 in the manufacture of a medicament for the prevention and/or treatment of a cardiovascular disease.
      • 123. The use of a MIC-1 compound according to any one of embodiments 1-109 and 132-152 in the manufacture of a medicament for the prevention and/or treatment of dyslipidaemia, arteriosclerosis, steatohepatitis, or diabetic nephropathy.
      • 124. Method of treating and/or preventing a metabolic disorder by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152, wherein the metabolic disorder is obesity, type 2 diabetes, dyslipidemia, or diabetic nephropathy.
      • 125. Method of treating and/or preventing eating disorders by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 126. Method of treating and/or preventing obesity by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 127. Method of treating and/or preventing obesity by decreasing food intake, reducing body weight, suppressing appetite and/or inducing satiety by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 128. Method of treating and/or preventing a cardiovascular disease by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 129. Method of treating and/or preventing dyslipidaemia, arteriosclerosis, steatohepatitis, or diabetic nephropathy by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 130. Polynucleotide molecule encoding a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 131. Method of treating and/or preventing overweight by decreasing food intake, reducing body weight, suppressing appetite and/or inducing satiety by administering a pharmaceutically active amount of a MIC-1 compound according to any one of embodiments 1-109 and 132-152.
      • 132. MIC-1 compound according to Formula 01:
  • Figure US20230364248A1-20231116-C00034
      • 133. MIC-1 compound according to Formula 02:
  • Figure US20230364248A1-20231116-C00035
      • 134. MIC-1 compound according to Formula 03:
  • Figure US20230364248A1-20231116-C00036
      • 135. MIC-1 compound according to Formula 04:
  • Figure US20230364248A1-20231116-C00037
      • 136. MIC-1 compound according to Formula 05:
  • Figure US20230364248A1-20231116-C00038
      • 137. MIC-1 compound according to Formula 06:
  • Figure US20230364248A1-20231116-C00039
      • 138 MIC-1 compound according to Formula 07:
  • Figure US20230364248A1-20231116-C00040
      • 139. MIC-1 compound according to Formula 08:
  • Figure US20230364248A1-20231116-C00041
      • 140. MIC-1 compound according to Formula 09:
  • Figure US20230364248A1-20231116-C00042
      • 141. MIC-1 compound according to Formula 10:
  • Figure US20230364248A1-20231116-C00043
      • 142. MIC-1 compound according to Formula 11:
  • Figure US20230364248A1-20231116-C00044
      • 143. MIC-1 compound according to Formula 12:
  • Figure US20230364248A1-20231116-C00045
      • 144. MIC-1 compound according to Formula 13:
  • Figure US20230364248A1-20231116-C00046
      • 145. MIC-1 compound according to Formula 14:
  • Figure US20230364248A1-20231116-C00047
      • 146. MIC-1 compound according to Formula 15:
  • Figure US20230364248A1-20231116-C00048
      • 147. MIC-1 compound according to Formula 16:
  • Figure US20230364248A1-20231116-C00049
      • 148. MIC-1 compound according to Formula 17:
  • Figure US20230364248A1-20231116-C00050
      • 149. MIC-1 compound according to Formula 18:
  • Figure US20230364248A1-20231116-C00051
      • 150. MIC-1 compound according to Formula 19:
  • Figure US20230364248A1-20231116-C00052
      • 151. MIC-1 compound according to Formula 20:
  • Figure US20230364248A1-20231116-C00053
      • 152. MIC-1 compound according to Formula 21:
  • Figure US20230364248A1-20231116-C00054
    • EXAMPLES List of Abbreviations
  • “Main peak” refers to the peak in a purification chromatogram which has the highest UV intensity in milliabsorbance units and which contains the fusion protein.
  • HPLC is High performance liquid chromatography.
  • SDS-PAGE is Sodium dodecyl sulfate Polyacrylamide gel electrophoresis.
  • IMAC is immobilized metal affinity chromatography.
  • SEC is size exclusion chromatography.
  • MS is mass spectrometry.
  • In this description, Greek letters may be represented by their symbol or the corresponding written name, for example: α=alpha; β=beta; ε=epsilon; γ=gamma; ω=omega; Δ=delta; etc. Also, the Greek letter of μ may be represented by “u”, e.g. in μl=ul, or in μM=uM.
  • MIC-1 Polypeptides with Improved Solubility
  • In an aspect of the invention, MIC-1 polypeptides were designed to have increased solubility.
  • In an aspect of the invention, this was achieved by adding an N-terminal “acidic” amino acid extension to the MIC-1 polypeptide.
  • In an aspect of the invention, solubility was enhanced and stability was improved by modification of the amino acid sequence of the MIC-1 polypeptide. For example, modification was done within the amino acid sequence of the MIC-1 polypeptide (in-sequence mutation).
  • MIC-1 polypeptides with an N-terminal amino acid extension can be expressed in bacteria such as E. coli. In the context of the present invention, large scale protein production of the MIC-1 polypeptides with an N-extension could take of using Inclusion Bodies (IB) as this represent an advantageous approach to controlling process recovery, protein purity, protease degradation and general protein stability. This becomes particular important for large scale protein production. Of critical importance for the quality of IB is the balance between improved solubility and IB formation of MIC-1 polypeptides with an N-extension.
    • N-Extension Design:
  • In the design of the N-terminal amino acid extension, F, I, L, M, V, W and Y were excluded, since they could contribute to protein aggregation. H, K, and R were also excluded, since they could cause undesired binding on cell membrane. A, C, E, G, P, S, T, D, N, and Q are preferred for the N-extension sequence. E and D are particularly preferred since they increase the solubility by decreasing pI value of the compound. C could provide a —SH group which can be used for protraction purpose, such as fatty acid conjugation and PEGylation. Particularly, for some N-extensions, one or two additional Alanine(s), Glycine(s) or Serine(s) were added at the very N-terminal to increase the initial Methionine removing efficiency when MIC-1 polypeptides with N-extension were expressed in E. coli.
  • Various N-terminal amino acid extensions were designed. Some N-extensions comprise sequences originating from human proteins (humanized sequences); some comprise artificially designed sequence(s) (e.g. GS, SG, AEE, AES, GEPQ (SEQ ID NO: 123), GEPS (SEQ ID NO:118)); some comprise several repeats of the humanized sequences or artificial sequences; some comprise a combination of the above. Several 6-residue sequences (6-mers) were designed. N-extensions could comprise one or more of a 6-mers, part of a 6-mers (e.g., 1-5 residues of a 6-mers), or a combination of the above. The amino acid residues of the artificial sequences (including 6-mers) and the humanized sequences could be arranged in any order.
  • Some representative 6-mers and combinations of 6-mers are listed in Table 2, and other examples of N-extension are listed in Table 3.
  • TABLE 2
    6-mers and combinations of 6-mers
    6-mers: 6-mer-1: SPAGSP (SEQ ID NO: 4)
    6-mer-2: TSESAT (SEQ ID NO: 5)
    6-mer-3: TSTEPE (SEQ ID NO: 6)
    6-mer-4: SEPATS (SEQ ID NO: 7)
    6-mer-5: TSTEEG (SEQ ID NO: 8)
    6-mer-6: PESGPG (SEQ ID NO: 9)
    6-mer-7: SGSAPG (SEQ ID NO: 10)
    6-mer-8: GSETPG (SEQ ID NO: 11)
    Combinations: SEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO: 12)
    SEPATSGSETPGTSESATPESGPG (SEQ ID NO: 13)
    SEPATSGSETPGTSTEPESGSAPG (SEQ ID NO: 14)
    SEPATSGSETPGSPAGSPTSTEEGSPAGSP (SEQ ID NO: 15)
    SEPATSGSETPGTSESATPESGPGSPAGSP (SEQ ID NO: 16)
    SEPATSGSETPGTSTEPESGSAPGSPAGSP (SEQ ID NO: 17)
    SEPATSGSETPGSPAGSPTSTEEGTSESAT (SEQ ID NO: 18)
    SEPATSGSETPGTSESATPESGPGTSESAT (SEQ ID NO: 19)
    SEPATSGSETPGTSTEPESGSAPGTSESAT (SEQ ID NO: 20)
    SEPATSGSETPGSPAGSPTSTEEGTSTEPE (SEQ ID NO: 21)
    SEPATSGSETPGTSESATPESGPGTSTEPE (SEQ ID NO: 22)
    SEPATSGSETPGTSTEPESGSAPGTSTEPE (SEQ ID NO: 23)
    SEPATSGSETPGSPAGSPTSTEEGSEPATS (SEQ ID NO: 24)
    SEPATSGSETPGTSESATPESGPGSEPATS (SEQ ID NO: 25)
    SEPATSGSETPGTSTEPESGSAPGSEPATS (SEQ ID NO: 26)
    SEPATSGSETPGSPAGSPTSTEEGTSTEEG (SEQ ID NO: 27)
    SEPATSGSETPGTSESATPESGPGTSTEEG (SEQ ID NO: 28)
    SEPATSGSETPGTSTEPESGSAPGTSTEEG (SEQ ID NO: 29)
    SEPATSGSETPGSPAGSPTSTEEGPESGPG (SEQ ID NO: 30)
    SEPATSGSETPGTSESATPESGPGPESGPG (SEQ ID NO: 31)
    SEPATSGSETPGTSTEPESGSAPGPESGPG (SEQ ID NO: 32)
    SEPATSGSETPGSPAGSPTSTEEGSGSAPG (SEQ ID NO: 33)
    SEPATSGSETPGTSESATPESGPGSGSAPG (SEQ ID NO: 34)
    SEPATSGSETPGTSTEPESGSAPGSGSAPG (SEQ ID NO: 35)
    SEPATSGSETPGSPAGSPTSTEEGGSETPG (SEQ ID NO: 36)
    SEPATSGSETPGTSESATPESGPGGSETPG (SEQ ID NO: 37)
    SEPATSGSETPGTSTEPESGSAPGGSETPG (SEQ ID NO: 38)
    SEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG (SEQ ID NO: 39)
    SEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEG (SEQ ID NO: 40)
    SEPATSGSETPGSPAGSPTSTEEGTSTEPESGSAPG (SEQ ID NO: 41)
    SEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG (SEQ ID NO: 42)
    SEPATSGSETPGTSESATPESGPGTSESATPESGPG (SEQ ID NO: 43)
    SEPATSGSETPGTSESATPESGPGTSTEPESGSAPG (SEQ ID NO: 44)
    SEPATSGSETPGTSESATPESGPGSEPATSGSETPG (SEQ ID NO: 45)
    SEPATSGSETPGTSTEPESGSAPGSPAGSPTSTEEG (SEQ ID NO: 46)
    SEPATSGSETPGTSTEPESGSAPGTSESATPESGPG (SEQ ID NO: 47)
    SEPATSGSETPGTSTEPESGSAPGTSTEPESGSAPG (SEQ ID NO: 48)
    SEPATSGSETPGTSTEPESGSAPGSEPATSGSETPG (SEQ ID NO: 49)
    SEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO: 50)
    SEPATSGSETPGSEPATSGSETPGTSESATPESGPG (SEQ ID NO: 51)
    SEPATSGSETPGSEPATSGSETPGTSTEPESGSAPG (SEQ ID NO: 52)
    SEPATSGSETPGSEPATSGSETPGSEPATSGSETPG (SEQ ID NO: 53)
  • TABLE 3
    Examples of N-extensions
    Residue
    SEQ ID NO number Sequence of N-extension
    SEQ ID NO: 54 6 AEEAES
    SEQ ID NO: 55 3 AES
    SEQ ID NO: 56 9 (AEE)2AES
    SEQ ID NO: 57 20 (GEPS)5
    SEQ ID NO: 58 24 SPAGSPTSTEEGTSESATPESGPG
    SEQ ID NO: 59 21 (AEE)6AES
    SEQ ID NO: 60 18 (AEE)5AES
    SEQ ID NO: 61 12 (AEE)3AES
    SEQ ID NO: 62 26 AASPAGSPTSTEEGTSESATPESGPG
    SEQ ID NO: 63 24 TSESATPESGPGTSESATPESGPG
    SEQ ID NO: 64 26 AASPAGSPTSTEEGTSESATPESGPG
    SEQ ID NO: 65 22 AAPEDEETPEQEGSGSGSGSGS
    SEQ ID NO: 66 12 AAPEDEETPEQE
    SEQ ID NO: 67 22 AAPDEGTEEETEGSGSGSGSGS
    SEQ ID NO: 68 24 SEPATSGSETPGSEPATSGSETPG
    SEQ ID NO: 69 25 A(GPEQGQEP)3
    SEQ ID NO: 70 30 SEPATSGSETPGTSESATPESGPGTS
    TEPS
    SEQ ID NO: 71 32 SEPATSGSETPGTSESATPESGPGTS
    TEPSEG
    SEQ ID NO: 72 24 (GEPS)6
    SEQ ID NO: 161 36 (GEPS)9
    SEQ ID NO: 162 36 (GPEQ)9
    SEQ ID NO: 163 25 AGPEQGQEPGEPQGQEPQPGEPEGQ
    • In-Sequence Mutations:
  • Certain internal residues of MIC-1 (SEQ ID NO: 1) were modified, e.g. by substitution. For example, to increase the solubility of MIC-1 compounds, a hydrophobic residue of MIC-1 could be substituted with a hydrophilic residue, preferably by with an acidic residue; a positive charged residue could be substituted with an acidic residue, etc. To decrease oxidation, methionine could be substituted with other amino acids, e.g. E, F or L.
  • In-sequence mutations for increasing solubility include but are not limited to: P11E, H18E, R21E, Δ30E, Δ47E, R53E, Δ54E, M57E, H66E, R67E, L68E, K69E, Δ75E, Δ81E, P85E, Q90E, T92E, L105E and K107E.
  • In-sequence mutations for decreasing oxidation include but are not limited to: M43L, M43E, M57E, M57L, M86F and M86L.
  • In-sequence mutations for increasing chemical stability include but are not limited to N3S, N3E, N3A, N3T, N3P, N3G, N3V, N3H, N3Y and N3Q.
  • In-sequence mutations for conjugation include but are not limited to K69R, K107R and K91R.
  • Other in-sequence mutations include but are not limited to a deletion of N3 (des-N3) and/or a deletion of the first 3 residues.
  • pI calculation
  • The calculated pI of a MIC-1 polypeptide with an N-terminal amino acid extension is defined as the pH at which the net calculated charge of the MIC-1 polypeptide with a N-terminal amino acid extension is zero. The calculated charge of the MIC-1 polypeptide with the N-terminal amino acid extension as a function of pH is obtained using the pKa values of the amino acid residues described in Table 1 and the method described by B. Skoog and A. Wichman (Trends in Analytical Chemistry, 1986, vol. 5, pp. 82-83). The side chain pKa of cysteine (Cys) is only included in the charge calculation for cysteines with a free sulfhydryl group. The N-extension may contain one cysteine mutation. As an example the calculated pI value of human wild type MIC-1 is 8.8 as the homodimer. The calculated pI values of MIC-1 polypeptide are shown in Table 4.
  • Herein, and throughout this document, pI calculations on the MIC-1 polypeptide with an N-terminal amino acid extension, if not stated otherwise, are made on homodimers.
  • TABLE 4
    Calculated pI values
    MIC-1-
    Δ1-3
    MIC-1- MIC-1- (M57E,
    MIC-1 MIC-1- Δ1-3 Δ1-3 H66E
    (SEQ ID MIC-1- MIC-1- Δ1-3 (M57E, (M57E, and
    NO: 1) des-N3 Δ1-3 (M57E) H66E) R67E) R67E)
    Any 6.1 6.1 5.8 5.5 5.0 5.0 4.7
    combinations
    of four of
    6mers 1-8∞
    Any 5.8 5.8 5.5 5.2 4.8 4.8 4.6
    combinations
    of five 6mers
    1-8∞
    (GEPQ*)5 or 5.8 5.8 5.5 5.2 4.8 4.8 4.6
    (GEPS*)5∞
    (GEPQ*)6∞ 5.5 5.5 5.2 5.2 4.7 4.7 4.5
    Humanized 4.5~5.5 4.5~5.5 4.2~5.3 4.2~5.2 4.2~5.1 4.2~5.1 4.2~5.0
    sequences in
    examples∞
    *The amino acid residues of “GEPQ” or “GEPS” may be arranged in any order
    ∞One Cys in the N-terminal extension change pI by less than ±0.1.
    • Materials and Methods General Methods of Preparation Example-1: Expression and Fermentation of the MIC-1 Polypeptide or the MIC-1 Polypeptide with an N-Terminal Extension
  • The cDNA of MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension was sub-cloned into a pET11b derived vector. Overexpression of MIC-1f polypeptide or MIC-1 polypeptide with an N-terminal extension as inclusion bodies was induced in E. coli by 0.5 mM isopropyl β-d-thiogalactoside (IPTG) when the cell density reached an OD600 of 1.0. After continuous growth in TB for 20 h at 37° C., the cells were harvested and samples for both LC/MS and UPLC were prepared to confirm the molecular weight.
  • Fermentation was carried out on fed-batch process in chemical defined medium as supplement. Fermentation yield largely depended on different polypeptide, which varied from 1 g/L to 8 g/L from polypeptide to polypeptide.
    • Example-2: Purification and Refolding
  • The MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension were further purified as follows:
  • Slurry (20% w/v) of E. coli in 10 mM Tris buffer pH 8.0 was sonicated (3 seconds on/off intervals on ice for 5 minutes) and the MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension was pelleted by centrifugation (10,000×g, for 30 minutes). The inclusion bodies were re-solubilised by 8 M urea in 20 mM Tris pH 8.0, and debris removed by centrifugation (10,000×g, for 30 minutes). The MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension in the resulting supernatant was collected and diluted into the refolding buffer (50 mM Tris, pH 8.5 and 10% DMF or 10% DMSO) to the final concentration of 0.1 mg/ml. The refolding process lasted for 48 hours in the cold room. The resulting solution was filtered by 0.4 μm filter and loaded onto Hydrophobic Interaction column or anion exchange chromatography (50 mM Tris pH 8.0, 0-500 mM NaCl) using Q Sepharose Fast Flow resin (GE Healthcare), as generally described in Protein Purification. Principles and Practice Series: Springer Advanced Texts in Chemistry Scopes, Robert K. 3rd ed., 1994 (Chapters 6 and 8). In some instances, further purification was done by size exclusion chromatography using a HiLoad 26/60 Superdex pg 75 column (GE Healthcare) operated with 50 mM Tris pH 8.0 and 200 mM NaCl. For storage, the MIC-1 polypeptide or MIC-1 polypeptide with an N-terminal extension was transferred to DPBS, and stored frozen. MIC-1 polypeptides or MIC-1 polypeptides with an N-terminal extension and their maximal solubility at pH8 in Tris buffer are shown in Table 5.
  • TABLE 5
    MIC-1 polypeptides or MIC-1 polypeptides with an N-terminal
    extension and their maximal solubility at pH8 in Tris buffer
    tested according to Example 4
    Max.
    Calculated solubility
    SEQ ID NO Structure pI (mg/ml)
    SEQ ID NO: 1 MIC-1 (SEQ ID NO: 1) 8.8 0.3
    SEQ ID NO: 73 MIC-1(R2A, N3E) 6.8 0.9
    SEQ ID NO: 74 MIC-1(R2A, N3E, A54E) 6.4 1.0
    SEQ ID NO: 75 MIC-1(R2A, N3E, A81E) 6.4 N.D.*
    SEQ ID NO: 76 MIC-1(R2A, N3E, H18E) 6.2 1.7
    SEQ ID NO: 77 MIC-1(R2A, N3E, K69E) 6.1 2.2
    SEQ ID NO: 78 MIC-1(R2A, N3E, K107E) 6.1 1.9
    SEQ ID NO: 79 MIC-1(R2A, N3E, L68E) 6.4 3.9
    SEQ ID NO: 80 MIC-1(R2A, N3E, A47E) 6.4 1.0
    SEQ ID NO: 81 MIC-1(R2A, N3E, L105E) 6.4 N.D.
    SEQ ID NO: 82 MIC-1(R2A, N3E, M57E) 6.4 1.7
    SEQ ID NO: 83 MIC-1(R2A, N3E, P85E) 6.4 N.D.
    SEQ ID NO: 84 MIC-1(R2A, N3E, P11E) 6.4 1.6
    SEQ ID NO: 85 MIC-1(R2A, N3E, R21E) 6.1 1.8
    SEQ ID NO: 86 MIC-1(R2A, N3E, R53E) 6.1 1.9
    SEQ ID NO: 87 MIC-1(R2A, N3E, R67E) 6.1 1.8
    SEQ ID NO: 88 MIC-1(R2A, N3E, A30E) 6.4 1.5
    SEQ ID NO: 89 AEEAES-MIC-1-Δ1-3 6.1 N.D.
    SEQ ID NO: 90 AES-MIC-1-Δ1-3 6.8 0.9
    SEQ ID NO: 91 (AEE)2AES-MIC-1-Δ1-3 5.5 N.D.
    SEQ ID NO: 92 (GEPS)5-MIC-1(SEQ ID NO: 1) 5.8 35.1
    SEQ ID NO: 93 SPAGSPTSTEEGTSESATPESGPG- 6.1 44.5
    MIC-1(SEQ ID NO: 1)
    SEQ ID NO: 94 (AEE)6AES-MIC-1(SEQ ID NO: 1) 4.5 39.0
    SEQ ID NO: 95 (AEE)5AES-MIC-1-Δ1-3 4.6 35.0
    SEQ ID NO: 96 (AEE)3AES-MIC-1-Δ1-3 5.0 36.0
    SEQ ID NO: 97 AASPAGSPTSTEEGTSESATPESG 6.1 N.D.
    PG-MIC-1(SEQ ID NO: 1)
    SEQ ID NO: 98 TSESATPESGPGTSESATPESGPG- 5.5 N.D.
    MIC-1(R2A, N3E)
    SEQ ID NO: 99 AASPAGSPTSTEEGTSESATPESG 5.8 N.D.
    PG-MIC-1-Δ1-3
    SEQ ID NO: 100 AAPEDEETPEQEGSGSGSGSGS- 5.2 35.7
    MIC-1-Δ1-3
    SEQ ID NO: 101 AAPEDEETPEQE-MIC-1-Δ1-3 5.2 N.D.
    SEQ ID NO: 102 AAPDEGTEEETEGSGSGSGSGS- 5.2 N.D.
    MIC-1-Δ1-3
    SEQ ID NO: 103 SEPATSGSETPGTSTEPSEGSAPG- 5.8 N.D.
    MIC-1-Δ1-3
    SEQ ID NO: 104 (SEPATSGSETPG)2-MIC-1-Δ1-3 5.8 35.4
    SEQ ID NO: 105 (SEPATSGSETPG)2-MIC-1-Δ1- 5.5 37.1
    3(M57E)
    SEQ ID NO: 106 (SEPATSGSETPG)2-MIC-1-Δ1- 5.8 32.5
    3(M57L)
    SEQ ID NO: 107 A(GPEQGQEP)3-MIC-1-Δ1-3 5.2 32.2
    SEQ ID NO: 108 SEPATSGSETPGTSESATPESGPG 5.5 40.0
    TSTEPS-MIC-1-Δ1-3
    SEQ ID NO: 109 SEPATSGSETPG TSESATPESGPG 5.2 40.0
    TSTEPSEG-MIC-1-Δ1-3
    SEQ ID NO: 110 (SEPATSGSETPG)2-MIC-1-Δ1- 5.8 N.D.
    3(M86L)
    SEQ ID NO: 111 (SEPATSGSETPG)2-MIC-1-Δ1- 5.8 31.1
    3(M57L, M86L)
    SEQ ID NO: 112 (SEPATSGSETPG)2-MIC-1-Δ1- 5.0 N.D.
    3(M57E, H66E)
    SEQ ID NO: 113 (SEPATSGSETPG)2-MIC-1-Δ1- 5.0 N.D.
    3(M57E, R67E)
    SEQ ID NO: 114 (SEPATSGSETPG)2-MIC-1-Δ1- 5.0 N.D.
    3(M57E, R67E, M86L)
    SEQ ID NO: 115 SEPATSGSETPG 5.5 N.D.
    TSESATPESGPGTSTEPSG-MIC-
    1-Δ1-3(M57L, M86L)
    SEQ ID NO: 116 (GEPS)6-MIC-1-Δ1-3 5.2 N.D.
    SEQ ID NO: 117 (SEPATSGSETPG)2-MIC-1-des- 6.1 N.D.
    N3
    *N.D.: Not determined
    • Example-3: pH-Dependent Solubility of MIC-1 Polypeptide with an N-Terminal Extension
  • The purpose of this experiment was to screen for a MIC-1 polypeptide with an N-extension with improved solubility, and determine the optimal pH window for formulation.
  • MIC-1 polypeptides with N-terminal extensions were dissolved in a mixture of water and ethanol (60% water and 40% ethanol) with a concentration range between 3 mg/ml to 10 mg/ml. The solvent was evaporated with SpeedVac (Concentrator Plus, Eppendorf) for 6 hours to obtain pellet of the MIC-1 polypeptide with N-terminal extension.
  • Below buffers were used for this pH-dependent solubility curve assay: acetate buffer (pH 3 to pH 6); Tris buffer (pH 7 to pH 9); CAPS buffer (pH 10 to pH 11).
  • Buffers were added into each well of the 96-well plate together with the MIC-1 polypeptides with N-terminal extensions. The amount used may not be exactly the same but all targeting a theoretical concentration within 12-18 mg/ml. The concentration of MIC-1 polypeptide with N-terminal extension in the supernatant was determined by UPLC (Table 6). Based on the results, solubility of the MIC-1 polypeptide with N-terminal extension of the invention was significantly improved between pH 6-9 compared with wtMIC-1. The optimal pH window of the MIC-1 polypeptides with an N-extension falls into the pH range that is preferred for formulation, e.g. pH 6.5-8.5.
  • TABLE 6
    pH-dependent solubility test of MIC-1 polypeptides
    with an N-terminal extension (mg/ml)
    SEQ ID pH
    NO Structure 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0
    SEQ ID MIC-1 (SEQ 12.8 2.0 0.2 0.3 0.2 0.3 0.6 3.6 13.9
    NO: 1 ID NO: 1)
    SEQ ID MIC- 13.3 1.3 0.4 0.6 0.5 1.0 1.5 3.6 15.5
    NO: 74 1(R2A, N3E,
    A54E)
    SEQ ID MIC- 14.5 3.4 0.4 0.4 0.9 1.7 3.0 14.3 13.6
    NO: 76 1(R2A, N3E,
    H18E)
    SEQ ID MIC- 13.6 1.4 1.4 1.7 3.2 3.9 3.9 4.0 12.1
    NO: 79 1(R2A, N3E,
    L68E)
    SEQ ID MIC- 13.4 2.5 0.5 0.6 0.9 1.0 1.0 2.9 10.8
    NO: 80 1(R2A, N3E,
    A47E)
    SEQ ID MIC- 14.9 1.6 0.5 0.5 1.4 1.8 1.7 2.5 12.9
    NO: 85 1(R2A, N3E,
    R21E)
    SEQ ID MIC- 13.9 1.7 0.8 0.8 1.4 1.5 2.1 2.4 13.7
    NO: 88 1(R2A, N3E,
    A30E)
    SEQ ID AES-MIC-1- 12.5 2.3 0.6 0.7 1.2 0.9 1.0 3.6 8.9
    NO: 90 Δ1-3
    SEQ ID SPAGSPTST 12.9 1.5 1.2 1.4 5.1 12.8 13.0 13.0 13.5
    NO: 93 EEGTSESAT
    PESGPG-
    MIC-1(SEQ
    ID NO: 1)
    SEQ ID (AEE)6AES- 7.3 0.2 2.9 9.5 11.6 15.3 15.1 15.0 14.8
    NO: 94 MIC-1-Δ1-3
    SEQ ID (AEE)5AES- 11.9 0.3 1.6 5.7 9.4 15.8 15.7 14.9 15.0
    NO: 95 MIC-1-Δ1-3
    SEQ ID AAPEDEETP 11.2 3.2 2.1 5.1 8.3 15.0 15.3 15.0 15.6
    NO: 100 EQEGSGSG
    SGSGS-
    MIC-1-Δ1-3
    SEQ ID (SEPATSGS 12.2 0.7 0.3 1.0 4.6 16.4 16.9 16.0 16.2
    NO: 104 ETPG)2-
    MIC-1-Δ1-3
    SEQ ID (SEPATSGS 7.2 1.2 0.8 3.8 11.5 15.6 15.2 14.9 16.2
    NO: 105 ETPG)2-
    MIC-1-Δ1-
    3(M57E)
    SEQ ID (SEPATSGS 10.1 0.2 0.3 1.6 4.3 15.6 16.1 16.1 16.8
    NO: 106 ETPG)2-
    MIC-1-Δ1-
    3(M57L)
    • Example 4: Maximal Solubility of MIC-1 Polypeptides with an N-Terminal Extension at pH 8
  • In order to test the maximal solubility, the MIC-1 polypeptides with an N-terminal extension were dissolved in a mixture of water and ethanol (60% water and 40% ethanol) with a concentration range between 3 mg/ml to 10 mg/ml. Then the solution (150 μL each well) was aliquot into a 96-well plate (Corning). The solvent was evaporated with SpeedVac (Concentrator Plus, Eppendorf) for 6 hours to obtain pellet of the MIC-1 polypeptide with an N-terminal extension. Tris buffer (pH 8.0, without excipients) was added into each well of the 96-well plate. The amount of buffer added to the well was less than the amount needed for solving the whole pellet in the well, so that maximal concentration was achieved. The plate was shaken on a plate shaker at 800 rpm (MixMate, Eppendorf) for 2 hours. The pellet was spun down at 3600 g for 5 min. The supernatants were transferred to a 96-deep-well plate and diluted 20 times with 40% ethanol. Then all of the samples were subject to UPLC (Acquity, Waters), plate reader (Infinite M200 pro, Tecan) and UV spectrometer (NanoDrop 8000, Thermo Scientific) to determine the concentration (Table 7)
  • Based on the results, solubility of the MIC-1 polypeptides with an N-terminal extension of the invention was significantly improved at pH 8.0. Especially, the MIC-1 polypeptides with an N-terminal extension achieved solubility of more than 30 mg/ml at pH 8.0.
  • TABLE 7
    Max solubility test of MIC-1 polypeptides with an
    N-terminal extension at pH 8.0
    Solubility
    SEQ IN NO Structure (mg/ml)
    SEQ ID NO: 96 (AEE)3AES-MIC-1-Δ1-3 36.0
    SEQ ID NO: 95 (AEE)5AES-MIC-1-Δ1-3 35.0
    SEQ ID NO: 94 (AEE)6AES-MIC-1(SEQ ID NO: 1) 39.0
    SEQ ID NO: 93 SPAGSPTSTEEGTSESATPESGPG-MIC-1 44.5
    SEQ ID NO: 92 (GEPS)5-MIC-1(SEQ ID NO: 1) 35.1
    SEQ ID NO: 100 AAPEDEETPEQEGSGSGSGSGS-MIC-1-Δ1-3 35.7
    SEQ ID NO: 79 MIC-1(R2A, N3E, L68E) 3.9
    SEQ ID NO: 85 MIC-1(R2A, N3E, R21E) 1.8
    SEQ ID NO: 88 MIC-1(R2A, N3E, A30E) 1.5
    SEQ ID NO: 74 MIC-1(R2A, N3E, A54E) 1.0
    SEQ ID NO: 76 MIC-1(R2A, N3E, H18E) 1.7
    SEQ ID NO: 77 MIC-1(R2A, N3E, K69E) 2.2
    SEQ ID NO: 80 MIC-1(R2A, N3E, A47E) 1.0
    SEQ ID NO: 90 AES-MIC-1-Δ1-3 0.9
    SEQ ID NO: 78 MIC-1(R2A, N3E, K107E) 1.9
    SEQ ID NO: 82 MIC-1(R2A, N3E, M57E) 1.7
    SEQ ID NO: 84 MIC-1(R2A, N3E, P11E) 1.6
    SEQ ID NO: 86 MIC-1(R2A, N3E, R53E) 1.9
    SEQ ID NO: 87 MIC-1(R2A, N3E, R67E) 1.8
    SEQ ID NO: 104 (SEPATSGSETPG)2-MIC-1-Δ1-3 35.4
    SEQ ID NO: 105 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57E) 37.1
    SEQ ID NO: 106 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57L) 32.5
    SEQ ID NO: 107 A(GPEQGQEP)3-MIC-1-Δ1-3 32.2
    SEQ ID NO: 108 SEPATSGSETPGTSESATPESGPGTSTEPS-MIC-1- 40.0
    Δ1-3
    SEQ ID NO: 109 SEPATSGSETPGTSESATPESGPG TSTEPSEG-MIC- 40.0
    1-Δ1-3
    SEQ ID NO: 111 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57L, M86L) 31.1
    SEQ ID NO: 73 MIC-1(R2A, N3E) 0.9
    SEQ ID NO: 164 SEPATSGSETPGTSESATPESGPGTSTEPSEG-MIC- 40.0
    1-des-N3 (M57L, M86L)
    SEQ ID NO: 1 MIC-1(SEQ ID NO: 1) 0.3
  • The improved solubility of MIC-1 polypeptides with an N-extension was retained in the MIC-1 compounds, i.e. adding a protractor did not significantly lower the solubility (Example 12).
    • General Methods of In Vitro Activity Screening Example 5: Establishment of BHK21-hGFRAL-IRES-hRET Cell Line
  • The purpose of this example was to establish a cell based in vitro assay for testing MIC-1 activity. Mammalian cells were transfected and stably expressed full length MIC-1 receptor (hGFRAL) and its full signaling co-receptor hRET51.
  • Plasmids expressing full length hGFRAL and full length hRET51 were constructed by inserting synthesized DNA nucleotides encoding full length hGFRAL and full length hRET51 into mammalian expression vector pEL. IRES (internal ribosome entry site) is a commonly used linker between two DNA sequences, so that the two DNA sequences can be simultaneously translated into mRNA. pEL vector backbone was provided by Taihegene CRO company.
  • Two millions of BHK21 cells were seeded in a 10 cm petri dish and cultured for overnight in culture medium (DMEM+10% FBS+1% PS). Cells were transfected with pEL-hGFRAL-IRES-hRET plasmids. Transfected cells were split into new 10 cm dishes at different densities and grew in selection medium (DMEM+10%/FBS+1%/PS+1 mg/ml G418) for more than 2 weeks to get single clones. The single clones were transferred to 6 well plates and cultured to 1000/confluence. mRNA expression of hGFRAL and hRET was measured by qPCR. Successfully transfected clones were picked up and tested for MIC-1 binding.
    • Example 6: MIC-1 Cell-Based In Vitro Activity Assay
  • wtMIC-1 and MIC-1 polypeptides with an N-terminal extension induced both phosphorylation of ERK1/2 in BHK21-hGFRAL-IRES-hRET stable cells (Table 8). It can be concluded from the results that the ternary complex of MIC-1, GFRAL and RET phosphorylates RET protein tyrosine kinase to induce in vivo activities of MIC-1 through signal pathways comprising ERK/MAPK pathway by phosphorylation of ERK1/2.
  • Results from screening MIC-1 polypeptides with an N-terminal extension using BHK21-hGFRAL-IRES-hRET is shown in Table 8. MIC-1 polypeptides with N-extensions only or MIC-1 analogues with in-sequence mutations only achieved in vitro activity equal to or even higher than wtMIC-1. Also, combination of N-extension and in-sequence mutations can also achieve similar activity.
  • TABLE 8
    In vitro activity
    pERK EC50 Emax
    SEQ IN NO Structure (nM) (%)
    SEQ ID NO: 1 MIC-1(SEQ ID NO: 1) 0.3 100%
    SEQ ID NO: 73 MIC-1(R2A, N3E) 0.3 100%
    SEQ ID NO: 74 MIC-1(R2A, N3E, A54E) 0.3 100%
    SEQ ID NO: 75 MIC-1(R2A, N3E, A81E) 0.3 100%
    SEQ ID NO: 76 MIC-1(R2A, N3E, H18E) 0.5 100%
    SEQ ID NO: 77 MIC-1(R2A, N3E, K69E) 0.5 100%
    SEQ ID NO: 78 MIC-1(R2A, N3E, K107E) 0.3 100%
    SEQ ID NO: 79 MIC-1(R2A, N3E, L68E) 0.8 100%
    SEQ ID NO: 80 MIC-1(R2A, N3E, A47E) 0.4 100%
    SEQ ID NO: 81 MIC-1(R2A, N3E, L105E) 0.7 100%
    SEQ ID NO: 82 MIC-1(R2A, N3E, M57E) 0.3  70%
    SEQ ID NO: 83 MIC-1(R2A, N3E, P85E) 0.6 100%
    SEQ ID NO: 84 MIC-1(R2A, N3E, P11E) 0.4 100%
    SEQ ID NO: 85 MIC-1(R2A, N3E, R21E) 0.6 100%
    SEQ ID NO: 86 MIC-1(R2A, N3E, R53E) 0.4 100%
    SEQ ID NO: 87 MIC-1(R2A, N3E, R67E) 0.5 100%
    SEQ ID NO: 88 MIC-1(R2A, N3E, A30E) 0.7 100%
    SEQ ID NO: 89 AEEAES-MIC-1-Δ1-3 0.3 100%
    SEQ ID NO: 90 AES-MIC-1-Δ1-3 0.3 100%
    SEQ ID NO: 91 (AEE)2AES-MIC-1-Δ1-3 0.4 100%
    SEQ ID NO: 92 (GEPS)5-MIC-1(SEQ ID NO: 1) 0.5 100%
    SEQ ID NO: 93 SPAGSPTSTEEGTSESATPESGPG-MIC- 0.4 100%
    1(SEQ ID NO: 1)
    SEQ ID NO: 94 (AEE)6AES-MIC-1 0.8 100%
    SEQ ID NO: 95 (AEE)5AES-MIC-1-Δ1-3 0.5 100%
    SEQ ID NO: 96 (AEE)3AES-MIC-1-Δ1-3 0.5 100%
    SEQ ID NO: 97 AASPAGSPTSTEEGTSESATPESGPG-MIC- 0.4 100%
    1(SEQ ID NO: 1)
    SEQ ID NO: 98 TSESATPESGPGTSESATPESGPG-MIC- 0.3 100%
    1(R2A, N3E)
    SEQ ID NO: 99 AASPAGSPTSTEEGTSESATPESGPG-MIC-1- 0.7 100%
    Δ1-3
    SEQ ID NO: 100 AAPEDEETPEQEGSGSGSGSGS-MIC-1-Δ1-3 0.5 100%
    SEQ ID NO: 101 AAPEDEETPEQE-MIC-1-Δ1-3 0.5 100%
    SEQ ID NO: 102 AAPDEGTEEETEGSGSGSGSGS-MIC-1-Δ1-3 0.5 100%
    SEQ ID NO: 103 SEPATSGSETPGTSTEPESGSAPG-MIC-1- 0.7 100%
    Δ1-3
    SEQ ID NO: 104 (SEPATSGSETPG)2-MIC-1-Δ1-3 0.4 100%
    SEQ ID NO: 105 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57E) 0.6  60%
    SEQ ID NO: 106 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57L) 0.6 100%
    SEQ ID NO: 107 A(GPEQGQEP)3-MIC-1-Δ1-3 0.8 100%
    SEQ ID NO: 108 SEPATSGSETPGTSESATPESGPGTSTEPS- 0.4 100%
    MIC-1-Δ1-3
    SEQ ID NO: 109 SEPATSGSETPGTSESATPESGPG 0.4 100%
    TSTEPSEG-MIC-1-Δ1-3
    SEQ ID NO: 110 (SEPATSGSETPG)2-MIC-1-Δ1-3(M86L) 0.4 100%
    SEQ ID NO: 111 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57L, 0.4 100%
    M86L)
    • In Vivo Efficacy Example 7: Effect of MIC-1 Polypeptides with an N-Terminal Extension on Food Intake in Lean Sprague Dawley Rats
  • The in vivo efficacy of MIC-1 polypeptides with an N-terminal extension was measured in 9-11 weeks old lean male Sprague Dawley rats. Animals were injected once daily with a dose of 8 nmol/kg body weight 1-2 hrs before the onset of the dark period. Compounds were administrate subcutaneously (1-4 ml/kg) in appropriate buffered solution. Changes in food intake were measured by automatic food monitoring systems (BioDAQ system and HM2 system for rat). In the BioDAQ system animals were single housed; and in the HM2 system animals were in group housed with up to 3 animals per cage. Each compound was tested in n=4-8 animals. Animals were acclimatized for at least 7 days prior to the experiment. Collected data are expressed as daily food intake (24 hour food intake) measured from the onset of each daily 12 hour dark phase to the next day dark phase. Daily changes in food intake in response to administrated compound were calculated by subtracting the average daily food intake of the vehicle group from the average daily food intake of the treatment group. Changes were considered significant if p<0.1 using a two-tailed student's t-test. Results are expressed as the “maximum reduction” in food intake compared with vehicle (percentage) recorded during the study period. Data are also expressed as the “accumulated reduction” in food intake which as the sum of significant (p<0.1) daily reductions in food intake (percentage) during the study period.
  • TABLE 9
    Effect of daily doses (8 nmol/kg) of MIC-1 polypeptides
    with an N-extension on food intake in lean SD rats.
    Maximum
    Efficacy Accumulated
    SEQ ID NO Structure (%) Efficacy (%)
    SEQ ID NO: 1 MIC-1(SEQ ID NO: 1) 68 361
    SEQ ID NO: 77 MIC-1(R2A, N3E, K69E) 46 247
    SEQ ID NO: 82 MIC-1(R2A, N3E, M57E) 72 395
    SEQ ID NO: 92 (GEPS)5-MIC-1(SEQ ID NO: 1) 84 469
    SEQ ID NO: 97 AASPAGSPTSTEEGTSESATPESGPG- 90 456
    MIC-1(SEQ ID NO: 1)
    SEQ ID NO: 98 TSESATPESGPGTSESATPESGPG-MIC- 90 503
    1(R2A, N3E)
    SEQ ID NO: 100 AAPEDEETPEQEGSGSGSGSGS-MIC-1- 84 446
    Δ1-3
    SEQ ID NO: 101 AAPEDEETPEQE-MIC-1-Δ1-3 75 408
    SEQ ID NO: 102 AAPDEGTEEETEGSGSGSGSGS-MIC-1- 82 423
    Δ1-3
    SEQ ID NO: 103 SEPATSGSETPGTSTEPESGSAPG-MIC-1- 82 452
    Δ1-3
    SEQ ID NO: 104 (SEPATSGSETPG)2-MIC-1-Δ1-3 93 509
    SEQ ID NO: 105 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57E) 97 532
    SEQ ID NO: 106 (SEPATSGSETPG)2-MIC-1-Δ1-3(M57L) 99 532
    SEQ ID NO: 107 A(GPEQGQEP)3-MIC-1-Δ1-3 81 395
    SEQ ID NO: 108 SEPATSGSETPGTSESATPESGPGTSTEPS- 80 448
    MIC-1-Δ1-3
    SEQ ID NO: 165 A(GPEQGQEPGEPQGQEPQPGEPEGQ)- 78 382
    MIC-1-Δ1-3
    SEQ ID NO: 109 SEPATSGSETPGTSESATPESGPGTSTEPS 82 445
    EG-MIC-1-Δ1-3
    SEQ ID NO: 110 (SEPATSGSETPG)2-MIC-1-Δ1-3 (M86L) 70 398
    SEQ ID NO: 111 (SEPATSGSETPG)2-MIC-1-Δ1-3 85 462
    (M57L/M86L)
    SEQ ID NO: 112 (SEPATSGSETPG)2-MIC-1-Δ1-3 80 369
    (M57E/H66E)
    SEQ ID NO: 113 (SEPATSGSETPG)2-MIC-1-Δ1-3 67 266
    (M57E/R67E)
    Note:
    * means the dose of administration is 4 nmol/kg body weight.
  • The inventors surprisingly found that these MIC-1 polypeptides with an N-extension not only increased the solubility molecules but also resulted in efficacy equal to or even better than wtMIC-1 (Table 9). For instance compounds according to SEQ ID NO: 105 and SEQ ID NO:106 had a maximum and accumulated in vivo efficacy which was 40-50% greater than wtMIC-1 with subcutaneous dosing. The increase in efficacy was furthermore associated with an increase in solubility as compounds according to SEQ ID NO:92, SEQ ID NO: 104, SEQ ID NO: 105 and SEQ ID NO:106 all had elevated solubility and a significant greater in vivo efficacy compared with wtMIC-1. This correlation seems not to be explained by changes in the in vitro Emax as all compounds in table 8, except compound according to SEQ ID NO: 105, had an Emax comparable with wtMIC-1. In fact, compound SEQ ID NO:105 had a lower Emax than wtMIC-1 and was still more efficacious than wtMIC-1 in vivo. Also, the in vitro potencies were comparable between compounds as none of the compounds had an EC50 which differed from wtMIC-1. Thus, the association between increased in vivo efficacies and increased solubility is surprising and cannot be simply be explained by changes in increased receptor activation in vitro.
    • Example 8: MIC-1 Expression and Initial Met Removal Efficiency of Different 12-Mer Blocks
  • In the human body, N-Formyl-Methionine is recognized by the immune system as foreign material, or as an alarm signal released by damaged cells, and stimulates the body to fight against potential infection (Pathologic Basis of Veterinary Disease5: Pathologic Basis of Veterinary Disease, By James F. Zachary, M. Donald McGavin). In addition, Methionine is an instable residue that could be easily oxidized. Therefore, the N-Met cleavage efficiency is very important to MIC-1 expression.
  • There are 4 different types of 12 mers, and all of them are comprised of 3 Ser, 2 Pro, 2 Gly, 2 Thr, 2 Glu and 1 Ala. However, the 12 residues in each repeat are arranged in different ways.
  • Little is known about the effects of different 12 mers on the expression level and the N-Met cleavage efficiency. Thus, systematically investigation of MIC-1 polypeptides initiating with single and double 12 mers respectively is quite necessary.
  • The cDNA of MIC-1 polypeptide with N-terminal extension was sub-cloned into a pET11b derived vector. Overexpression of MIC-1 polypeptides with an N-terminal extension as inclusion bodies or soluble protein was induced in E. coli by 0.5 mM isopropyl β-d-thiogalactoside (IPTG) when the cell density reached an OD600 of 1.0. After continuous growth in TB for 20 h at 37° C., the cells were harvested and sonicated in buffer A (20 mM Tris, pH 8.0). The resulting mixture was centrifugated at 10,000 g for 20 min and analysed by LC/MS and SDS-PAGE to confirm the molecular weight.
  • Fermentation was carried out on fed-batch process in chemical defined medium as supplement. Fermentation yield largely depended on different compounds, which varied from 1 g/L to 8 g/L from compound to compound.
  • Compounds designed for the single-12 mer test and the result are shown in Table 10 and FIG. 1 .
  • TABLE 10
    Initial Met removal efficiency of single
    12-mer building blocks
    N-Met
    cleavage
    N- MIC-1 efficiency
    extension N-aa sequence polypeptide (%)
    12mer-1 SPAGSPTSTEEG MIC-1 Δ1-3 N/A
    (SEQ ID NO: 166)
    12mer-2 TSESATPESGPG 0
    (SEQ ID NO: 167)
    12mer-3 TSTEPSEGSAPG 0
    (SEQ ID NO: 168)
    12mer-4 SEPATSGSETPG 100
    (SEQ ID NO: 169)
    N/A: means MIC-1 with the N-terminal extension did not express in E. coli.

    Compounds bearing double 12 mers are listed in Table 11, and the results are shown as well (see Table 11 and FIG. 2 ).
  • TABLE 11
    Initial Met removal efficiency of double 12-mers
    building blocks
    N-Met
    cleavage
    SEQ ID N- MIC-1 efficiency
    NO extension N-aa sequence polypeptide (%)
    N/A 12mer- SPAGSPTSTEEG- MIC-1 N/A
    (1 + 1) SPAGSPTSTEEG Δ1-3
    (SEQ ID NO: 170)
    N/A 12mer- SPAGSPTSTEEG- N/A
    (1 + 3) TSTEPSEGSAPG
    (SEQ ID NO: 171)
    N/A 12mer- SPAGSPTSTEEG- N/A
    (1 + 4) SEPATSGSETPG
    (SEQ ID NO: 172)
    N/A 12mer- TSESATPESGPG- 58.1
    (2 + 1) SPAGSPTSTEEG
    (SEQ ID NO: 173)
    N/A 12mer- TSESATPESGPG- 30.0
    (2 + 2) TSESATPESGPG
    (SEQ ID NO: 174)
    N/A 12mer- TSESATPESGPG- 58.5
    (2 + 3) TSTEPSEGSAPG
    (SEQ ID NO: 175)
    N/A 12mer- TSESATPESGPG- 64.5
    (2 + 4) SEPATSGSETPG
    (SEQ ID NO: 176)
    N/A 12mer- TSTEPSEGSAPG- 10.0
    (3 + 1) SPAGSPTSTEEG
    (SEQ ID NO: 177)
    N/A 12mer- TSTEPSEGSAPG- 1.0
    (3 + 2) TSESATPESGPG
    (SEQ ID NO: 178)
    N/A 12mer- TSTEPESGSAPG- 26.4
    (3 + 3) TSTEPESGSAPG
    (SEQ ID NO: 179)
    N/A 12mer- TSTEPSEGSAPG- 10.5
    (3 + 4) SEPATSGSETPG
    (SEQ ID NO: 180)
    N/A 12mer- SEPATSGSETPG- N/A
    (4 + 1) SPAGSPTSTEEG
    (SEQ ID NO: 12)
    SEQ ID 12mer- SEPATSGSETPG- 100
    NO: 182 (4 + 2) TSESATPESGPG
    (SEQ ID NO: 13)
    SEQ ID 12mer- SEPATSGSETPG- 100
    NO: 103 (4 + 3) TSTEPSEGSAPG
    (SEQ ID NO: 14)
    SEQ ID 12mer- SEPATSGSETPG- 100
    NO: 104 (4 + 4) SEPATSGSETPG
    (SEQ ID NO: 181)
    N/A: means MIC-1 polypeptide with N-terminal extension did not express in E. coli.
  • In conclusion, N-extensions starting with the 2mer-1 block could not be expressed in E. coli. For the other 12 mer blocks, protein expression was achieved but only 12 mer-4 as the initial sequence resulted in complete methionine cleavage. In addition, the N-met cleavage efficiency of 12 mer-2 series is better than that of 12 mer-3 series.
    • Example 9: Expression Level and Inclusion Body Ratio of MIC-1 Polypeptide with 2* or 2.5*12 Mer N-Extension
  • (1) Expression of MIC-1 Polypeptide with 2.5*12Mer N-Extension
  • See Example 8 for protein production method. The results are shown in Table 12, FIG. 3 and FIG. 4 .
  • TABLE 12
    Constructs and protein production for 2.5*12mer test
    UPLC UPLC
    SEQ ID N- N-aa MIC-1 Shaker Flask Fermenter
    NO extension sequence polypeptide (g/L/10OD) (g/L/10OD)
    SEQ ID 12mer- SEPATSGSETPG MIC-1 N.D.
    NO: 200 (4 + 2 + 1.6 TSESATPESGPG Δ1-3
    latter) TSTEEG
    (SEQ ID NO: 28)
    SEQ ID 12mer- SEPATSGSETPG 0.197
    NO: 201 (4 + 2 + 2.6) TSESATPESGPG
    TSESAT
    (SEQ ID NO: 19)
    SEQ ID 12mer- SEPATSGSETPG 0.206
    NO: 202 (4 + 2 + 2.6 TSESATPESGPG
    inter) ESATPE (SEQ
    ID NO: 183)
    SEQ ID 12mer- SEPATSGSETPG 0.367 0.374
    NO: 108 (4 + 2 + 3.6) TSESATPESGPG
    TSTEPS (SEQ ID
    NO: 70)
    SEQ ID 12mer- SEPATSGSETPG 0.243
    NO: 203 (4 + 2 + 3.6 TSESATPESGPG
    inter) STEPSE (SEQ
    ID NO: 184)
    SEQ ID 12mer- SEPATSGSETPG 0.273 0.162
    NO: 109 (4 + 2 + 3.8) TSESATPESGPG
    TSTEPSEG
    (SEQ ID NO: 71)
    SEQ ID 12mer- SEPATSGSETPG 0.373
    NO: 204 (4 + 2 + 4.6) TSESATPESGPG
    SEPATS
    (SEQ ID NO: 25)
    SEQ ID 12mer- SEPATSGSETPG MIC-1 Δ1-3, 0.195
    NO: 205 (4 + 3 + 1.6 TSTEPSEGSAPG M57L
    latter) TSTEEG (SEQ
    ID NO: 185)
    SEQ ID 12mer- SEPATSGSETPG 0.234
    NO: 206 (4 + 3 + 2.6) TSTEPSEGSAPG
    TSESAT (SEQ
    ID NO: 186)
    SEQ ID 12mer- SEPATSGSETPG 0.367
    NO: 207 (4 + 3 + 3.6) TSTEPSEGSAPG
    TSTEPS (SEQ ID
    NO: 187)
    SEQ ID 12mer- SEPATSGSETPG 0.324
    NO: 208 (4 + 3 + 4.6) TSTEPSEGSAPG
    SEPATS (SEQ
    ID NO: 188)
    SEQ ID 12mer- SEPATSGSETPG MIC-1 Δ1-3, 0.148
    NO: 209 (4 + 4 + 1.6 SEPATSGSETPG M57L
    latter) TSTEEG(SEQ ID
    NO: 189)
    SEQ ID 12mer- SEPATSGSETPG MIC-1 0.361
    NO: 210 (4 + 4 + 2.6) SEPATSGSETPG Δ1-3
    TSESAT (SEQ
    ID NO: 190)
    SEQ ID 12mer- SEPATSGSETPG N.D.
    NO: 211 (4 + 4 + 2.6 SEPATSGSETPG
    inter) ESATPE (SEQ
    ID NO: 191)
    SEQ ID 12mer- SEPATSGSETPG MIC-1 Δ1-3, 0.262
    NO: 212 (4 + 4 + 3.6) SEPATSGSETPG M57L
    TSTEPS (SEQ ID
    NO: 192)
    SEQ ID 12mer- SEPATSGSETPG MIC-1 N.D.
    NO: 213 (4 + 4 + 3.6 SEPATSGSETPG Δ1-3
    inter2) STEPSE (SEQ
    ID NO: 193)
    SEQ ID 12mer- SEPATSGSETPG 0.330
    NO: 214 (4 + 4 + 4.6) SEPATSGSETPG
    SEPATS (SEQ
    ID NO: 194)
    Notes:
    “.6” means the first 6aa of 12mers,
    “latter” means the last 6aa of 12mers,
    “inter” means the internal 6aa from 12mers.
    “N.D.” means “not detected”.
  • Although the extended 12 mer (6aa) locate 24aa away from the N-terminal, the expression levels of MIC-1 polypeptide with an N-terminal extension vary a lot among different groups. It is clear that the fragment from 12 mer-1 is not suitable for expression, which is consistent with previous results. The average expression levels of 2mer-(4+_+3.6) and -(4+_+4.6) are relatively higher than others.
  • (2) Inclusion Body Ratio of MIC-1 Polypeptide with 2* or 2.5*2Mer N-Extension
  • For large scale protein production, inclusion body is usually considered as a good choice mainly due to its better up-scaling properties, which mainly include: high expression level, simple recovery step and high purity, protease-resistant and good process stability.
  • MIC-1 polypeptides with an N-terminal extension could be expressed either inclusion body or soluble form, which is mainly dependent on compounds' pI and extension The results are shown in Table 13 and FIG. 4 .
  • TABLE 13
    Solubility in cell cytosol and their pI values
    Sequences of MIC-1 Inclusion pI
    SEQ ID NO N-extension N-extension polypeptide body ratio★ values
    SEQ ID NO: 12mer-(4 + 4) SEPATSGSETPG MIC-1 100%  5.8
    104 SEPATSGSETPG Δ1-3
    (SEQ ID NO:
    181)
    SEQ ID NO: 12mer-(4 + 2 + 3.6) SEPATSGSETPG 100%  5.5
    108 TSESATPESGPG
    TSTEPS
    (SEQ ID NO: 70)
    SEQ ID NO: 12mer-(4 + 2 + 3.8) SEPATSGSETPG 90% 5.2
    109 TSESATPESGPG
    TSTEPSEG
    (SEQ ID NO: 71)
    SEQ ID NO: 12mer-(4 + 2)- SEPATSGSETPG 90% 5.2
    215 GPEQGPEQ TSESATPESGPG
    GPEQGPEQ
    (SEQ ID
    NO: 195)
    SEQ ID NO: 12mer-(4 + 2)- SEPATSGSETPG 95% 5.2
    216 GEPSGEPS TSESATPESGPG
    GEPSGEPS
    (SEQ ID
    NO: 196)
    SEQ ID NO: 12mer-(4 + 4) SEPATSGSETPG 70% 5.0
    112 M57E, H66E SEPATSGSETPG
    (SEQ ID NO:
    181)
    SEQ ID NO: 12mer-(4 + 4) SEPATSGSETPG 70% 5.0
    113 M57E, R67E SEPATSGSETPG
    (SEQ ID NO:
    181)
    SEQ ID NO: 12mer-(three SEPATSGSETPG MIC-1-des- 85% 5.4
    217 repeats) TSESATPESGPG N3
    TSTEPSEGSAPG
    (SEQ ID NO:
    197)
    SEQ ID NO: 12mer-(four SEPATSGSETPG MIC-1-des- 30% 5.1
    218 repeats) TSESATPESGPG N3
    TSTEPSEGSAPG
    TSTEPSEGSAPG
    (SEQ ID NO:
    198)
    SEQ ID NO: 12mer-(five SPAGSPTSTEEG MIC-1  0% 4.8
    219 repeats) TSESATPESGPG
    TSTEPSEGSAPG
    SPAGSPTSTEEG
    TSTEPSEGSAPG
    (SEQ ID NO:
    199)
    SEQ ID NO: 12mer-(4 + 4) SEPATSGSETPG MIC-1  0% 4.7
    220 M57E, H66E, R67E SEPATSGSETPG Δ1-3
    (SEQ ID NO:
    181)
    SEQ ID NO: 12mer-(4 + 2 + 3.6) SEPATSGSETPG  0% 4.7
    221 M57E, R67E TSESATPESGPG
    TSTEPS
    (SEQ ID NO: 70)
    Note:
    ★The number here is estimated by SDS-PAGE.
  • The solubility of MIC-1 polypeptides with in-sequence mutations are shown in Table 14 and FIG. 5 (the MIC-1 polypeptide sequence is MIC-1 Δ1-3).
  • TABLE 14
    Solubility of MIC-1 polypeptide with
    in-sequence mutations
    Solubility
    N-extension In-sequence M in cell
    SEPATSGSETPG M57E IBs
    SEPATSGSETPG M57E/H66E Partially soluble
    (12mer-(4 + 4)) M57E/H66E/R67E Fully soluble
    (SEQ ID NO: 181)
    SEPATSGSETPG M57E N.D.
    TSESATPESGPG- M57E/H66E Fully soluble
    TSTEPS M57E/H66E/R67E Fully soluble
    (12mer-
    (4 + 2 + 3.6))
    (SEQ ID NO: 70)
  • MIC-1 polypeptides initiating with 12 mer-(4+2+_), -(4+4+_) and -(4+3+_) were investigated with their ability to express inclusion body. It was shown that the inclusion body ratio is >90 when pI>5.1. In addition, MIC-1 polypeptides with in-sequence mutations M57E/H66E mainly expressed soluble fractions.
    • Example 9: Production of MIC-1 Polypeptides with an N-Terminal Extension Including a Cys Mutation
  • To increase the half-life of MIC-1 polypeptides with an N-terminal extension, different fatty acid chains that were used for protraction were conjugated to the N-terminal extension through alkylation mediated by Cysteine introduced by site-directed mutation. The position for the Cys mutation has been systematically mapped and resulting MIC-1 polypeptides with an N-terminal extension were refolded and purified according to the methods described in Example 8.
  • 1. Introduce a Cys Mutation to the N-Terminal Extension for Protraction
  • Total of 20 different cysteine mutants were generated by site-directed mutations using PCR method and constructs are listed as Table 15.
  • TABLE 15
    Constructs having the Cys mutation at different positions
    Constructs N-term. Cys MIC-1 Inclusion pI
    (SEQ ID NO) extension mutation polypeptide body ratio★ values
    SEQ ID NO: 301 SEPATCGSETPG- S(−25)C MIC-1, des- 100% 5.7
    TSESATPESGPG- N3
    TSTEPS (SEQ ID
    NO: 223)
    SEQ ID NO: 302 SEPATSGCETPG- S(−23)C 100% 5.7
    TSESATPESGPG-
    TSTEPS(SEQ ID
    NO: 224)
    SEQ ID NO: 288 SEPCTSGSETPG- A(−29)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 225)
    SEQ ID NO: 291 SEPATCGSETPG- S(−27)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 226)
    — SEPATSCSETPG- G(−26)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 227)
    — SEPCTSGSETPG- A(−29)C MIC-1, des- 100% 5.4
    TSESATPESGPG- N3, M57L
    TSTEPSEG(SEQ
    ID NO: 225)
    — SEPATSCSETPG- G(−26)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 227)
    — SEPCTSGSETPG- A(−29)C MIC-1, des- 100% 5.4
    TSESATPESGPG- N3, M57L,
    TSTEPSEG(SEQ M86L
    ID NO: 228)
    — SEPACSGSETPG- T(−28)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 229)
    SEQ ID NO: 289 SEPATSCSETPG- G(−26)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 227)
    SEQ ID NO: 303 SEPATSGCETPG- S(−25)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 230)
    SEQ ID NO: 304 SEPATSGSECPG- T(−23)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 231)
    SEQ ID NO: 305 SEPATSGSETPC- G(−21)C 100% 5.4
    TSESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 232)
    SEQ ID NO: 306 SEPATSGSETPG- S(−19)C 100% 5.4
    TCESATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 233)
    SEQ ID NO: 307 SEPATSGSETPG- S(−17)C 100% 5.4
    TSECATPESGPG-
    TSTEPSEG(SEQ
    ID NO: 234)
    SEQ ID NO: 292 SEPATSGSETPG- T(−15)C 100% 5.4
    TSESACPESGPG-
    TSTEPSEG(SEQ
    ID NO: 235)
    SEQ ID NO: 308 SEPATSGSETPG- S(−12)C 100% 5.4
    TSESATPECGPG-
    TSTEPSEG(SEQ
    ID NO: 236)
    SEQ ID NO: 309 SEPATSGSETPG- G(−11)C 100% 5.4
    TSESATPESCPG-
    TSTEPSEG(SEQ
    ID NO: 237)
    SEQ ID NO: 310 SEPATSGSETPG- T(−6)C 100% 5.4
    TSESATPESGPG-
    TSCEPSEG(SEQ
    ID NO: 238)
    SEQ ID NO: 293 SEPATSGSETPG- S(−3)C 100% 5.4
    TSESATPESGPG-
    TSTEPCEG(SEQ
    ID NO: 239)
    SEQ ID NO: 316 GEQPCEQPGEQP G(−24)C MIC-1 100% 5.3
    GEQPGEQPGEQP
    GEQP (SEQ ID
    NO: 317)
    N.A. = Not available.
    * The number in bracket (of the Column Cys mutation) means the distance between Cys and the N-terminal amino acid of MIC-1 polypeptide.
  • It shows that the expression level of MIC-1 polypeptide with an N-terminal extension with a Cys mutation is similar to those without Cys mutation.
  • 2. Refolding and Purification of MIC-1 Polypeptide with an N-Terminal Extension Including a Cys Mutation
  • WtMIC-1 homo-dimer contains total of 9 pairs of disulphide bonds and in theory, introducing a new cysteine will disturb the original disulphide bond matching by disulphide bond scrambling, which could further decrease refolding yield. While in our experiments, it is surprising to find that these Cys mutants listed were tested in the same refolding buffer used for wtMIC-1 refolding and showed similar refolding yield (−50% to 60%) as wtMIC-1 or solubility-engineered MIC-1 polypeptide with an N-terminal extension described.
  • 3. pH-Dependent Solubility and Maximal Solubility of MIC-1 Polypeptide with an N-Terminal Extension Including a Cys Mutation
  • The pH-dependent solubility and maximal solubility were determined by the same method as described in Example 4. The results are shown in Table 16 and Table 17.
  • TABLE 16
    pH-dependent solubility test of MIC-1 polypeptide with an
    N-terminal extension including a Cys mutation
    SEQ pH
    ID NO Structure 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0
    SEQ ID SEPCTSGSETPGTS 8.81 4.22 1.34 5.18 13.52 15.65 15.1 15.84 15.97
    NO: ESATPESGPGTSTE
    288 PSEG-MIC-1-Δ3
    SEQ ID SEPATSCSETPGTS 7.91 5.12 1.37 5.91 13.59 15.62 15.15 15.83 16.47
    NO: ESATPESGPGTSTE
    289 PSEG-MIC-1
    (M57L, M86L)
    SEQ ID GEQPCEQPGEQPG 6.24 3.14 2.54 4.71 9.43 13.24 14.21 15.21 15.2
    NO: EQPGEQPGEQPGE
    316 QP-MIC-1
  • TABLE 17
    Maximal solubility determination test of
    MIC-1 polypeptide with an N-terminal
    extension including a Cys mutation
    Max.
    solubility
    SEQ ID NO Structure (mg/ml)
    SEQ ID NO: SEPCTSGSETPGTSESATPESGPGTST 36.1
    288 EPSEG-MIC-1-Δ3
    SEQ ID NO: SEPATSCSETPGTSESATPESGPGTST 38.4
    289 EPSEG-MIC-1 (M57L, M86L)
    SEQ ID NO: GEQPCEQPGEQPGEQPGEQPGEQPG 32.1
    316 EQP-MIC-1

    It can be seen that a Cys mutation does not impact the improved solubility obtained by adding an N-terminal amino acid extension to a MIC-1 polypeptide.
    • Example 10: Preparation of Protractors for MIC-1 Compounds Example 10.1: Preparation of 17-[(S)-1-carboxy-3-(2-{2-[(2-{2-[(4-formylbenzylcarbamoyl)methoxy]ethoxy}ethylcarbamoyl)-methoxy]ethoxy}ethylcarbamoyl)propylcarbamoyl]heptadecanoic acid
  • Figure US20230364248A1-20231116-C00055
  • t-Bu-N-(4-Formylbenzyl) carbamate (100 mg) was treated with TFA/DCM (1:1) for 1 h. The mixture was concentrated in vacuo and co-concentrated with toluene (twice). The residue was dissolved in THF (2.5 ml) and a solution of 17-((S)-1-carboxy-3-{2-[2-({2-[2-(2,5-dioxopyrrolidin-1-yloxycarbonylmethoxy)-ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethylcarbamoyl}propylcarbamoyl)heptadecanoic acid (320 mg, prepared as described previously in WO2009/083549) in THF (5 ml) was added. DIPEA (0.5 ml) was added slowly. After 130 min, the mixture was concentrated in vacuo. The residue was dissolved in EtOAc and 1N HCl. The organic layer was extracted with 1N HCl and brine. The organic layer was dried (Na2SO4) and concentrated in vacuo to give the title compound as a white solid, which was used without further purification.
  • Yield 234 mg (72%)
  • LCMS2: Theoretical mass: 851.0 Found: 851.5 (M+1).
    • Example 10.2 (C16): Preparation of 16-[[(15)-4-[2-[2-[2-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-carboxy-4-oxo-butyl]amino]-16-oxo-hexadecanoic acid
  • Figure US20230364248A1-20231116-C00056
    • Solid Phase Synthetic Protocol:
  • A solution of N-(benzyloxycarbonyloxy)succinimide (ZOSu, 100 g, 401 mmol) in dichloromethane (500 mL) was added dropwise over 2 hours to a solution of ethylenediamine (1, 189 mL, 2.81 mol) in dichloromethane (750 mL). After 30 minutes the suspension was filtered and solids washed with dichloromethane. The filtrate was evaporated to dryness and the residue diluted with toluene (1.00 L) and water (0.50 L). The resulting mixture was filtered and the filtrate was separated to afford two phases. The aqueous phase contained the product; therefore it was extracted with dichloromethane (2×250 mL). All organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was diluted with toluene (750 mL) and extracted with 2 M aqueous hydrochloric acid (500 mL) and 1 M aqueous hydrochloric acid (100 mL). Acidic aqueous phases were combined and basified with a solution of sodium hydroxide (60.0 g, 1.50 mol) in water (90 mL). The resulting mixture was extracted with dichloromethane (4×200 mL), dried over anhydrous sodium sulfate, filtered, concentrated in vacuo and diluted with hexanes (200 mL). 4 M Solution of hydrogen chloride in ether (100 mL, 400 mmol) was added to the solution, the resulting suspension was concentrated in vacuo and diluted with hexanes (1.00 L). The precipitated solid was filtered, washed with hexanes and dried in vacuo to give (2-amino-ethyl)-carbamic acid benzyl ester hydrochloride as white powder.
  • Yield: 62.62 g (68%).
  • RF (SiO2, dichloromethane/methanol 4:1): 0.25 (free base).
  • 1H NMR spectrum (300 MHz, AcOD-d4, 80° C., dH): 7.42-7.26 (m, 5H); 5.16 (s, 2H); 3.60 (t, J=5.7 Hz, 2H); 3.32 (t, J=5.7 Hz, 2H).
  • 2-Chlorotrityl resin 100-200 mesh 1.7 mmol/g (3, 40.1 g, 68.1 mmol) was left to swell in dry dichloromethane (250 mL) for 20 minutes. A solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-Ado-OH, 17.5 g, 45.4 mmol) and N,N-diisopropylethylamine (30.1 mL, 173 mmol) in dry dichloromethane (50 mL) was added to resin and the mixture was shaken for 5 hours. Resin was filtered and treated with a solution of N,N-diisopropylethylamine (15.8 mL, 90.8 mmol) in methanol/dichloromethane mixture (4:1, 250 mL, 2×5 min). Then resin was washed with N,N-dimethylformamide (2×250 mL), dichloromethane (2×250 mL) and N,N-dimethylformamide (3×250 mL). Fmoc group was removed by treatment with 20% piperidine in dimethylformamide (1×5 min, 1×10 min, 1×30 min, 3×250 mL). Resin was washed with N,N-dimethylformamide (3×250 mL), 2-propanol (2×250 mL) and dichloromethane (300 mL, 2×250 mL). Solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-Ado-OH, 26.3 g, 68.1 mmol), 0-(6-chloro-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TCTU, 24.2 g, 68.1 mmol) and N,N-diisopropylethylamine (21.4 mL, 123 mmol) in N,N-dimethylformamide (140 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (2×250 mL), dichloromethane (2×250 mL) and N,N-dimethylformamide (250 mL). Fmoc group was removed by treatment with 20% piperidine in dimethylformamide (1×5 min, 1×10 min, 1×30 min, 3×250 mL). Resin was washed with N,N-dimethylformamide (3×250 mL), 2-propanol (2×250 mL) and dichloromethane (300 mL, 2×250 mL). Solution of (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-pentanedioic acid 1-tert-butyl ester (Fmoc-Glu-OtBu, 29.0 g, 68.1 mmol), 0-(6-chloro-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TCTU, 24.2 g, 68.1 mmol) and N,N-diisopropylethylamine (21.4 mL, 123 mmol) in N,N-dimethylformamide (140 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (2×250 mL), dichloromethane (2×250 mL) and N,N-dimethylformamide (250 mL). Fmoc group was removed by treatment with 20% piperidine in dimethylformamide (1×5 min, 1×10 min, 1×30 min, 3×250 mL). Resin was washed with N,N-dimethylformamide (3×250 mL), 2-propanol (2×250 mL) and dichloromethane (300 mL, 2×250 mL). Solution of 16-(tert-butoxy)-16-oxohexadecanoic acid (23.3 g, 68.1 mmol), 0-(6-chloro-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TCTU, 24.2 g, 68.1 mmol) and N,N-diisopropylethylamine (21.4 mL, 123 mmol) in N,N-dimethylformamide/dichloromethane mixture (4:1, 200 mL) was added to resin. Resin was shaken for 1 hour, filtered and washed with N,N-dimethylformamide (3×250 mL), dichloromethane (2×250 mL), methanol (2×250 mL) and dichloromethane (350, 6×250 mL). The product was cleaved from resin by treatment with 2,2,2-trifluoethanol (250 mL) for 18 hours. Resin was filtered off and washed with dichloromethane (2×250 mL), 2-propanol/dichloromethane mixture (1:1, 2×250 mL), 2-propanol (250 mL) and dichloromethane (3×250 mL). Solutions were combined; solvent evaporated and crude product was purified by flash column chromatography (Silicagel 60, 0.040-0.060 mm; eluent: dichloromethane/methanol 1:0-9:1). Pure (S)-22-(tert-butoxycarbonyl)-41,41-dimethyl-10,19,24,39-tetraoxo-3,6,12,15,40-pentaoxa-9,18,23-triazadotetracontanoic acid was dried in vacuo and obtained as pale yellow thick yellow oil.
  • Yield: 30.88 g (83%).
  • RF (SiO2, dichloromethane/methanol 4:1): 0.30.
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.36 (t, J=5.7 Hz, 1H); 7.02 (t, J=5.4 Hz, 1H); 6.55 (d, J=7.7 Hz, 1H); 4.46 (m, 1H); 4.18 (s, 2H); 4.02 (s, 2H); 3.83-3.36 (m, 16H); 2.44-2.12 (m, 7H); 2.02-1.86 (m, 1H); 1.60 (m, 4H); 1.47 (s, 9H); 1.45 (s, 9H); 1.36-1.21 (m, 20H).
  • LC-MS method 4:
  • Purity: 100%
  • Rt (Kinetex 4.6 mm×50 mm, acetonitrile/water 50:50 to 100:0+0.1% FA): 3.60 min.
  • Found m/z, z=1: 818.7 (M+H)+
  • 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 11.4 g, 30.1 mmol) and triethylamine (8.77 mL, 62.9 mmol) were subsequently added to a solution of (S)-22-(tert-butoxycarbonyl)-41,41-dimethyl-10,19,24,39-tetraoxo-3,6,12,15,40-pentaoxa-9,18,23-triazadotetracontanoic acid (22.4 g, 27.4 mmol) in dry dichloromethane (110 mL). Triethylamine (5.72 mL, 41.0 mmol) was added to a suspension of (2-amino-ethyl)-carbamic acid benzyl ester hydrochloride (6.94 g, 30.1 mmol) in dry dichloromethane (165 mL) and the resulting mixture was added to the above solution. The mixture was stirred at room temperature overnight, and then it was evaporated to dryness. The residue was re-dissolved in ethyl acetate (500 mL); washed with 1 M aqueous hydrochloric acid (2×200 mL), 5% aqueous solution of sodium carbonate (2×200 mL, very slow separation of phases), 1 M aqueous hydrochloric acid (8×200 mL) and brine; dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The residue was purified by flash column chromatography (Silicagel 60, 0.040-0.060 mm; eluent: dichloromethane/methanol 95:5) to afford 15-[(S)-3-(2-{2-[(2-{2-[(2-benzyloxycarbonylamino-ethylcarbamoyl)-methoxy]-ethoxy}-ethylcarbamoyl)-methoxy]-ethoxy}-ethylcarbamoyl)-1-tert-butoxycarbonyl-propylcarbamoyl]-pentadecanoic acid tert-butyl ester as pale yellow thick oil.
  • Yield: 23.84 g (88%)
  • RF (SiO2, dichloromethane/methanol 9:1): 0.35
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.39-7.26 (m, 6H); 7.19 (t, J=6.3 Hz, 1H); 6.91 (t, J=5.7 Hz, 1H); 6.52 (d, J=7.5 Hz, 1H); 5.83 (t, J=5.5 Hz, 1H); 5.09 (s, 2H); 4.41 (ddd, J=12.3, 4.6 and 4.3 Hz, 1H); 3.99 (s, 2H); 3.97 (s, 2H); 3.71-3.30 (m, 20H); 2.33-2.08 (m, 7H); 1.97-1.83 (m, 1H); 1.67-1.51 (m, 4H); 1.45 (s, 9H); 1.44 (s, 9H); 1.35-1.20 (m, 20H).
  • LCMS method 4
  • Purity: 100%
  • Rt (Kinetex 4.6 mm×50 mm, acetonitrile/water 50:50 to 100:0+0.1% FA): 4.18 min Found m/z, z=1: 994.9 (M+H)+
  • Palladium on carbon (10%, 1.27 g, 1.20 mmol) was added to a solution of the above compound (23.8 g, 24.0 mmol) in methanol (350 mL) and the resulting mixture was hydrogenated at normal pressure for 4 hours. The catalyst was filtered off and the filtrate evaporated to dryness. The residue was evaporated several times from dichloromethane in order to remove residues of methanol and dried in vacuo to yield tert-butyl (S)-1-amino-25-(tert-butoxycarbonyl)-4,13,22,27-tetraoxo-6,9,15,18-tetraoxa-3,12,21,26-tetraazadotetracontan-42-oate as thick colourless oil.
  • Yield: 20.50 g (99%).
  • RF (SiO2, dichloromethane/methanol 9:1): 0.05.
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.54 (t, J=5.7 Hz, 1H); 7.41 (t, J=5.6 Hz, 1H); 7.14 (t, J=5.5 Hz, 1H); 6.68 (d, J=7.5 Hz, 1H); 5.25 (bs, 2H); 4.39 (td, J=8.3 and 4.2 Hz, 1H); 4.01 (s, 4H); 3.74-3.39 (m, 18H); 2.96 (t, J=5.7 Hz, 2H); 2.34-2.06 (m, 7H); 1.97-1.83 (m, 1H); 1.68-1.50 (m, 4H); 1.45 (s, 9H); 1.43 (s, 9H); 1.37-1.19 (m, 20H).
  • LCMS method 4
  • Purity: 100%
  • Rt (Kinetex 4.6 mm×50 mm, acetonitrile/water 50:50 to 100:0+0.1% FA): 1.43 min Found m/z, z=1: 860.8 (M+H)+
  • N,N-Diisopropylethylamine (4.98 mL, 28.6 mmol) was added to a solution of the above amine (6, 20.5 g, 23.8 mmol) in dry dichloromethane (290 mL) at −30° C. under argon. Bromoacetyl bromide (2.48 mL, 28.6 mmol) was added dropwise and the resulting solution was stirred at −30° C. for additional 3 hours. The cooling bath was removed, the mixture was stirred at room temperature for 1 hour, and then the solvent was removed in vacuo. The residue was re-dissolved in ethyl acetate (450 mL) and washed with 5% aqueous solution of citric acid (300 mL). The phases were separated within 1 hour. The organic layer was washed with water (300 mL) and the resulting emulsion was left to separate overnight to give 3 phases. The clear aqueous layer was removed and the residual 2 phases were shaken with saturated aqueous solution of potassium bromide (100 mL) was added. The phases were left to separate overnight, the aqueous one was then removed and the organic one dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the residue was purified by flash column chromatography (Silicagel 60, 0.040-0.060 mm; eluent: dichloromethane/methanol 95:5) to afford tert-butyl (S)-1-bromo-28-(tert-butoxycarbonyl)-2,7,16,25,30-pentaoxo-9,12,18,21-tetraoxa-3,6,15,24,29-pentaazapentatetracontan-45-oate as colorless solid.
  • Yield: 19.46 g (83%).
  • RF (SiO2, dichloromethane/methanol 9:1): 0.25
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.46 (m, 1H); 7.33 (t, J=5.9 Hz, 1H); 7.21 (t, J=5.1 Hz, 1H); 6.92 (t, J=5.2 Hz, 1H); 6.50 (d, J=7.5 Hz, 1H); 4.41 (ddd, J=12.2, 4.5 and 4.2 Hz, 1H); 4.01 (s, 4H), 3.85 (s, 2H); 3.75-3.40 (m, 20H), 2.36-2.08 (m, 7H); 1.99-1.84 (m, 1H); 1.68-1.51 (m, 4H), 1.46 (s, 9H); 1.44 (s, 9H); 1.38-1.19 (m, 20H)
  • LCMS method 4
  • Purity: 100%
  • Rt (Kinetex 4.6 mm×50 mm, acetonitrile/water 50:50 to 100:0+0.1% FA): 3.51 min.
  • Found: m/z, z=1: 980.9, 982.9 (M+H)+
  • The above compound (19.5 g, 19.8 mmol) was dissolved in trifluoroacetic acid (120 mL) and the resulting solution was stirred at room temperature for 1.5 hours. Trifluoroacetic acid was removed in vacuo and the residue was evaporated from dichloromethane (6×200 mL). Diethyl ether (200 mL) was added to the oily residue and the mixture was stirred overnight to give a suspension. Solid product was filtered, washed with diethyl ether and hexanes and dried in vacuo to afford the title product 15-{(S)-1-carboxy-3-[2-(2-{[2-(2-{[2-(2-Bromoacetylamino)ethylcarbamoyl]methoxy}-ethoxy)ethylcarbamoyl]methoxy}ethoxy)ethylcarbamoyl]propylcarbamoyl}pentadecanoic acid as white powder.
  • Yield: 16.74 g (97%).
  • 1H NMR spectrum (300 MHz, AcOD-d4, dH): 4.61 (dd, J=8.8 and 4.8 Hz, 1H); 4.12 (s, 2H), 4.10 (s, 2H); 3.96 (s, 2H); 3.77-3.39 (m, 20H), 2.49-2.18 (m, 7H); 2.16-1.04 (m, 1H); 1.71-1.56 (m, 4H), 1.30 (bs, 20H)
  • LCMS method 4:
  • Purity: 100%
  • Rt (Kinetex 4.6 mm×50 mm, acetonitrile/water 50:50 to 100:0+0.1% FA): 3.51 min
  • Theoretical m/z, z=1: 869.8, Found: m/z, z=1: 868.7, 870.7.
    • Example 10.3 (C14): Preparation of 14-[[(15)-4-[2-[2-[2-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-carboxy-4-oxo-butyl]amino]-14-oxo-tetradecanoic acid
  • Figure US20230364248A1-20231116-C00057
  • 13-{(S)-1-carboxy-3-[2-(2-{[2-(2-{[2-(2-Bromoacetylamino)ethylcarbamoyl]methoxy}-ethoxy)ethyl-carbamoyl]methoxy}ethoxy)ethylcarbamoyl]propylcarbamoyl}tridecanoic acid was prepared by the same method as described in Example 10.2 resulting in a thick yellow oil.
  • 1H NMR spectrum (300 MHz, AcOD-d4, dH): 4.61 (dd, J=8.9 and 4.9 Hz, 1H); 4.13 (s, 2H); 4.11 (s, 2H); 3.96 (s, 2H); 3.77-3.40 (m, 20H); 2.49-2.18 (m, 7H); 2.16-2.07 (m, 1H); 1.70-1.56 (m, 4H); 1.31 (bs, 16H).
  • LCMS method 4:
  • Purity: 100% (ELSD)
  • Rt (Kinetex, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 2.94 min
  • Theoretical m/z, z=1: 841.9, Found: m/z, z=1: 841.7, 843.7.
    • Example 10.4 (C18): Preparation of 18-[[(15)-4-[2-[2-[2-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-carboxy-4-oxo-butyl]amino]-18-oxo-octadecanoic acid
  • Figure US20230364248A1-20231116-C00058
    • Solution Phase Synthetic Protocol: Step 1: benzyl 18-[[(1S)-4-[2-[2-[2-[2-[2-[2-(2-aminoethylamino)-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-benzyloxycarbonyl-4-oxo-butyl]amino]-18-oxo-octadecanoate
  • To a solution of ethylenediamine (8.5 ml ml) in DCM (80 ml) and triethylamine (5.2 ml) at 0° C. was added a solution of benzyl 18-[[(1S)-1-benzyloxycarbonyl-4-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoate (26 g), prepared as described in WO10029159, in DCM (320 ml) dropwise over 75 min. After stirring for 2 h the precipitate was filtered off. To the filtrate was added water (200 ml) and isopropanol (50 ml). The mixture was extracted. The organic layer was dried using MgSO4. The MgSO4 was removed by filtration and the filtrate was dried in vacuo to give the title compound 20.07 g (81%) LCMS: Theoretical mass: 956.2; Found m/z, z=1: 957.0
    • Step 2: benzyl 18-[[(1S)-1-benzyloxycarbonyl-4-[2-[2-[2-[2-[2-[2-[2-[(2-chloroacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoate
  • Chloroacetic acid (0.19 g) was dissolved in DCM (15 ml). N-hydroxysuccinimide (0.22 g) and EDAC HCl (0.42 g) was added. After stirring for 2.5 h benzyl 18-[[(1S)-4-[2-[2-[2-[2-[2-[2-(2-aminoethylamino)-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-benzyloxycarbonyl-4-oxo-butyl]amino]-18-oxo-octadecanoate (1.5 g) in DCM (5 ml) was added. After stirring over night at RT the mixture was extracted with 1M HCl (2×20 ml) and water/brine 2:1 (30 ml). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give a clear oil, 1.37 g (84%)
  • LCMS: Theoretical mass: 1032.7; Found m/z, z=1: 1033.1
    • Step 3: 18-[[(1S)-1-Carboxy-4-[2-[2-[2-[2-[2-[2-[2-[(2-chloroacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoic acid
  • To a solution of benzyl 18-[[(1S)-1-benzyloxycarbonyl-4-[2-[2-[2-[2-[2-[2-[2-[(2-chloroacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoate (10.5 g) in acetone (140 ml) was added 10% PD/C (1.0 g) after Nitrogen aeration. After hydrogenation for 6 h, the mixture was heated to 40-50° C. before filtration. The precipitate in the cold filtrate was isolated and washed with acetone and dried to give the title compound, 7.42 g (85%).
    • Step 4: 8-[[(1S)-4-[2-[2-[2-[2-[2-[2-[2-[(2-Bromoacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-carboxy-4-oxo-butyl]amino]-18-oxo-octadecanoic acid
  • To a suspension of 18-[[(1S)-1-Carboxy-4-[2-[2-[2-[2-[2-[2-[2-[(2-chloroacetyl)amino]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoic acidin acetone (60 ml) was added sodium bromide (5 eq, 1.21 g). The mixture was stirred at RT in the dark. After 2 h more sodium bromide (10 eq, 2.41 g) was added. After 2 days more sodium bromide (5 eq, 1.21 g) was added. After 5 days the mixture was concentrated. To half the residue was added DCM (30 ml), 10% ascorbic acid (20 ml) and water 30 ml. To the emulsion was added isopropanol (50 ml) and water (30 ml). The organic phase was separated and washed twice with a mixture of 10% ascorbic acid (20 ml) and isopropanol (10 ml). The organic layer was dried (MgSO4), filtered and concentrated to give a solid oil, which was crystalised in acetone and isolated by filtration to give the title compound contaminated with starting material, 0.80 g (72%).
  • LCMS: Theoretical mass: 896.9. Found m/z, z=1: 898.9 (M+1)
    • Example 10.5 (C12): Preparation of 12-[[(1S)-1-carboxy-4-[2-[2-[2-[2-[2-[2-[(4-formylphenyl)methylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-12-oxo-dodecanoic acid
  • Figure US20230364248A1-20231116-C00059
  • The compound was prepared by the same method as described as for example 10.1.
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.39-7.29 (m, 1H); 7.03-6.93 (m, 1H); 6.59-6.51 (m, 1H); 4.49-4.37 (m, 1H); 4.15 (s, 2H); 4.01 (s, 2H); 3.78-3.39 (m, 16H); 2.36-2.10 (m, 7H); 2.01-1.85 (m, 1H); 1.68-1.50 (m, 4H); 1.48-1.41 (m, 18H); 1.34-1.22 (m, 12H).
    • Example 10.6: Preparation of (2S)-5-[2-[2-[2-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxo-2-(16-sulfohexadecanoylamino)pentanoic acid
  • Figure US20230364248A1-20231116-C00060
  • 2-Chlorotrityl resin 100-200 mesh 1.5 mmol/g (18.0 g, 27.0 mmol) was left to swell in dry dichloromethane (160 mL) for 20 minutes. A solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-OEG-OH, 6.94 g, 18.0 mmol) and N,N-diisopropylethylamine (12.5 mL, 72.0 mmol) in dry dichloromethane (100 mL) was added to resin and the mixture was shaken overnight. Resin was filtered and treated with a solution of N,N-diisopropylethylamine (4.12 mL, 23.7 mmol) in methanol/dichloromethane mixture (4:1, 2×5 min, 2×100 mL). Then resin was washed with N,N-dimethylformamide (2×100 mL), dichloromethane (2×100 mL) and N,N-dimethylformamide (3×100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×5 min, 1×30 min, 2×100 mL). Resin was washed with N,N-dimethylformamide (3×100 mL), 2-propanol (2×100 mL) and dichloromethane (3×100 mL). Solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-OEG-OH, 10.4 g, 27.0 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 9.60 g, 27.0 mmol) and N,N-diisopropylethylamine (8.50 mL, 48.6 mmol) in N,N-dimethylformamide (100 mL) was added to resin and mixture was shaken for 2 hours. Resin was filtered and washed with N,N-dimethylformamide (2×100 mL), dichloromethane (2×100 mL) and N,N-dimethylformamide (3×100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×5 min, 1×30 min, 2×100 mL). Resin was washed with N,N-dimethylformamide (3×100 mL), 2-propanol (2×100 mL) and dichloromethane (3×100 mL). Solution of (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-pentanedioic acid 1-tert-butyl ester (Fmoc-gGlu-OtBu, 11.5 g, 27.0 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 9.60 g, 27.0 mmol) and N,N-diisopropylethylamine (8.50 mL, 48.6 mmol) in N,N-dimethylformamide (100 mL) was added to resin and mixture was shaken for 2 hours. Resin was filtered and washed with N,N-dimethylformamide (2×100 mL), dichloromethane (2×100 mL) and N,N-dimethylformamide (2×100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×5 min, 1×30 min, 2×100 mL). Resin (2) was washed with N,N-dimethylformamide (3×100 mL), 2-propanol (2×100 mL) and dichloromethane (3×100 mL). Resin was divided into 4 equal parts and this synthesis was continued with one quarter of the original amount (4.50 mmol). Solution of sodium 16-sulfo-hexadecanoic acid (3, 6.16 g, 17.2 mmol, preparation is described in the procedure for synthesis of compound REaD-22296, Batch No. 195-257-1), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 8.95 g, 17.2 mmol) and N,N-diisopropylethylamine (6.00 mL, 34.0 mmol) in dimethyl sulfoxide (180 mL) was added to resin and mixture was shaken for 4 hours. Resin was filtered and washed with N,N-dimethylformamide (2×100 mL), N,N-dimethylformamide/water (2:1, 2×100 mL), dimethylsulfoxide (2×100 mL), water (2×100 mL) and N,N-dimethylformamide (3×100 mL). The product was cleaved from resin by treatment with 1,1,1,3,3,3-hexafluoro-2-propanol (80 mL) for 2 hours. Resin was filtered off and washed with dichloromethane (4×100 mL). Solutions were combined, volatiles evaporated and crude (S)-22-(tert-butoxycarbonyl)-10,19,24-trioxo-39-sulfo-3,6,12,15-tetraoxa-9,18,23-triazanonatriacontanoic acid (4) was used for the next step without further purification.
  • Yield: quantitative (based on ELSD).
  • LC-MS purity: 96%.
  • LC-MS Rt (Kinetex C18, 4.6 mm×100 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 3.07 min.
  • LC-MS m/z: 812.9 (M+H)+.
  • 1-((Dimethylamino)(dimethyliminio)methyl)-1H-[1,2,3]triazolo[4,5-b]pyridine 3-oxide hexafluorophosphate(V) (HATU, 1.87 g, 4.92 mmol) and triethylamine (3.43 mL, 24.6 mmol) were subsequently added to a solution of (S)-22-(tert-butoxycarbonyl)-10,19,24-trioxo-39-sulfo-3,6,12,15-tetraoxa-9,18,23-triazanonatriacontanoic acid (4.5 mmol) in dry dichloromethane (40 mL). Triethylamine (1.82 mL, 13.1 mmol) was added to a suspension of (2-amino-ethyl)-carbamic acid benzyl ester hydrochloride (5, 1.93 g, 8.37 mmol) in dry dichloromethane (20 mL) and the resulting mixture was added to the above solution. The mixture was stirred overnight at room temperature. After 16 hours, another portion of 1-((dimethylamino)(dimethyliminio)methyl)-1H-[1,2,3]triazolo[4,5-b]pyridine 3-oxide hexafluorophosphate(V) (HATU, 0.38 g, 1 mmol), triethylamine (2.00 mL, 14.3 mmol) and (2-amino-ethyl)-carbamic acid benzyl ester hydrochloride (5, 0.40 g, 1.70 mmol) were added and the mixture was stirred for another 2 hours. The solution was washed with 1 M aqueous hydrochloric acid (2×100 mL) and brine (50 mL), dried over anhydrous sodium sulfate and evaporated to dryness. Crude (S)-29-(tert-butoxycarbonyl)-3,8,17,26,31-pentaoxo-1-phenyl-2,10,13,19,22-pentaoxa-4,7,16,25,30-pentaazahexatetracontane-46-sulfonic acid (6) was used for the next step without further purification.
  • Yield: quantitative (based on ELSD).
  • LC-MS purity: 83% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 3.35 min.
  • LC-MS m/z: 989.1 (M+H)+.
  • Palladium on carbon (10%, 0.22 g, 0.20 mmol) was added to a solution of the above compound (4.50 mmol) in methanol (100 mL) and the resulting mixture was hydrogenated at normal pressure for 16 hours and then in sonicator for 1 hour at 40° C. The catalyst was filtered off over Celite™ and the filtrate was evaporated to dryness under reduced pressure. The residue was purified by preparative HPLC (Column DeltaPak C18, 15 m; 50×500 mm; acetonitrile/water 30:70 during 80 min+0.05% TFA) and freeze-dried to afford (S)-1-amino-25-(tert-butoxycarbonyl)-4,13,22,27-tetraoxo-6,9,15,18-tetraoxa-3,12,21,26-tetraazadotetracontane-42-sulfonic acid (7) as colorless solid.
  • Yield: 1.95 g (45% from 1).
  • LC-MS purity: 98% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 2.87 min.
  • LC-MS m/z: 854.7 (M+H)+.
  • 2,4,6-Collidine (1.60 mL, 12.0 mmol) was added to a solution of the above amine (7, 2.06 g, 2.11 mmol) in anhydrous N,N-dimethylformamide (20 mL) at 0° C. under argon. 2-Bromoacetic anhydride (0.68 g, 2.61 mmol) was added and the resulting solution was stirred at 0° C. for 1 hour. Reaction mixture was then evaporated to dryness under reduced pressure and the residue was triturated with diethyl ether (2×10 mL). Remaining compound (S)-1-bromo-28-(tert-butoxycarbonyl)-2,7,16,25,30-pentaoxo-9,12,18,21-tetraoxa-3,6,15,24,29-pentaazapentatetracontane-45-sulfonic acid (8) was used for the next step without further purification.
  • Yield: quantitative (based on ELSD).
  • LC-MS purity: 95% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 3.04 min.
  • LC-MS m/z: 976.9 (M+H)+.
  • The above compound (8, 2.00 mmol) was dissolved in dichloromethane (20 mL), water (2 mL) and trifluoroacetic acid (25 mL) and the resulting solution was stirred for 2 hours. Trifluoroacetic acid was removed under reduced pressure and the residue was co-evaporated with dichloromethane (3×80 mL). The residue was purified by preparative HPLC (Column DeltaPak C18, 15 m; 50×500 mm; acetonitrile/water 30:70 during 70 min+0.05% TFA) and freeze-dried to afford (S)-1-bromo-2,7,16,25-tetraoxo-28-(16-sulfohexadecanamido)-9,12,18,21-tetraoxa-3,6,15,24-tetraazanonacosan-29-oic acid (9) as white solid.
  • Yield: 1.92 g (98% over 2 steps).
  • 1H NMR spectrum (300 MHz, AcOD-d4, 80 C, dH): 4.68-4.58 (m, 1H); 4.20-4.08 (m, 4H); 3.94 (s, 2H); 3.82-3.64 (m, 12H); 3.60-3.46 (m, 8H); 3.20-3.10 (m, 2H); 2.51 (t, J=7.2 Hz, 2H); 2.37 (t, J=7.3 Hz, 2H); 2.26 (bs, 1H); 1.92-1.80 (m, 2H); 1.73-1.62 (m, 2H); 1.55-1.44 (m, 2H); 1.43-1.29 (m, 21H).
  • LC-MS purity: 95% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 2.73 min.
  • LC-MS m/z: 920.9 (M+H)+.
    • Example 10.7: Preparation of (2S)-6-[(2-bromoacetyl)amino]-2-[[2-[2-[2-[[2-[2-[2-[4-[17-(1H-tetrazol-5-yl)heptadecanoylsulfamoyl]butanoylamino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]hexanoic acid
  • Figure US20230364248A1-20231116-C00061
  • Wang Fmoc-Lys(Mtt) resin 0.29 mmol/g (17.24 g, 5.0 mmol) was left to swell and washed in DMF (60 mL) for 7×5 minutes. Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (2×60 mL, 2×15 min). Resin was washed with N,N-dimethylformamide (6×60 mL). Fmoc-OEG-OH was weight out for two reactions (2×20 mmol 15.416 g). Dissolved in 120 mL DMF with Oxyma (0.3M) and split out in volume of 2×53 mL. A solution of Fmoc-OEG-OH and Oxyma in DMF (53.2 mL, 0.3 M) was mixed with DIC (26.6 mL, 0.6M) in DMF. The AA was activated over 10 min then added to the resin and the mixture was shaken for 8 hours.
  • The resin was drained and washed with N,N-dimethylformamide (4×60 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (2×60 mL, 2×15 min). Resin was washed with N,N-dimethylformamide (6×60 mL) A solution of Fmoc-OEG-OH and Oxyma in DMF (53.2 mL, 0.3 M) was mixed with DIC (26.6 mL, 0.6M) in DMF. The AA was activated over 10 min then added to the resin and the mixture was shaken for 8 hours. The resin was drained and washed with N,N-dimethylformamide (4×60 mL) and then with acetonitrile (2×60 mL 2×8 h).
  • The above resin, 0.27 mmol/g (2.46 g, 0.66 mmol) was swelled in DMF (12 mL, 3×5 min). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (2×12 mL, 1×15 min+1×30 min). The Resin was washed with N,N-dimethylformamide (2×15 mL), DCM (2×15 mL), DMF (2×15 mL).
  • A solution of 4-[17-(1H-tetrazol-5-yl)heptadecanoylsulfamoyl]butanoic acid (0.966 g, 1.98 mmol), Oxyma (0.281 g, 1.98 mmol) and DIC (0.309 mL) in N,N-dimethylformamide (15 mL) was made and left for approximately 10 min in order to activate the amino acid. The mixture was then added to the reaction-tube and shaken overnight.
  • The Resin was drained and washed with N,N-dimethylformamide (2×15 mL), DCM (5×15 mL). The MTT group was cleaved by 1,1,1,3,3,3-hexafluoro-2-propanol/DCM/Triisopropylsilane 80/18/2, 3×20 ml, (3×20 min with DCM wash between each treatment) and then washed with 4×20 mL DCM. Bromoacetic acid (1.10 g, 7.92 mmol) and DIC (0.62 mL, 3.96 mmo) in 10 mL DMF were added to the resin and shaken for 1 h. The resin was washed with N,N-dimethylformamide (3×20 mL) and dichloromethane (5×20 mL).
  • The product was cleaved from the resin with TFA (98%), water (2%), 20 mL for 1 h and 20 mL for ½h. The resin was washed with 20 mL DCM. The solvents were evaporated to give a yellow oil. The oil was dissolved in EtOAc (50 mL) and washed with water 2×100 mL). White solid precipitated in the EtOAc layer. The amount of EtOAc was reduced in vacuum and filtered. The precipitate was washed with EtOAc and dried on the filter giving 270 mg of white solid.
  • LC-MS m/z: 1026.39 (M+H)+.
    • Example 10.8: Preparation of 4-[10-[[(15)-4-[2-[2-[2-[2-[2-[2-[[(55)-5-[(2-bromoacetyl)amino]-5-carboxypentyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-10-oxodecoxy]benzoic acid
  • Figure US20230364248A1-20231116-C00062
  • 2-Chlorotrityl resin 100-200 mesh 1.5 mmol/g (1, 2.70 g, 4.05 mmol) was left to swell in dry dichloromethane (40 mL) for 30 minutes. A solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-OEG-OH, 1.04 g, 2.70 mmol) and N,N-diisopropylethylamine (1.82 mL, 10.3 mmol) in dry dichloromethane (40 mL) was added to resin and the mixture was shaken overnight. Resin was filtered and treated with a solution of N,N-diisopropylethylamine (0.94 mL, 5.40 mmol) in methanol/dichloromethane mixture (4:1, 2×5 min, 2×40 mL). Then resin was washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL) and N,N-dimethylformamide (4×40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×40 mL). Resin was washed with N,N-dimethylformamide (3×40 mL), 2-propanol (2×40 mL), dichloromethane (3×40 mL) and N,N-dimethylformamide (3×40 mL). Solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-OEG-OH, 3.18 g, 8.20 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 2.93 g, 8.20 mmol) and N,N-diisopropylethylamine (2.87 mL, 16.4 mmol) in N,N-dimethylformamide (40 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL) and N,N-dimethylformamide (4×40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×40 mL). Resin was washed with N,N-dimethylformamide (3×40 mL), 2-propanol (2×40 mL), dichloromethane (3×40 mL) and N,N-dimethylformamide (3×40 mL). Solution of (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-pentanedioic acid 1-tert-butyl ester (Fmoc-L-Glu-OtBu, 3.50 g, 8.20 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 2.93 g, 8.20 mmol) and N,N-diisopropylethylamine (2.87 mL, 16.4 mmol) in N,N-dimethylformamide (40 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL) and N,N-dimethylformamide (4×40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×40 mL). Resin was washed with N,N-dimethylformamide (3×40 mL), 2-propanol (2×40 mL), dichloromethane (3×40 mL) and N,N-dimethylformamide (3×40 mL). Solution of 10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid (CNB, 3.00 g, 8.20 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 2.93 g, 8.20 mmol) and N,N-diisopropylethylamine (2.87 mL, 16.4 mmol) in N,N-dimethylformamide (40 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL), N,N-dimethylformamide (4×40 mL) and dichloromethane (10×40 mL).
  • The product was cleaved from the resin by the treatment with 2,2,2-trifluoroethanol (40 mL) overnight. Resin was filtered off and washed with dichloromethane (4×40 mL). The solvent was evaporated to dryness to afford pure (S)-22-(tert-butoxycarbonyl)-33-(4-(tert-butoxycarbonyl)phenoxy)-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazatritriacontanoic acid as yellow oil.
  • Yield: 2.26 g (100%).
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.95-7.87 (m, 2H); 7.41-7.32 (m, 1H); 7.05-6.95 (m, 1H); 6.92-6.82 (m, 2H); 6.61 (d, J=7.7 Hz, 1H); 4.49-4.37 (m, 1H); 4.15 (s, 2H); 4.04-3.95 (m, 4H); 3.76-3.36 (m, 17H); 2.39-2.09 (m, 5H); 2.04-1.85 (m, 1H); 1.84-1.70 (m, 2H); 1.67-1.52 (m, 10H); 1.50-1.39 (m, 11H); 1.37-1.24 (m, 8H).
  • LC-MS purity: 100% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 50:50 to 100:0+0.1% FA): 4.49 min.
  • LC-MS m/z: 841.2 (M+H)+.
  • Wang-Fmoc-Lys(Mtt)-OH resin 0.33 mmol/g (3, 4.15 g, 1.37 mmol) was left to swell in dichloromethane (50 mL) for 30 minutes. Mtt group was removed by treatment with 80% 1,1,1,3,3,3-hexafluoropropan-2-ol in dichloromethane (2×5 min, 2×10 min, 1×15 min, 1×30 min, 6×50 mL). Resin 3 was washed with dichloromethane (4×70 mL), 10% N,N-diisopropylethylamine in dichloromethane (1×50 mL) and dichloromethane (2×50 mL).
  • A solution of (S)-22-(tert-butoxycarbonyl)-33-(4-(tert-butoxycarbonyl)phenoxy)-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazatritriacontanoic acid (2, 2.30 g, 2.73 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 0.97 g, 2.73 mmol) and N,N-diisopropylethylamine (1.20 mL, 6.85 mmol) in N,N-dimethylformamide (50 mL) was added to resin and mixture was shaken overnight. Resin was filtered and washed with N,N-dimethylformamide (4×50 mL), dichloromethane (4×50 mL) and N,N-dimethylformamide (4×50 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×50 mL). Resin was washed with N,N-dimethylformamide (3×50 mL), 2-propanol (2×50 mL), dichloromethane (3×50 mL) and N,N-dimethylformamide (3×50 mL). A solution of bromoacetic acid (0.76 g, 5.48 mmol), N,N′-diisopropylcarbodiimide (DIC, 0.85 mL, 5.48 mmol), 2,4,6-collidine (0.91 mL, 5.48 mmol) in N,N-dimethylformamide (50 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×50 mL), dichloromethane (4×50 mL), N,N-dimethylformamide (4×50 mL) and dichloromethane (10×40 mL). The product (4) was cleaved from the resin by the treatment with trifluoroacetic acid/dichloromethane mixture (2:1, 30 mL) for 3 hours. Resin was filtered off and washed with dichloromethane (4×40 mL). The solvent was evaporated to dryness to afford pure (2S,29S)-29-(2-bromoacetamido)-2-(10-(4-carboxyphenoxy)decanamido)-5,14,23-trioxo-9,12,18,21-tetraoxa-6,15,24-triazatriacontanedioic acid (4) as yellow oil.
  • Yield: 1.33 g (100%).
  • 1H NMR spectrum (300 MHz, DMSO-d6+DCI, dH): 7.93-7.76 (m, 2H); 7.05-6.89 (m, 2H); 4.16-4.05 (m, 3H); 4.05-3.93 (m, 2H); 3.93-3.79 (m, 5H); 3.60-3.48 (m, 9H); 3.46-3.32 (m, 4H); 3.30-3.21 (m, 2H); 3.21-3.12 (m, 2H); 3.10-3.00 (m, 2H); 2.19-1.77 (m, 6H); 1.77-1.49 (m, 7H); 1.48-1.22 (m, 12H).
  • LC-MS purity: 95% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 3.02 min.
  • LC-MS m/z: 977.3 (M+H)+.
    • Example 10.9: Preparation of 4-[12-[[(15)-4-[2-[2-[2-[2-[2-[2-[[(65)-6-[(2-bromoacetyl)amino]-6-carboxyhexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-12-oxododecoxy]benzoic acid
  • Figure US20230364248A1-20231116-C00063
  • 2-Chlorotrityl chloride resin 100-200 mesh 1.5 mmol/g (2.60 g, 3.90 mmol) was left to swell in dry dichloromethane (40 mL) for 30 minutes. A solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-OEG-OH, 1.02 g, 2.60 mmol) and N,N-diisopropylethylamine (1.75 mL, 10.0 mmol) in dry dichloromethane (40 mL) was added to resin and the mixture was shaken overnight. Resin was filtered and treated with a solution of N,N-diisopropylethylamine (0.90 mL, 5.20 mmol) in methanol/dichloromethane mixture (4:1, 2×5 min, 2×40 mL). Then resin was washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL) and N,N-dimethylformamide (4×40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×40 mL). Resin was washed with N,N-dimethylformamide (3×40 mL), 2-propanol (2×40 mL), dichloromethane (3×40 mL) and N,N-dimethylformamide (3×40 mL). Solution of {2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-acetic acid (Fmoc-OEG-OH, 3.06 g, 7.90 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 2.82 g, 7.90 mmol) and N,N-diisopropylethylamine (2.76 mL, 15.0 mmol) in N,N-dimethylformamide (40 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL) and N,N-dimethylformamide (4×40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×40 mL). Resin was washed with N,N-dimethylformamide (3×40 mL), 2-propanol (2×40 mL), dichloromethane (3×40 mL) and N,N-dimethylformamide (3×40 mL). Solution of (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-pentanedioic acid 1-tert-butyl ester (Fmoc-L-Glu-OtBu, 3.40 g, 7.90 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 2.82 g, 7.90 mmol) and N,N-diisopropylethylamine (2.76 mL, 15.0 mmol) in N,N-dimethylformamide (40 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL) and N,N-dimethylformamide (4×40 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×40 mL). Resin was washed with N,N-dimethylformamide (3×40 mL), 2-propanol (2×40 mL), dichloromethane (3×40 mL) and N,N-dimethylformamide (3×40 mL). Solution of 12-(4-(tert-butoxycarbonyl)phenoxy)dodecanoic acid (CUB, 3.12 g, 7.90 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 2.82 g, 7.90 mmol) and N,N-diisopropylethylamine (2.76 mL, 15.0 mmol) in N,N-dimethylformamide (40 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×40 mL), dichloromethane (4×40 mL), N,N-dimethylformamide (4×40 mL) and dichloromethane (10×40 mL).
  • The product was cleaved from the resin by the treatment with 2,2,2-trifluoroethanol (40 mL) overnight. Resin was filtered off and washed with dichloromethane (4×40 mL). The solvent was evaporated to dryness to afford pure (S)-22-(tert-butoxycarbonyl)-35-(4-(tert-butoxycarbonyl)phenoxy)-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazapentatriacontanoic acid as yellow oil.
  • Yield: 1.93 g (86%).
  • LC-MS purity: 100% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 4.88 min.
  • LC-MS m/z: 869.2 (M+H)+.
  • Wang-Fmoc-Lys(Mtt)-OH resin 0.33 mmol/g (3.40 g, 1.11 mmol) was left to swell in dichloromethane (50 mL) for 30 minutes. Mtt group was removed by treatment with 80% 1,1,1,3,3,3-hexafluoropropan-2-ol in dichloromethane (2×5 min, 2×10 min, 1×15 min, 1×30 min, 6×50 mL). Resin was washed with dichloromethane (4×70 mL), 10% N,N-diisopropylethylamine in dichloromethane (1×50 mL) and dichloromethane (2×50 mL).
  • A solution of (S)-22-(tert-butoxycarbonyl)-35-(4-(tert-butoxycarbonyl)phenoxy)-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazapentatriacontanoic acid (1.93 g, 2.22 mmol), 5-chloro-1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide tetrafluoroborate (TCTU, 0.79 g, 2.22 mmol) and N,N-diisopropylethylamine (0.86 mL, 6.66 mmol) in N,N-dimethylformamide (50 mL) was added to resin and mixture was shaken overnight. Resin was filtered and washed with N,N-dimethylformamide (4×50 mL), dichloromethane (4×50 mL) and N,N-dimethylformamide (4×50 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×10 min, 1×30 min, 2×50 mL). Resin was washed with N,N-dimethylformamide (3×50 mL), 2-propanol (2×50 mL), dichloromethane (3×50 mL) and N,N-dimethylformamide (3×50 mL). A solution of bromoacetic acid (0.62 g, 4.44 mmol), N,N′-diisopropylcarbodiimide (DIC, 0.69 mL, 4.44 mmol) and 2,4,6-collidine (0.59 mL, 4.44 mmol) in N,N-dimethylformamide (50 mL) was added to resin and mixture was shaken for 1 hour. Resin was filtered and washed with N,N-dimethylformamide (4×50 mL), dichloromethane (4×50 mL), N,N-dimethylformamide (4×50 mL) and dichloromethane (10×40 mL). The product was cleaved from the resin by the treatment with trifluoroacetic acid/dichloromethane mixture (2:1, 30 mL) for 3 hours. Resin was filtered off and washed with dichloromethane (4×40 mL). The solvent was evaporated to dryness to afford pure (2S,29S)-29-(2-bromoacetamido)-2-(12-(4-carboxyphenoxy)dodecanamido)-5,14,23-trioxo-9,12,18,21-tetraoxa-6,15,24-triazatriacontanedioic acid as yellow oil.
  • Yield: 1.10 g (99%).
  • 1H NMR spectrum (300 MHz, DMSO-d6+DCI, dH): 7.93-7.74 (m, 2H); 7.06-6.86 (m, 2H); 4.20-3.93 (m, 5H); 3.92-3.78 (m, 6H); 3.54 (s, 9H); 3.46-2.94 (m, 12H); 2.19-1.84 (m, 5H); 1.81-1.52 (m, 6H); 1.51-1.23 (m, 15H).
  • LC-MS purity: 97% (ELSD).
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 3.20 min.
  • LC-MS m/z: 1005.3 (M+H)+.
    • Example 10.10: Preparation of (2S)-5-[2-[2-[2-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxo-2-[16-(1H-tetrazol-5-yl)hexadecanoylamino]pentanoic acid
  • Figure US20230364248A1-20231116-C00064
  • 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCHCl, 6.25 g, 32.6 mmol) was added to a stirred solution of 16-(1H-tetrazol-5-yl)hexadecanoic acid (1, 5.28 g, 16.3 mmol) and N-hydroxysuccinic imide (HOSu, 3.75 g, 32.6 mmol) in N,N-dimethylformamide (70 mL) and mixture was stirred overnight. The reaction mixture was diluted with 1 M aqueous solution of hydrochloric acid (400 mL). The crude product was extracted with ethyl acetate (4×400 mL) and the organic phase was dried over anhydrous sodium sulfate. After filtration the solvent was removed under reduced pressure. 2-Propanol (100 mL) was added to the oily residue and the precipitated white solid was filtered off. The pure product (2) was obtained by recrystallization from 2-propanol (70 mL) as white microcrystalline solid.
  • Yield: 4.73 g (69%).
  • RF (SiO2, ethyl acetate): 0.35.
  • 1H NMR spectrum (300 MHz, AcOD-d4, dH): 3.02 (t, J=7.7 Hz, 2H); 2.86 (s, 4H); 2.62 (t, J=7.3 Hz, 2H); 1.90-1.63 (m, 4H); 1.30 (bs, 22H).
  • 2-Chlorotrityl resin bound Fmoc-gGlu(tBu)-OEG-OEG- (11.5 mmol, preparation is described in the procedure for synthesis of the protractor of Example 10.6) was left to swell in dichloromethane (100 mL) for 20 minutes. Resin was washed with N,N-dimethylformamide (2×100 mL). Fmoc group was removed by treatment with 20% piperidine in N,N-dimethylformamide (1×5 min, 1×30 min, 2×100 mL). Resin was washed with N,N-dimethylformamide (3×100 mL), 2-propanol (2×100 mL) and dichloromethane (8×100 mL). The product was cleaved from resin by treatment with 1,1,1,3,3,3-hexafluoro-2-propanol in dichloromethane (2:8, 80 mL) for 2 hours. Resin was filtered off and washed with dichloromethane (2×80 mL). Solutions were combined; solvents evaporated to obtain product (4) as brownish oil. The crude product contained 2 equivalents of 1,1,1,3,3,3-hexafluoro-2-propanol.
  • Yield: 9.49 g (99%, counted for adduct with 2 equivalents of HFIP).
  • 1H NMR spectrum (300 MHz, CDCl3, dH): 7.72-7.64 (m, 1H); 7.59-7.50 (m, 1H); 4.00 (s, 2H); 3.94 (s, 2H); 3.94-3.85 (m, 1H); 3.71-3.32 (m, 16H); 2.56-2.45 (m, 2H); 2.42-2.26 (m, 1H); 2.16-2.02 (m, 1H); 1.49 (s, 9H).
  • To a solution of the above acid (6.10 g, 7.93 mmol) in tetrahydrofuran (50 mL) and 2,5-dioxopyrrolidin-1-yl 16-(1H-tetrazol-5-yl)hexadecanoate (2, 3.33 g, 7.93 mmol) was added N,N-diisopropylethylamine (6.91 mL, 39.6 mmol) and the reaction mixture was stirred overnight. Then the solvent was removed under reduced pressure and the residue purified by flash column chromatography (Silicagel 60, 0.040-0.063 mm; eluent: dichloromethane/methanol/acetic acid 15:1:0.2 to 5:1:0.2). Residual acetic acid was removed by freeze-drying from acetonitrile/water mixture 1:1 giving pure (5) as off-white solid.
  • Yield: 1.39 g (22%).
  • 1H NMR spectrum (300 MHz, DMSO-d6, dH): 8.13-8.07 (m, 1H); 8.01-7.93 (m, 1H); 7.74-7.68 (m, 1H); 4.11-3.99 (m, 1H); 3.88 (s, 2H); 3.82 (s, 2H); 3.62-3.49 (m, 8H); 3.49-3.37 (m, 4H); 3.33-3.15 (m, 4H); 2.73-2.65 (m, 2H); 2.18-2.03 (m, 4H); 1.94-1.81 (m, 1H); 1.80-1.67 (m, 1H); 1.66-1.53 (m, 2H); 1.53-1.41 (m, 2H); 1.38 (s, 9H); 1.23 (s, 22H).
  • To a solution of the above compound (1.39 g, 1.73 mmol), 1-((dimethylamino)(dimethyliminio)methyl)-1H-[1,2,3]triazolo[4,5-b]pyridine 3-oxide hexafluorophosphate(V) (HATU, 657 mg, 1.73 mmol) and N,N-diisopropylethylamine (1.21 mL, 6.90 mmol) in N,N-dimethylformamide (30 mL) was added benzyl (2-aminoethyl)carbamate (6, 400 mg, 1.73 mmol) and the reaction mixture was stirred overnight. Then the solvent was removed under reduced pressure and the residue was purified by flash column chromatography (Silicagel 60, 0.040-0.063 mm; eluent: ethyl acetate/methanol/acetic acid 15:1:0.2 to dichloromethane/methanol/acetic acid 15:1:0.2) giving pure product (7) as brownish sticky solid.
  • Yield: 1.63 g (97%).
  • 1H NMR spectrum (300 MHz, AcOD-d4, dH): 7.35 (bs, 5H); 5.25-5.12 (m, 2H); 4.50-4.42 (m, 1H); 4.14 (s, 2H); 4.09 (s, 2H); 3.79-3.30 (m, 20H); 3.02 (t, J=7.6 Hz, 2H); 2.46-2.27 (m, 4H); 2.26-2.09 (m, 1H); 2.05-1.92 (m, 1H); 1.88-1.72 (m, 2H); 1.72-1.53 (m, 2H); 1.47 (s, 9H); 1.29 (bs, 22H).
  • To a solution of the above compound (1.63 g, 1.67 mmol) in methanol was added palladium on carbon (10%, 0.25 g, 0.23 mmol) under hydrogen blanket and the reaction mixture was vigorously stirred for 2 hours. Then the reaction mixture was filtered through a short pad of diatomite and washed with methanol. The solvent was removed under reduced pressure giving pure product (8) as white solid foam.
  • Yield: 1.32 g (94%).
  • 1H NMR spectrum (300 MHz, AcOD-d4, dH): 4.50-4.42 (m, 1H); 4.16-4.10 (m, 4H); 3.71-3.61 (m, 14H); 3.59-3.51 (m, 2H); 3.51-3.45 (m, 2H); 3.40-3.32 (m, 2H); 3.02 (t, J=7.6 Hz, 2H); 2.45-2.28 (m, 4H); 2.27-2.12 (m, 1H); 2.05-1.93 (m, 1H); 1.89-1.74 (m, 2H); 1.70-1.58 (m, 2H); 1.47 (s, 9H); 1.30 (bs, 22H).
  • The above compound (1.32 g, 1.57 mmol) was dissolved in a mixture of trifluoroacetic acid (90 mL) and water (10 mL). After 90 minutes the volatiles were removed under reduced pressure and the residue was evaporated with toluene (3×50 mL). The residue was dissolved in N,N-dimethylformamide (15 mL) and cooled to 0° C. Bromoacetic anhydride (678 mg, 2.61 mmol) and sodium bicarbonate (2.02 g, 24.0 mmol) were added while stirring and the reaction mixture was allowed to warm up to ambient temperature. After 60 minutes additional bromoacetic anhydride (200 mg, 0.77 mmol) was added to complete the reaction. After 30 minutes the solvent was removed under reduced pressure giving brownish liquid immiscible with dichloromethane, ethyl acetate and water. The residue was placed to separatory funnel and tried to dissolve in ethyl acetate (50 mL) and water (50). It created three phases. Ethyl acetate phase and water phase were removed and the third phase was purified by preparative HPLC (Column labio DeltaPak C18, 15 mm, 50×500 mm, acetonitrile/water 25:75 to 50:50+0.05% TFA). Resulting solution was freeze-dried to give the title product (9) as white solid.
  • Yield: 210 mg (15%).
  • 1H NMR spectrum (300 MHz, AcOD-d4, dH): 4.64-4.56 (m, 1H); 4.12 (s, 2H); 4.10 (s, 2H); 3.95 (s, 2H); 3.77-3.59 (m, 12H); 3.59-3.37 (m, 8H); 3.02 (t, J=7.6 Hz, 2H); 2.44 (t, J=7.8 Hz, 2H); 2.34 (t, J=8.0 Hz, 2H); 2.28-2.18 (m, 1H); 2.15-2.04 (m, 1H); 1.86-1.70 (m, 2H); 1.70-1.56 (m, 2H), 1.29 (bs, 22H).
  • LC-MS purity: 100%.
  • LC-MS Rt (Kinetex C18, 4.6 mm×50 mm, acetonitrile/water 20:80 to 100:0+0.1% FA): 3.35 min.
  • LC-MS m/z: 908.8 (M+H)+.
    • Example 11: Preparation of MIC-1 Compounds with Protractors Example 11.1: Compound 01
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]amino]ethylamino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1,des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00065
  • 30 mg protractor (example 10.4, 8 equivalents) was dissolved in 1.5 mL of sat. NaHCO3 and added to 108 mg MIC-1 polypeptide with N-extension (SEQ ID NO: 288) in PBS buffer, pH 7.4, 2.1 mg/mL. Added 19 mg bis(p-sulfonatophenyl)phenylphosphine, Kalium salt dihydrate, Sigma-Aldrich 698539 (8 equivalent). After 24 h standing at room temperature the protein was purified on a C4 reverse phase column using a 10-50% ethanol/phosphate buffer pH 3.0 gradient. Yield ˜20% after purification.
  • Theoretical mass: 32006.3; Found: 32006.5.
    • Example 11.2: Compound 02
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00066
  • Compound 02 was prepared using the procedure described in example 11.1 using MIC-1 polypeptide with N-extension (SEQ ID NO: 291).
  • Theoretical mass: 31974.3; Found: 31974.0.
    • Example 11.3: Compound 03
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-27GlyA-26,SerA-25GluA-24ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00067
  • Compound 03 was prepared using the procedure described in example 11.1 using the protractor described in example 10.2 and MIC-1 polypeptide with N-extension (SEQ ID NO: 291).
  • Theoretical mass: 31918.2; Found: 31918.0.
    • Example 11.4: Compound 04
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(13-carboxytridecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(13-carboxytridecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ac etyl]amino]ethylamino]-2-oxoethyl]CysB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00068
  • Compound 04 was prepared using the procedure described in example 11.1 using the protractor described in example 10.3 and MIC-1 polypeptide with N-extension (SEQ ID NO: 291).
  • Theoretical mass: 31862.1; Found: 31862.0.
    • Example 11.5: Compound 05
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-26,SerA-25,GluA-24ThrA-23ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00069
  • Compound 05 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 289).
  • Theoretical mass: 31962.2; Found: 31962.0.
    • Example 11.6: Compound 06
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00070
  • Compound 06 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 303).
  • Theoretical mass: 31902.1; Found: 31902.0.
    • Example 11.7: Compound 07
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00071
  • Compound 07 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 292).
  • Theoretical mass: 31874.1; Found: 31873.0.
    • Example 11.8: Compound 08
  • SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00072
  • Compound 08 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 293).
  • Theoretical mass: 31902.1; Found: 31901.0.
    • Example 11.9 and Example 11.10: Compound 09 and Compound 10 Compound 09
  • N{B-32}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl-SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
    • Compound 10:
  • N{A-32}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl,N{B-32}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl-SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00073
  • Figure US20230364248A1-20231116-C00074
  • 20 mg of protractor (example 10.1, 8 equivalents) dissolved in 2 mL 40% Hydroxypropyl-beta-cyclodextrin was added to 75 mg of MIC-1 polypeptide with N-extension (SEQ ID NO: 164) in 40 mL PBS buffer, pH 7.4. 100 μL of borane pyridine complex (8M) was added. After 24 h standing at room temperature 20 mg of the protractor and 100 μL of borane reagent were added again.
  • After 48 h the mono and dialkylated protein mixture was purified on a C4 reverse phase column using a 10-50% ethanol/phosphate buffer pH 3.0 gradient. Yield ˜19% monoalkylated protein (Compound 09) and 6% dialkylated protein (Compound 10) after purification.
  • Compound 09: Theoretical mass: 31073.0; Found: 31073.5.
  • Compound 10: Theoretical mass: 31908.1; Found: 31908.5.
    • Example 11.11: Compound 11
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,LeuA86,LeuB57,LeuB86],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00075
  • Compound 11 was prepared using the procedure described in example 11.1 using the protractor described in example 10.4 and MIC-1 polypeptide with N-extension (SEQ ID NO: 290).
  • Theoretical mass: 31934.1; Found: 31938.5.
    • Example 11.12 and Example 11.13: Compound 12 and Compound 13 Compound 12:
  • N{A-9}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl,N{B-9}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl-GluA-9,GluA-8,AlaA-7,GluA-6,AlaA-5,AspA-4,AspA-3,AspA-2,AspA-1,GluB-9,GluB-8,AlaB-7,GluB-6,AlaB-5,AspB-4,AspB-3,AspB-2,AspB-1[LysA1,GluA2,SerA3,LysB1,GluB2,SerB3]-MIC-1
    • Compound 13:
  • N{B-9}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl-GluA-9,GluA-8,AlaA-7,GluA-6,AlaA-5,AspA-4,AspA-3,AspA-2,AspA-1,GluB-9,GluB-8,AlaB-7,GluB-6,AlaB-5,AspB-4,AspB-3,AspB-2,AspB-1[LysA1,GluA2,SerA3,LysB1,GluB2,SerB3]-MIC-1
  • Figure US20230364248A1-20231116-C00076
  • Figure US20230364248A1-20231116-C00077
  • Compounds 12 and 13 were prepared using the procedure described in example 11.10 using the protractor described in example 10.1 and MIC-1 polypeptide with N-extension (SEQ ID NO: 311).
  • Compound 12: Theoretical mass: 28212.3; Found: 28211.9.
  • Compound 13: Theoretical mass: 27377.2; Found: 27376.8.
    • Example 11.14: Compound 14
  • N{A-9}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(11-carboxyundecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ac etyl]amino]methyl]phenyl]methyl,N{B-9}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(11-carboxyundecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ac etyl]amino]methyl]phenyl]methyl-GluA-9,GluA-8,AlaA-7GluA-6,AlaA-5,AspA-4,AspA-3,AspA-2,AspA-1,GluB-9,GluB-8,AlaB-7,GluB-6,AlaB-5,AspB-4,AspB-3,AspB-2,AspB-1[LysA1,GluA2,SerA3,LysB1,GluB2,SerB3]-MIC-1
  • Figure US20230364248A1-20231116-C00078
  • Compound 14 was prepared using the procedure described in example 11.10 using the protractor described in example 10.5 and MIC-1 polypeptide with N-extension (SEQ ID NO: 311).
  • Theoretical mass: 28043.9; Found: 28043.6.
    • Example 11.15 and Example 11.16: Compound 15 and Compound 16 Compound 15:
  • N{B-32}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl-SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,ArgA69,LeuA86,ArgA91,ArgA107,LeuB57,ArgB69,LeuB86,ArgB91,ArgB107],des-AsnA3,AsnB3-MIC-1
    • Compound 16:
  • N{A-32}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl,N{B-32}-[4-[[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]methyl]phenyl]methyl-SerA-32,GluA-31,ProA-30,AlaA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,AlaB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1[LeuA57,ArgA69,LeuA86,ArgA91,ArgA107,LeuB57,ArgB69,LeuB86,ArgB91,ArgB107],des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00079
  • Figure US20230364248A1-20231116-C00080
  • Compounds 15 and 16 were prepared using the procedure described in example 11.10 using the protractor described in example 10.1 MIC-1 polypeptide N-extension (SEQ ID NO: 312).
  • Compounds 15: Theoretical mass: 31241.1; Found: 31242.0.
  • Compounds 16: Theoretical mass: 32076.0; Found: 32075.0.
    • Example 11.17: Compound 17
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(16-sulfohexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(16-sulfohexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00081
  • 4 mL 2M TRIS buffer was added to 176 mg of MIC-1 polypeptide with N-extension (SEQ ID NO: 288) in 15 mM citric acid/450 mM sodium chloride, pH 3, 2.2 mg/mL. The protractor described in Example 10.6 was dissolved in saturated sodium hydrogen carbonate to 20 mg/L, 8 equivalents. The protractor was then added to the polypeptide solution. 12.4 mg of bis(p-sulfonatophenyl)phenylphosphine, kalium salt dihydrate, Sigma-Aldrich 698539 dissolved in water (0.1 mg/mL) were added and the reaction mixture was gently shaken for 10 s. After 6 hours the compound was purified on a C4 column using a C4 reverse phase column using a 10-50% ethanol/phosphate buffer pH 3.0.
  • Theoretical mass: 32050.3; Found: 32050.0.
    • Example 11.18: Compound 18
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[[(5S)-5-carboxy-5-[[2-[2-[2-[[2-[2-[2-[4-[17-(1H-tetrazol-5-yl)heptadecanoylsulfamoyl]butanoylamino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ac etyl]amino]pentyl]amino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[[(5S)-5-carboxy-5-[[2-[2-[2-[[2-[2-[2-[4-[17-(1H-tetrazol-5-yl)heptadecanoylsulfamoyl]butanoylamino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ac etyl]amino]pentyl]amino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00082
  • Compounds 18 was prepared using the procedure described in Example 11.17 using the protractor described in Example 10.7 and MIC-1 polypeptide with N-extension (SEQ ID NO: 288).
  • Theoretical mass: 32266.6; Found: 32266.0.
    • Example 11.19: Compound 19
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[[(1S)-1-carboxy-5-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]pentyl]amino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15, ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[[(1S)-1-carboxy-5-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]pentyl]amino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00083
  • Compounds 19 was prepared using the procedure described in Example 11.17 using the protractor described in Example 10.8 and MIC-1 polypeptide with N-extension (SEQ ID NO: 288).
  • Theoretical mass: 32166.3; Found: 32166.0.
    • Example 11.20: Compound 20
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[[(1S)-1-carboxy-5-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[12-(4-carboxyphenoxy)dodecanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]pentyl]amino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[[(1S)-1-carboxy-5-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[12-(4-carboxyphenoxy)dodecanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]pentyl]amino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00084
  • Compounds 20 was prepared using the procedure described in Example 11.17 using the protractor described in Example 10.9 and MIC-1 polypeptide with N-extension (SEQ ID NO: 288).
  • Theoretical mass: 32222.4; Found: 32222.0.
    • Example 11.21: Compound 21
  • SerA-32,GluA-31,ProA-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[16-(1H-tetrazol-5-yl)hexadecanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysA-29,ThrA-28,SerA-27,GlyA-26,SerA-25,GluA-24,ThrA-23,ProA-22,GlyA-21,ThrA-20,SerA-19,GluA-18,SerA-17,AlaA-16,ThrA-15,ProA-14,GluA-13,SerA-12,GlyA-11,ProA-10,GlyA-9,ThrA-8,SerA-7,ThrA-6,GluA-5,ProA-4,SerA-3,GluA-2,GlyA-1,SerB-32,GluB-31,ProB-30,S{Beta}-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[16-(1H-tetrazol-5-yl)hexadecanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethylamino]-2-oxoethyl]CysB-29,ThrB-28,SerB-27,GlyB-26,SerB-25,GluB-24,ThrB-23,ProB-22,GlyB-21,ThrB-20,SerB-19,GluB-18,SerB-17,AlaB-16,ThrB-15,ProB-14,GluB-13,SerB-12,GlyB-11,ProB-10,GlyB-9,ThrB-8,SerB-7,ThrB-6,GluB-5,ProB-4,SerB-3,GluB-2,GlyB-1des-AsnA3,AsnB3-MIC-1
  • Figure US20230364248A1-20231116-C00085
  • Compounds 21 was prepared using the procedure described in Example 11.17 using the protractor described in Example 10.10 and MIC-1 polypeptide with N-extension (SEQ ID NO: 288).
  • Theoretical mass: 32026.3; Found: 32026.0.
  • The structures of Compounds 01-21 are summarized in Table 18.
  • TABLE 18
    The structures of MIC-1 compounds
    Compound
    No N-extension MIC-1 polypeptide protractor
    Compound SEPCTSGSETPGTSE MIC-1, des-N3 (SEQ Formula D
    01 SATPESGPGTSTEPS ID NO: 2) (C18)
    EG (SEQ ID NO:
    225)
    Compound SEPATCGSETPGTSE MIC-1, des-N3 (SEQ Formula D
    02 SATPESGPGTSTEPS ID NO: 2) (C18)
    EG (SEQ ID NO:
    226)
    Compound SEPATCGSETPGTSE MIC-1, des-N3 (SEQ Formula B (C16)
    03 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    226)
    Compound SEPATCGSETPGTSE MIC-1, des-N3 (SEQ Formula C (C14)
    04 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    226)
    Compound SEPATSCSETPGTSE MIC-1, des-N3, Formula D
    05 SATPESGPGTSTEPS M57L, M86L (SEQ ID (C18)
    EG (SEQ ID NO: NO: 222)
    227)
    Compound SEPATSGCETPGTSE MIC-1, des-N3, Formula D
    06 SATPESGPGTSTEPS M57L, M86L (SEQ ID (C18)
    EG (SEQ ID NO: NO: 222)
    230)
    Compound SEPATSGSETPGTSE MIC-1, des-N3, Formula D
    07 SACPESGPGTSTEPS M57L, M86L (SEQ ID (C18)
    EG (SEQ ID NO: NO: 222)
    235)
    Compound SEPATSGSETPGTSE MIC-1, des-N3, Formula D
    08 SATPESGPGTSTEPC M57L, M86L (SEQ ID (C18)
    EG (SEQ ID NO: NO: 222)
    239)
    Compound SEPATSGSETPGTSE MIC-1, des-N3, Formula A
    09 SATPESGPGTSTEPS M57L, M86L (SEQ ID (C18)*
    EG (SEQ ID NO: NO: 222)
    71)
    Compound SEPATSGSETPGTSE MIC-1, des-N3, Formula A (C18)
    10 SATPESGPGTSTEPS M57L, M86L (SEQ ID
    EG (SEQ ID NO: NO: 222)
    71)
    Compound SEPCTSGSETPGTSE MIC-1, des-N3, Formula D
    11 SATPESGPGTSTEPS M57L, M86L (SEQ ID (C18)
    EG (SEQ ID NO: NO: 222)
    225)
    Compound EEAEADDDDK (SEQ MIC-1, des-A1, R2E, Formula D
    12 ID NO: 313) N3S (C18)
    Compound EEAEADDDDK (SEQ MIC-1, des-A1, R2E, Formula D
    13 ID NO: 313) N3S (SEQ ID (C18)*
    NO: 314)
    Compound EEAEADDDDK (SEQ MIC-1, des-A1, R2E, Formula E (C12)
    14 ID NO: 313) N3S (SEQ ID
    NO: 314)
    Compound SEPATSGSETPGTSE MIC-1, del-N3, M57L, Formula A
    15 SATPESGPGTSTEPS M86L, K69R, K107R, (C18)*
    EG (SEQ ID NO: K91R (SEQ ID
    71) NO: 315)
    Compound SEPATSGSETPGTSE MIC-1, del-N3, M57L, Formula A (C18)
    16 SATPESGPGTSTEPS M86L, K69R, K107R,
    EG (SEQ ID NO: K91R (SEQ ID
    71) NO: 315)
    Compound SEPCTSGSETPGTSE MIC-1, des-N3 (SEQ Formula F
    17 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    225)
    Compound SEPCTSGSETPGTSE MIC-1, des-N3 (SEQ Formula G
    18 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    225)
    Compound SEPCTSGSETPGTSE MIC-1, des-N3 (SEQ Formula H
    19 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    225)
    Compound SEPCTSGSETPGTSE MIC-1, des-N3 (SEQ Formula K
    20 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    225)
    Compound SEPCTSGSETPGTSE MIC-1, des-N3 (SEQ Formula J
    21 SATPESGPGTSTEPS ID NO: 2)
    EG (SEQ ID NO:
    225)
    Note:
    *means only one protractor is attached to Compound 09, Compound 13 or Compound 15, i.e. Compound 09, Compound 13 or Compound 15 as a dimer has only one protractor attached to one of its two N-terminal extensions. For the other Compounds, one protractor is attached to each of the two N-terminal extensions of the dimer, i.e. two protractors per dimer Compound.
    • Example 12: Solubility of MIC-1 Compounds
  • Samples of MIC-1 compounds was prepared in PBS buffer pH 7.4 followed by an up-concentrating the samples to above 35 mg/ml.
  • MIC-1 compound samples in PBS were concentrated on a Vivaspin 20 10 kDa MWCO (Sartorius) according to the description in the Vivaspin manual. A Heraus Multifuge X3R centrifuge equipped with swinging-bucket rotor (Thermo Scientific) was used at 4000 rpm (3310×g) to concentrate the MIC-1 compound samples. The concentration was subsequently determined by measuring UV at 280 nm on a Nanodrop 2000 (Thermo Scientific). The measured concentrations are presented in Table 19.
  • TABLE 19
    The solubility of MIC-1 compounds
    MIC-1 Solubility
    compounds (mg/ml)
    Compound 03 43
    Compound 05 36
    Compound 01 32
    Compound 07 35
    Compound 17 41
    Compound 19 37
    Compound 20 39
    Compound 21 31
  • It can be seen that attaching various protractors does not impact the improved solubility obtained by adding an N-terminal amino acid extension to a MIC-1 polypeptide.
    • Example 13: In Vitro Potency and Binding Activity Assay of MIC-1 Compounds with Protractors Cell Line
  • The stable cell line BHK21-hGFRAL-IRES-hRET was generated at Novo Nordisk with the addition of a vector with the Serum Response Element (SRE) in front of the luciferase reporter (See Example 5). Sequence for human GFRAL and human RET was obtained at Uniprot: UniProtKB—Q6UXVO (GFRAL_HUMAN) and UniProtKB—P07949 (RET_HUMAN). This cell line was used for the functional luciferase assay as well as for membrane preparation for Scintillation proximity assay (SPA) binding.
  • Luciferase assay: BHK21 cells stably transfected with hGFRAL, hRET receptors and SRE-Luciferase reporter genes were treated by different concentrations of MIC-1 compounds. Activation of receptors was measured by quantification of luciferase activity and potencies of compounds were calculated by EC50.
  • SPA binding: Cell membrane of BHK21-hGFRAL-IRES-hRET, SRE-Luciferase cells were isolated treated by 50 pM of 1125 labelled MIC-1 with different concentrations of MIC-1 compounds. Binding potencies of MIC-1 compounds were calculated by IC50 of displacement curves.
    • Luciferase Assay
  • Vials with frozen cells were rapidly thawed and the cells moved to a 50 ml corning tube with 10 ml pre-warmed complete medium consisting of DMEM with high glucose and sodium pyrovate, heat inactivated 10% Fetal Bovine Serum, 1% Penicillin-Streptomycin, 1 mg/ml G418-Geneticin and 400 μg/ml Hygromycin. Cells were centrifuged at 1200 rpm and the supernatant was discarded. This washing procedure was repeated once resulting in 2 times washing of the cells. Cells were resuspended in complete media to a concentration of 1.2×106 cells per ml. Cells were seeded 1.2×105 cells per well (100 μl/well) in 96 well Poly-D-Lysine coated assay palates. Cells were let to attach to the bottom surface of the wells for 4-6 hours at +34° C. followed by change of medium to 80 μl starvation medium consisting of RPMI medium with 15 mM HEPES. Cells were left to incubate over night at +34° C. in a humidified milieu with 5% C02. Test compounds were serial diluted in assay medium consisting of RPMI, 15 mM HEPES and 0.5% ovalbumin with or without 5% human serum albumin (HSA). 20 μl of assay buffer containing test compounds was added to each well resulting in a final concentration of 0.1% ovalbumin, 1% HSA and test compounds ranging from 30000 pM to 3 pM with a blank included. Plates were incubated for 4 hours at +37° C. in a humidified milieu with 5% C02. After incubation, 100 μl luciferase substrate solutions was added to each well and sealed. The plate was let to incubate for 15 minutes followed by reading of luminescence. An intensity measurement of luminescence was used for calculations of EC50 values by nonlinear regression analysis of sigmoidal dose response curves.
    • SPA Binding
  • BHK21-hGFRAL-IRES-hRET cells were cultured at +37° C. in a humidified atmosphere with 5% CO2 in complete medium consisting of DMEM with high glucose and sodium pyrovate, heat inactivated 10% Fetal Bovine Serum, 1% Penicillin-Streptomycin, 1 mg/ml G418-Geneticin and 400 ug/ml Hygromycin. Cells were washed twice in ice cold Dulbecco's phosphate-buffered saline (DPBS) and detached mechanically by scraping, transferred in ice cold DPBS into conical centrifuge tubes and centrifuged for 5 min at 1500 rpm at +20° C. Cell pellet was resuspended in a total amount of 10 ml ice cold homogenization buffer A (50 mM Tris, 2.5 mM EDTA, adjust pH7.4 with one EDTA-free protease inhibitor cocktail tablet/50 ml) and homogenized for 20 seconds. The homogenate was centrifuged at 16000 rpm in 20 minutes at +4° C. The supernatant was discarded and the pellet was reconstituted in 10 ml homogenization buffer B (50 mM Tris, 320 mM Sucrose, adjust pH 7.4 with one EDTA-free protease inhibitor cocktail tablet/50 ml) and homogenized for 20 seconds and centrifuged at 16000 rpm in 20 minutes at +4° C. This procedure was repeated one more time. The supernatant was discarded and the pellet was reconstituted in 3 ml homogenization buffer B and homogenized for 10 seconds at low speed. Protein concentration was determined by standard Bradford method and 1.5 mg protein/tube was aliquoted to cryotubes and stored at −80° C. Binding assays were performed in white 96-well plates in a total volume of 200 μl per well. Wheat germ agglutinin SPA beads were reconstituted in assay buffer (50 mM Tris/HCl, 4.5 mM MgCl2, 0.020/Tween 20 and 0.250/Ovalbumin pH 7.4) and mixed with membrane preparation to give a final concentration of 0.5 mg SPA beads and 10 μg total protein per well. Fifty thousand counts per minute per well of the radio ligand human [125I]-MIC-1 (Generated at Novo Nordisk) was added corresponding to a concentration of 50 pM. MIC-1 compounds to be tested were serial diluted in assay buffer to give a final assay concentration ranging from 1 μM to 1 pM. The plate was sealed and incubated at +22° C. for 2 hours in a plate shaker set at 350 rpm and thereafter centrifuged at 1500 rpm for 10 minutes prior to reading of SPA bead light emission. Displacement of radio ligand was measured as reduction of light emission from SPA beads and IC50 values were calculated by nonlinear regression analysis of sigmoidal dose-response curves (Table 20).
  • TABLE 20
    Potency and binding activity of MIC-1 compounds
    Luciferase Luciferase + 0.1% MIC-1 SPA
    Compound No/ NNDK EC50 HSA NNDK EC50 binding IC50
    SEQ ID NO (pM) (pM) (nM)
    SEQ ID NO: 1 59 36 0.67
    SEQ ID NO: 164 85 64 119
    SEQ ID NO: 288 70 47 6.7
    SEQ ID NO: 291 80 45 10
    SEQ ID NO: 312 42 35 116
    SEQ ID NO: 303 57 34 43
    SEQ ID NO: 292 125 115 29
    SEQ ID NO: 293 217 243 83
    SEQ ID NO: 289 35 26 36
    SEQ ID NO: 290 100 75 80
    Compound 10 71 146 20
    Compound 02 123 107 4.9
    Compound 03 96 106 11
    Compound 04 90 58 17
    Compound 01 72 59 3.8
    Compound 15 61 39 39
    Compound 16 63 51 11
    Compound 06 81 61 21
    Compound 05 57 63 23
    Compound 08 139 651 56
    Compound 11 55 62 29
    Compound 07 121 198 29
    Compound 17 43 65 4.7
    Compound 18 66 67 1.3
    Compound 19 45 62 17
    Compound 20 49 77 6.5
    Compound 21 53 56 1.0
  • As can be seen from Table 20, MIC-1 compounds with fatty acids have similar in vitro potency compared to MIC-1 polypeptides without fatty acids. But in vitro potency would be lower if the Cys mutation is close to N-terminal of MIC-1 polypeptide, such as Cys mutation S(−3)C.
  • The finding that MIC-1 compounds with fatty acids have similar potency as MIC-1 polypeptides without fatty acids is surprising. In general, adding fatty acids to pharmaceutical biological compounds for protraction results in a decrease in potency and this decrease is in general further enhanced by measuring the potency in the presence of albumin. Therefore, the finding of no reduction in potency of MIC-1 compounds with fatty acid protractors is unexpected.
    • Example 14: Effect of MIC-1 Compounds on Food Intake and Body Weight in Lean Sprague Dawley Rats
  • The in vivo efficacy of MIC-1 compounds of the invention was measured in 9-11 weeks old lean male Sprague Dawley rats. Animals were injected daily with a dose of 8 nmol/kg body weight 1-2 hrs before the onset of the dark period. Compounds were administrated subcutaneously (1-4 ml/kg) in appropriate buffered solution. Changes in food intake were measured for 7 days using automatic food monitoring systems (BioDAQ system and HM2 system for rat). In the BioDAQ system animals were single housed; and in the HM2 system animals were in group housed with up to 3 animals per cage. On day 8, a tail blood sample was collected 2-3 hrs after administration of compound, and this sample was used for measuring plasma concentrations of administrated compounds. Each compound was tested in n=4-8 animals. Animals were acclimatized for at least 7 days prior to the experiment. Collected food intake data are expressed as daily food intake (24 hour food intake) measured from the onset of each daily 12 hour dark phase to the next day dark phase. Daily changes in food intake in response to administrated compound were calculated by subtracting the average daily food intake of the vehicle group from the average daily food intake of the treatment group. Changes were considered significant if p<0.1 using a two-tailed student's t-test. Results are expressed as the “maximum reduction” in food intake compared with vehicle (buffer solution, percentage) recorded during the study period. Data are also expressed as the “accumulated reduction” in food intake which as the sum of significant (p<0.1) daily reductions in food intake (percentage) during the study period. The body weight of the animals was measured at the day of study termination using a calibrated scale. The effect of treatment on the body weight was calculated as the percentage difference in body weight between compound treated animals compared with vehicle treated animals at study termination (Table 21).
  • TABLE 21
    Food intake and body weight reduction in SD rats
    Food intake reduction
    Max efficacy @ Acc efficacy,
    8 nmol/kg [% 7 days [% Body weight
    reduction reduction reduction [%
    Compound No/ compared to compared to compared with
    SEQ ID NO vehicle] vehicle] vehicle]
    SEQ ID NO: 1 67 391 18.4
    Compound 12 66 342 18.5
    SEQ ID NO: 300 87 431 23.5
    SEQ ID NO: 299 92 453 26.0
    SEQ ID NO: 298 83 446 24.2
    SEQ ID NO: 297 92 495 26.6
    SEQ ID NO: 296 86 427 22.6
    SEQ ID NO: 295 92 533 29.5
    SEQ ID NO: 311 77 420 23.4
    Compound 13 75 431 25.2
    Compound 14 89 484 26.1
    SEQ ID NO: 164 71 408 23.3
    Compound 09 54 283 16.5
    Compound 10 61 288 18.4
    Compound 02 86 470 27.2
    Compound 03 86 458 27.4
    Compound 04 79 497 30.2
    Compound 07 77 375 20.0
    Compound 08 70 353 17.7
    Compound 05 75 405 19.9
    Compound 01 77 426 23.4
    Compound 11 58 287 17.5
    Compound 17 63 371 18.6
    Compound 18 72 384 21.2
    Compound 19 68 398 23.5
    Compound 20 69 374 22.5
    Compound 21 73 394 23.1
  • It is shown from the experimental data of Table 21 that MIC-1 compounds with or without protractors has an equivalent or better in vivo efficacy in rats when compared with wild type MIC-1 polypeptide. The data also show that these protractors don't have a negative impact on the in vivo efficacy of MIC-1 compounds.
    • Example 15: Pharmacodynamic (PD) Study in Pigs
  • The purpose of this experiment was to investigate the effect of the MIC-1 compounds on food intake and body weight in pigs. This was done in a pharmacodynamic (PD) study as described below, in which food intake was measured from 1 to 21 days after administration of a single dose of the MIC-1 compound, as compared to a vehicle-treated control group.
  • Female Landrace Yorkshire Duroc (LYD) pigs approximately 3 months of age, weighing approximately 30-35 kg were used (n=4-6 per group). The animals were housed in a group for approximately 1 week during acclimatisation to the animal facilities. During the last part of the acclimatisation period the animals were placed in individual pens (2 weeks before dosing) and during the entire experiment for measurement of individual food intake. The food intake measured the last three days before dosing served as baseline.
  • The animals were fed ad libitum with pig fodder (Svinefoder Danish Top SI 611+3′, Danish Agro) at all times both during the acclimatisation and the experimental period. Food intake was monitored on line by logging the weight of fodder continuously using the HMview system (Ellegaard Systems, Faaborg, Denmark). Any notable spillage was collected and weighed, and the automatically measured food intake was corrected for this amount.
  • Body weight was measured once or twice weekly during the study.
  • The MIC-1 compounds were dissolved in an appropriate buffer at concentrations of approximately 25 or 100 nmol/ml corresponding to doses of 1 or 9 nmol/kg. The buffer solution also served as vehicle.
  • Animals were dosed with a single subcutaneous dose of the MIC-1 compounds or vehicle on the morning of day 1, and food intake was measured for 21 days after dosing. At the end of the study the animals were euthanised with an i.v. overdose of Euthasol administered through the ear vein catheter.
  • Food intake was calculated in 24 h intervals (0-24 h, 24-48 h, 48-72 h, 72-96 h up to 20-21 days). In Table 22, the resulting mean food intake is presented as percentage of the mean food intake of the vehicle group in the same time interval.
  • TABLE 22
    Effect on food intake in pigs
    PD in pig,
    food intake (% of vehicle)
    at indicated time intervals
    Time interval (days)
    MIC-1 compound 6-7 13-14 20-21
    Vehicle 100 100 100
    Compound 05 (1 nmol/kg) 88 100 117
    Compound 05 (9 nmol/kg) 36 38 65
    Compound 01 (1 nmol/kg) 49 86 103
    Compound 01 (9 nmol/kg) 29 22 23
  • The data shows that a single s.c. injection of the tested compounds in pigs caused a reduced food intake for up to and even more than 21 days after the injection (for the 9 nmol/kg doses of Compound 01).
  • Body weight was measured during the study and the pigs gained less weight in the groups treated with MIC-1 compounds (Table 23, FIG. 6 ).
  • TABLE 23
    Change in body weight gain relative to vehicle group
    PD in pig,
    Δbody weight
    (relative to vehicle (%))
    Time (days)
    MIC-1 compounds 7 14 21
    Vehicle 0 0 0
    Compound 05 (1 nmol/kg) −5.7 −5.7 −1.1
    Compound 05 (9 nmol/kg) −15.7 −26.5 −22.0
    Compound 01 (1 nmol/kg) −9.8 −9.1 −6.6
    Compound 01 (9 nmol/kg) −18.4 −26.9 −29.4
    • Example 16: Pharmacokinetic Study in Lean SD Rats
  • The purpose of this study is to determine the terminal half-life (T/2), the mean residence time (MRT), the time for maximal plasma levels (Tmax) and the bioavailability (F) time in vivo of the MIC-1 compounds after intravenous and subcutaneous administration to lean Sprague Dawley rats This is done in a pharmacokinetic (PK) study, where the PK parameters of the MIC-1 compounds in question are determined. By T½ is generally meant the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase with intravenous dosing. By MRT is in general meant the average amount of time that the compound in question stays in the body. By Tmax is in general meant the point in time after subcutaneous administration of the compound in question when the compound in question reaches the highest concentration in the blood plasma during. By F is in general meant the fraction of subcutaneously administrated compound which appears in the blood plasma. The aforementioned PK parameters were measured in 300 g-500 g lean SD rats by injecting the compound into either the tail vein or to the subcutis of the neck followed by collection of blood plasma samples at various time points for exposure analysis. Compounds (4-5 nmol/kg body weight) were administered intravenously (1 ml/kg) in an appropriate buffer solution. The group size of the intravenous group was typically 4 and the groups size of the subcutaneous group was typically 5. The rats were awake during the whole experiment and have access to food and water.
  • For compounds with a T½ of less than 12 hrs blood samples were collected from the tongue typically at time 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 14 h, 22 h, 30 h, 48 h after dosing or at times 0 min, 15 min, 30 min, 60 min, 90 min, 2 h, 2½ h, 3 h, 4 h, 5 h, 6 h, 8 h, 24 h, 30 h, 48 h after dosing. For compounds with a T½ of more than 24 hrs blood samples were typically collected from the tongue at time 5 min, 15 min, 30 min, 60 min, 120 min, 360 min, 720 min, 24 h, 30 h, 48 h, 54 h, 72 h, 96 h, 168 h, 216 h, 264 h, 336 h after dosing, 200 μl of blood was collected into EDTA tubes and stored on ice for up to 20 minutes. Plasma samples were generated by centrifuging blood samples for 5 minutes at 10000 G at 4° C. The sample was subsequent pipetted into Micronic tubes on dry ice, and kept at −20° C. until analysed for plasma concentration of the respective MIC-1 compound using LOCI or a similar antibody based assay such as ELISA. The individual plasma concentration-time profiles were analysed by a non-compartmental model in Phoenix v. 6.4 software (Pharsight Inc., Mountain View, CA, USA), and the resulting T½, MRT, Tmax and F determined (Table 24).
  • TABLE 24
    Pharmacokinetic profiles of MIC-1 compounds/polypeptides with N-
    terminal extension
    Compound MRT Tmax
    No/SEQ T1/2 hrs hrs hrs BA %
    ID NO Dose ROA (mean) (mean) (mean) (mean)
    SEQ ID 4 nmol/kg IV  1.7  0.53 NA NA
    NO: 1
    SEQ ID 4 nmol/kg IV  3.9  2.2 NA NA
    NO: 92
    SEQ ID 4 nmol/kg IV  4.0  3.0 NA NA
    NO: 100
    SEQ ID 4 nmol/kg IV  3.8  3.2 NA NA
    NO: 104
    SEQ ID 4 nmol/kg IV  3.4  2.1 NA NA
    NO: 105
    SEQ ID 4 nmol/kg IV  3.4  1.7 NA NA
    NO: 106
    SEQ ID 4 nmol/kg IV  2.8  1.4 NA NA
    NO: 107
    SEQ ID 4 nmol/kg IV  3.8  3.8 NA NA
    NO: 108
    SEQ ID 4 nmol/kg IV  2.9  1.5 NA NA
    O: 294
    SEQ ID 4 nmol/kg SC  1.9  4.1  2.2 70
    NO: 1
    SEQ ID 4 nmol/kg SC  3.3  6.7  3.0 88
    NO: 106
    SEQ ID 4 nmol/kg SC  3.4  6.8  2.8 82
    NO: 107
    SEQ ID 4 nmol/kg SC  4.1  8.6  3.0 90±
    NO: 108
    SEQ ID 4 nmol/kg SC  2.8  6.2  3.0 67
    NO: 294
    Compound 5 nmol/kg IV 26.3  33.1 NA NA
    13
    Compound 5 nmol/kg IV 42.1  54.8 NA NA
    12
    Compound 5 nmol/kg IV  2.9  2.1 NA NA
    14
    Compound 4 nmol/kg IV 37.0  45.7 NA NA
    10
    Compound 4 nmol/kg IV 73.8 106.2. NA NA
    02
    Compound 4 nmol/kg IV 62.4  89.3 NA NA
    03
    Compound 4 nmol/kg IV 15.6  16.8 NA NA
    04
    Compound 4 nmol/kg IV 46.6  63.8 NA NA
    06
    SEQ ID 4 nmol/kg IV  5.1  2.8 NA NA
    NO: 289
    Compound 4 nmol/kg IV 58  82 NA NA
    01
    Compound 4 nmol/kg IV 53  71 NA NA
    05
    Compound 4 nmol/kg IV 50  72 NA NA
    11
    Compound 4 nmol/kg SC 56 114 50 36
    01
    Compound 4 nmol/kg SC 53 106 50 35
    05
    Compound 4 nmol/kg SC 57 116 50 52
    11
    Compound 4 nmol/kg SC 55.8  57.2 55.5 42.3
    17
    Compound 4 nmol/kg SC 52.9  53.1 54.0 38.2
    18
    Compound 4 nmol/kg IV 68.5  90.1 NA NA
    17
    Compound 4 nmol/kg IV 50.8  67.4 NA NA
    18
  • It can be seen that MIC-1 compounds with protractors have much longer T½, MRT and Tmax compared to their non-protracted MIC-1 polypeptides with N-extensions. Protraction of pharmaceutical biological compounds with comparable fatty acid protractors in general results in a terminal half-life rarely exceeding 12 hours in rat. The finding of terminal half-lives of more than 48 hours is unexpected and surprising.
    • Example 17: Pharmacokinetic Study in Mini Pigs
  • The purpose of this study was to determine the protraction in vivo of the MIC-1 compound after i.v. administration to minipigs, i.e. the prolongation of their time in the body and thereby their time of action. This was done in pharmacokinetic (PK) studies, where the terminal half-life of the compound in question was determined. By terminal half-life is meant the time it takes to halve a certain plasma concentration in the terminal elimination phase.
  • Female Gottingen minipigs were obtained from Ellegaard Gottingen Minipigs (Dalmose, Denmark) approximately 8 months of age and weighing approximately 23-25 kg were used in the studies. The minipigs were housed individually (pigs with permanent catheters) in pens with straw as bedding and fed restrictedly once daily with Altromin 9030 minipig diet (Altromin Spezialfutter GmbH & Co. KG).
  • After three weeks of acclimatisation two permanent central venous catheters were implanted in vena cava caudalis in each animal. The animals were allowed 1 week recovery after the surgery, and were then used for repeated pharmacokinetic studies with a suitable wash-out period between successive dosing.
  • Intravenous injections (the volume corresponding to 0.17 ml/kg) of the compound was given through one catheter, and blood was sampled at predefined time points for up till 12 days post dosing (preferably from the other catheter).
  • Blood samples (for example 0.8 ml) were collected in EDTA (8 mM) coated tubes and then centrifuged at 4° C. and 1942 g for 10 minutes. Blood samples were collected at predefined timepoints. In example blood samples were collected at t=predose, 0.0833, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 30, 48, 72, 96, 120, 168, 192, 216, 240, 264, and 288 hours after dose.
  • Plasma was pipetted into Micronic tubes on dry ice, and kept at −20° C. until analysed for plasma concentration of the MIC-1 compound using LOCI. Individual plasma concentration-time profiles were analysed by a non-compartmental pharmacokinetic method in Phoenix v. 6.4 (Pharsight Inc., Mountain View, CA, USA), and the resulting terminal half-lives (harmonic mean) determined.
    • Results
  • The following result was obtained (Table 25).
  • TABLE 25
    In vivo study in Göttingen minipigs
    after intravenous administration
    Minipig iv PK
    t1/2 MRT
    Compound no. (hours) (hours)
    Compound 02 338 487
    Compound 05 290 420
    Compound 11 347 489
    Terminal half-life (t1/2) is harmonic mean, n = 3
  • Protraction of pharmaceutical biological compounds with comparable fatty acid protractors in general results in a terminal half-life rarely exceeding 100 hours in mini pig. The finding of a terminal half-life of more than 300 hours is unexpected and surprising.

Claims (15)

1. A MIC-1 compound comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor attached to the amino acid extension, wherein the amino acid extension comprises 3 to 36 amino acid residues, and wherein the MIC-1 polypeptide with the amino acid extension has a calculated pI lower than 6.5.
2. The MIC-1 compound according to claim 1, wherein the N-terminal amino acid extension comprises one Cysteine residue, and wherein the protractor is attached to the amino acid extension at the Cysteine residue.
3. The MIC-1 compound according to claim 2, wherein the protractor comprises Chem. 1, Chem. 2, Chem. 3 and Chem. 4;
wherein Chem. 1 is selected from the group consisting of:

HOOC—(CH2)x—CO—*,  Chem. 1A:

HO—S(═O)2—(CH2)x—CO—*,  Chem. 1B:

HOOC-benzene-O—(CH2)y—CO—*, and  Chem. 1C:

(1H-tetrazol-5-yl)-(CH2)x—CO—*,  Chem. 1D:
wherein x is an integer in the range of 12-20,
wherein y is an integer in the range of 5-15;
wherein Chem. 2 is selected from the group consisting of:

*—(NH—CH(COOH)—(CH2)m—CO)k*,  Chem. 2A:

*—(NH—S(═O)2—(CH2)m—CO)k*, and  Chem. 2B:

*—(NH—(CH2)m-cyclohexane-CO)k—*,  Chem. 2C:
wherein m of Chem. 2 is an integer in the range of 1-5, and
k of Chem. 2 is an integer in the range of 0-4;
wherein Chem. 3 is

*(NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*)l,
wherein k of Chem. 3 is an integer in the range of 1-10,
n is an integer in the range of 1-5, and
l is an integer in the range of 0-5;
wherein Chem. 4 is selected from

*—NH—(CH2)m—NH—CO—CH2—*, and  Chem. 4A:

*—NH—CH(COOH)—(CH2)m—NH—CO—CH2—*,  Chem. 4B:
wherein m of Chem. 4 is an integer in the range of 1-5; and
wherein Chem. 1, Chem. 2, Chem. 3, and Chem. 4 are interconnected via amide bonds, connecting the *—NH end of a Chem. to the CO—* end of another Chem., and wherein the CH2—* end of Chem. 4 is connected to a sulphur atom of the Cysteine residue of the amino acid extension.
4. The MIC-1 compound according to claim 3, wherein Chem. 1 is selected from the group consisting of:

HOOC—(CH2)16—CO—*,  Chem. 1a:

HO—S(═O)2—(CH2)15—CO—* and  Chem. 1b:

HOOC-benzene-O—(CH2)9—CO—*.  Chem. 1c:
5. The MIC-1 compound according to claim 3, wherein Chem. 2 is selected from the group consisting of:

*—NH—CH(COOH)—(CH2)2—CO—*,  Chem. 2a:

*—NH—S(═O)2—(CH2)3—CO—* and  Chem. 2b:

*—NH—CH2-cyclohexane-CO—*.  Chem. 2c:
6. The MIC-1 compound according to claim 3, wherein Chem. 4 is selected from the group consisting of:

*—NH—(CH2)2—NH—CO—CH2—* and  Chem. 4a:

*—NH—CH(COOH)—(CH2)4—NH—CO—CH2—*.  Chem. 4b:
7. The MIC-1 compound according to claim 1, wherein the protractor is selected from the group consisting of Formula IX, Formula X, Formula XI, Formula XII and Formula XIII:
Figure US20230364248A1-20231116-C00086
8. The MIC-1 compound according to claim 1, wherein the N-terminal amino acid extension has surplus of acidic amino acid residues (such as Aspartic acid and/or Glutamic acid) of at least 3, 4, 5 or 6 compared to the number of basic amino acid residues (such as Lysine, Arginine and/or Histidine).
9. The MIC-1 compound according to claim 8, wherein the N-terminal amino acid extension is composed of amino acid residues selected among the group consisting of A, C, E, G, P, S and T.
10. The MIC-1 compound according to claim 2, wherein the distance between the Cysteine residue of the amino acid extension and N-terminal amino acid of the MIC-1 polypeptide is at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32 amino acids.
11. The MIC-1 compound according to claim 1, wherein the N-terminal amino acid extension comprises one or more of the following sequences:
(SEQ ID NO: 223) SEPATCGSETPGTSESATPESGPGTSTEPS, (SEQ ID NO: 224) SEPATSGCETPGTSESATPESGPGTSTEPS, (SEQ ID NO: 225) SEPCTSGSETPGTSESATPESGPGTSTEPSEG, (SEQ ID NO: 226) SEPATCGSETPGTSESATPESGPGTSTEPSEG, (SEQ ID NO: 227) SEPATSCSETPGTSESATPESGPGTSTEPSEG, (SEQ ID NO: 229) SEPACSGSETPGTSESATPESGPGTSTEPSEG, (SEQ ID NO: 230) SEPATSGCETPGTSESATPESGPGTSTEPSEG, (SEQ ID NO: 231) SEPATSGSECPGTSESATPESGPGTSTEPSEG, (SEQ ID NO: 232) SEPATSGSETPCTSESATPESGPGTSTEPSEG, (SEQ ID NO: 233) SEPATSGSETPGTCESATPESGPGTSTEPSEG, (SEQ ID NO: 234) SEPATSGSETPGTSECATPESGPGTSTEPSEG, (SEQ ID NO: 235) SEPATSGSETPGTSESACPESGPGTSTEPSEG, (SEQ ID NO: 236) SEPATSGSETPGTSESATPECGPGTSTEPSEG, and (SEQ ID NO: 237) SEPATSGSETPGTSESATPESCPGTSTEPSEG.
12. The MIC-1 compound according to claim 1, wherein the MIC-1 polypeptide comprises at least one substitution of M57L and/or M86L, compared to MIC-1 of SEQ ID NO: 1, and/or comprises a deletion of the first three residues or a deletion of N3 compared to MIC-1 of SEQ ID NO:1.
13. The MIC-1 compound according to claim 1, wherein the MIC-1 polypeptide with the N-terminal amino acid extension comprises an amino acid sequence according to SEQ ID NO: 100, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 164, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291 or SEQ ID NO: 292.
14. The MIC-1 compound according to claim 1, where the compound is selected from the group consisting of:
Figure US20230364248A1-20231116-C00087
Figure US20230364248A1-20231116-C00088
Figure US20230364248A1-20231116-C00089
Figure US20230364248A1-20231116-C00090
Figure US20230364248A1-20231116-C00091
Figure US20230364248A1-20231116-C00092
Figure US20230364248A1-20231116-C00093
Figure US20230364248A1-20231116-C00094
Figure US20230364248A1-20231116-C00095
Figure US20230364248A1-20231116-C00096
Figure US20230364248A1-20231116-C00097
15. The MIC-1 compound according to claim 1 for use in the prevention and/or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, diabetes, cardiovascular like dyslipidaemia, arteriosclerosis, steatohepatitis, or diabetic nephropathy.
US18/083,729 2017-05-23 2022-12-19 Mic-1 compounds and uses thereof Pending US20230364248A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/083,729 US20230364248A1 (en) 2017-05-23 2022-12-19 Mic-1 compounds and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017085576 2017-05-23
WOPCT/CN2017/085576 2017-05-23
CN2017113335 2017-11-28
WOPCT/CN2017/113335 2017-11-28
PCT/EP2018/063476 WO2018215525A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof
US201916614454A 2019-11-18 2019-11-18
US18/083,729 US20230364248A1 (en) 2017-05-23 2022-12-19 Mic-1 compounds and uses thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2018/063476 Continuation WO2018215525A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof
US16/614,454 Continuation US20200079829A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof

Publications (1)

Publication Number Publication Date
US20230364248A1 true US20230364248A1 (en) 2023-11-16

Family

ID=62567604

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/614,454 Abandoned US20200079829A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof
US15/986,961 Active US10398782B2 (en) 2017-05-23 2018-05-23 MIC-1 compounds and uses thereof
US18/083,729 Pending US20230364248A1 (en) 2017-05-23 2022-12-19 Mic-1 compounds and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US16/614,454 Abandoned US20200079829A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof
US15/986,961 Active US10398782B2 (en) 2017-05-23 2018-05-23 MIC-1 compounds and uses thereof

Country Status (17)

Country Link
US (3) US20200079829A1 (en)
EP (1) EP3630805A1 (en)
JP (1) JP7015322B2 (en)
KR (1) KR20200010353A (en)
CN (1) CN111183148A (en)
AU (1) AU2018272911B2 (en)
BR (1) BR112019024102A2 (en)
CA (1) CA3064320A1 (en)
CL (1) CL2019003441A1 (en)
CO (1) CO2019013768A2 (en)
MA (1) MA48956A (en)
MX (1) MX2019013801A (en)
PE (1) PE20200514A1 (en)
PH (1) PH12019550241A1 (en)
RU (1) RU2019141031A (en)
TW (1) TWI710377B (en)
WO (1) WO2018215525A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN109414471A (en) 2016-05-24 2019-03-01 诺和诺德股份有限公司 MIC-1 compound and application thereof
TWI710377B (en) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1 compounds and uses thereof
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
CN1241946C (en) 2002-07-01 2006-02-15 美国福源集团 Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
PT2929891T (en) 2004-04-13 2020-04-08 St Vincents Hospital Sydney Ltd Method for modulating appetite
US20050256576A1 (en) 2004-05-13 2005-11-17 Moskowitz Nathan C Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs
ATE444306T1 (en) 2004-05-13 2009-10-15 Lilly Co Eli FGF-21 FUSION PROTEINS
MX2007001180A (en) 2004-07-26 2007-04-13 Asterion Ltd Linkers.
EP2076527B1 (en) 2006-10-13 2014-12-10 Novo Nordisk Health Care AG Processing enzymes fused to basic protein tags
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
MX2011007544A (en) * 2009-01-23 2011-08-12 Novo Nordisk As Fgf21 derivatives with albumin binder a-b-c-d-e- and their use.
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CN102348715B (en) * 2009-02-03 2017-12-08 阿穆尼克斯运营公司 Extension recombinant polypeptide and the composition for including the extension recombinant polypeptide
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (en) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド Compositions and methods of use in the treatment of metabolic disorders
EP3763734A1 (en) 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9272019B2 (en) * 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
AR103246A1 (en) * 2014-12-23 2017-04-26 Novo Nordiks As DERIVATIVES OF FGF21 AND ITS USES
MA41794A (en) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res MODIFIED THERAPEUTIC AGENTS AND ASSOCIATED COMPOSITIONS
WO2017055613A2 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
JP6858181B2 (en) 2015-10-02 2021-04-14 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク GDF-15 as a diagnostic marker for predicting clinical outcomes of treatment with immune checkpoint blockers
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
CN109414471A (en) * 2016-05-24 2019-03-01 诺和诺德股份有限公司 MIC-1 compound and application thereof
TWI710377B (en) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1 compounds and uses thereof

Also Published As

Publication number Publication date
WO2018215525A8 (en) 2020-01-02
TWI710377B (en) 2020-11-21
CO2019013768A2 (en) 2020-04-01
JP2020520918A (en) 2020-07-16
AU2018272911A1 (en) 2019-12-19
PH12019550241A1 (en) 2020-12-07
RU2019141031A3 (en) 2021-07-16
CA3064320A1 (en) 2018-11-29
RU2019141031A (en) 2021-06-16
CN111183148A (en) 2020-05-19
US20180339057A1 (en) 2018-11-29
US20200079829A1 (en) 2020-03-12
KR20200010353A (en) 2020-01-30
US10398782B2 (en) 2019-09-03
EP3630805A1 (en) 2020-04-08
BR112019024102A2 (en) 2020-06-02
WO2018215525A1 (en) 2018-11-29
JP7015322B2 (en) 2022-02-02
MX2019013801A (en) 2020-01-30
AU2018272911B2 (en) 2022-09-08
TW201900219A (en) 2019-01-01
PE20200514A1 (en) 2020-03-05
MA48956A (en) 2020-04-08
CL2019003441A1 (en) 2020-05-08

Similar Documents

Publication Publication Date Title
US20230364248A1 (en) Mic-1 compounds and uses thereof
US10124039B2 (en) FGF21 derivatives and uses thereof
US12006344B2 (en) MIC-1 compounds and use thereof
KR101817607B1 (en) Double―acylated glp―1 derivatives
RU2598273C2 (en) Insulin derivatives containing additional disulfide bonds
US20130040877A1 (en) Long-acting y2 receptor agonists
US20170313750A1 (en) Selective pyy compounds and uses thereof
JP7484018B2 (en) GLP-1 PRODRUGS AND USES THEREOF
US20200254065A1 (en) Long-acting glp-2 analogs
US20130143815A1 (en) Growth hormone conjugates
US20100035814A1 (en) N-Terminal Pegylated Prolactin Receptor Molecules
TWI850599B (en) Prodrugs and uses thereof
CN116490212A (en) GLP-1 prodrugs and uses thereof
TW202346324A (en) Prodrugs and uses thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION